<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    <meta name="referrer" content="strict-origin-when-cross-origin">
    <meta http-equiv="Content-Security-Policy" content="default-src 'none'; form-action 'none'; base-uri 'none'; font-src 'self'; img-src 'self' data:; style-src 'self'; script-src 'self';">
    
    <title>Enterprise Prompt Engineering Library</title>
    
    <link rel="stylesheet" href="styles.css">
</head>
<body>
    <a href="#main-content" class="skip-link">Skip to main content</a>

    <div class="edge-nav">
        <a href="index.html" class="edge-dot">
            <img src="assets/icons/SVG/home.svg" alt="Home">
        </a>
        <a href="https://www.linkedin.com/in/basiliso-rosario/" target="_blank" rel="noopener noreferrer" class="edge-dot">
            <img src="assets/icons/SVG/linkedin.svg" alt="LinkedIn">
        </a>
        <a href="mailto:bas.rosario@gmail.com" class="edge-dot">
            <img src="assets/icons/SVG/email.svg" alt="Email">
        </a>
    </div>

    <nav class="sidebar">
        <div class="brand-area">
            PROMPT<span class="text-red">LIBRARY</span>
        </div>
        <button class="nav-toggle" aria-label="Toggle navigation">
            <span></span>
            <span></span>
            <span></span>
        </button>
        <div class="nav-scroller">
            <a href="index.html" class="nav-item back-link">
                <img src="assets/icons/SVG/arrow-left.svg" alt="Back" class="local-icon icon-red"> Back to Main Site
            </a>

            <div class="nav-header">Prompt Foundations</div>
            <div class="nav-item active" data-tab="foundation">Methodologies (CRISP/CRISPE/COSTAR/ReAct)</div>

            <div class="nav-header">Role-Based Examples</div>

            <div class="nav-accordion">
                <div class="nav-accordion-header">
                    Information Technology
                    <img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-icon icon-grey">
                </div>
                <div class="nav-accordion-content">
                    <div class="nav-item" data-tab="engineer">IT Engineer</div>
                    <div class="nav-item" data-tab="manager">IT Manager</div>
                    <div class="nav-item" data-tab="support">IT Site Support</div>
                    <div class="nav-item" data-tab="data-analyst">Data Analyst / BI</div>
                    <div class="nav-item" data-tab="cybersecurity">Cybersecurity Analyst</div>
                    <div class="nav-item" data-tab="sysadmin">Systems Administrator</div>
                    <div class="nav-item" data-tab="dba">Database Administrator</div>
                    <div class="nav-item" data-tab="devops">Cloud / DevOps Engineer</div>
                    <div class="nav-item" data-tab="it-pm">IT Project Manager</div>
                    <div class="nav-item" data-tab="network">Network Engineer</div>
                </div>
            </div>

            <div class="nav-accordion">
                <div class="nav-accordion-header">
                    Quality & Regulatory
                    <img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-icon icon-grey">
                </div>
                <div class="nav-accordion-content">
                    <div class="nav-item" data-tab="regulatory">Regulatory Affairs</div>
                    <div class="nav-item" data-tab="qa">Quality Assurance</div>
                    <div class="nav-item" data-tab="pv">Pharmacovigilance</div>
                    <div class="nav-item" data-tab="qc-analyst">QC Analyst</div>
                    <div class="nav-item" data-tab="validation">Validation Specialist</div>
                    <div class="nav-item" data-tab="doc-control">Document Control</div>
                    <div class="nav-item" data-tab="cmc">CMC Regulatory</div>
                    <div class="nav-item" data-tab="labeling">Labeling Specialist</div>
                    <div class="nav-item" data-tab="audit">Audit & Inspection</div>
                    <div class="nav-item" data-tab="capa">CAPA Specialist</div>
                </div>
            </div>

            <div class="nav-accordion">
                <div class="nav-accordion-header">
                    Clinical & Medical
                    <img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-icon icon-grey">
                </div>
                <div class="nav-accordion-content">
                    <div class="nav-item" data-tab="msl">Medical Science Liaison</div>
                    <div class="nav-item" data-tab="clinical">Clinical Operations</div>
                    <div class="nav-item" data-tab="cdm">Clinical Data Manager</div>
                    <div class="nav-item" data-tab="cta">Clinical Trial Associate</div>
                    <div class="nav-item" data-tab="biostat">Biostatistician</div>
                    <div class="nav-item" data-tab="med-writer">Medical Writer</div>
                    <div class="nav-item" data-tab="drug-safety">Drug Safety Scientist</div>
                    <div class="nav-item" data-tab="med-info">Medical Information</div>
                    <div class="nav-item" data-tab="cra">Clinical Research Associate</div>
                    <div class="nav-item" data-tab="recruitment">Patient Recruitment</div>
                </div>
            </div>

            <div class="nav-accordion">
                <div class="nav-accordion-header">
                    Corporate Services
                    <img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-icon icon-grey">
                </div>
                <div class="nav-accordion-content">
                    <div class="nav-item" data-tab="ea">Executive Assistant</div>
                    <div class="nav-item" data-tab="hr">Human Resources</div>
                    <div class="nav-item" data-tab="finance">Finance & Planning</div>
                    <div class="nav-item" data-tab="training">Training & Development</div>
                    <div class="nav-item" data-tab="comms">Communications & PR</div>
                    <div class="nav-item" data-tab="facilities">Facilities Management</div>
                    <div class="nav-item" data-tab="admin">Administrative Coordinator</div>
                    <div class="nav-item" data-tab="travel">Travel & Events</div>
                    <div class="nav-item" data-tab="records">Records Management</div>
                    <div class="nav-item" data-tab="office-mgr">Office Manager</div>
                </div>
            </div>

            <div class="nav-accordion">
                <div class="nav-accordion-header">
                    Operations & Compliance
                    <img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-icon icon-grey">
                </div>
                <div class="nav-accordion-content">
                    <div class="nav-item" data-tab="compliance">Compliance & Legal</div>
                    <div class="nav-item" data-tab="supply">Supply Chain</div>
                    <div class="nav-item" data-tab="ehs">Environmental Health & Safety</div>
                    <div class="nav-item" data-tab="manufacturing">Manufacturing Operations</div>
                    <div class="nav-item" data-tab="packaging">Packaging Operations</div>
                    <div class="nav-item" data-tab="warehouse">Warehouse & Distribution</div>
                    <div class="nav-item" data-tab="qc-lab">QC Laboratory Technician</div>
                    <div class="nav-item" data-tab="production">Production Planning</div>
                    <div class="nav-item" data-tab="continuous">Continuous Improvement</div>
                    <div class="nav-item" data-tab="vendor-quality">Vendor Quality</div>
                </div>
            </div>

            <div class="nav-accordion">
                <div class="nav-accordion-header">
                    AI & Innovation
                    <img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-icon icon-grey">
                </div>
                <div class="nav-accordion-content">
                    <div class="nav-item" data-tab="brainstorming">Brainstorming</div>
                    <div class="nav-item" data-tab="lateral">Lateral Thinking</div>
                    <div class="nav-item" data-tab="research">Research & Validation</div>
                    <div class="nav-item" data-tab="data-science">Data Science Lead</div>
                    <div class="nav-item" data-tab="ai-engineer">AI/ML Engineer</div>
                    <div class="nav-item" data-tab="innovation-pm">Innovation Project Manager</div>
                    <div class="nav-item" data-tab="digital-transform">Digital Transformation</div>
                    <div class="nav-item" data-tab="automation">Process Automation</div>
                    <div class="nav-item" data-tab="process-excellence">Process Excellence</div>
                    <div class="nav-item" data-tab="knowledge-mgmt">Knowledge Management</div>
                </div>
            </div>

            <div class="nav-accordion">
                <div class="nav-accordion-header">
                    Research & Development
                    <img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-icon icon-grey">
                </div>
                <div class="nav-accordion-content">
                    <div class="nav-item" data-tab="research-scientist">Research Scientist</div>
                    <div class="nav-item" data-tab="lab-manager">Lab Manager</div>
                    <div class="nav-item" data-tab="formulation">Formulation Scientist</div>
                    <div class="nav-item" data-tab="analytical-dev">Analytical Development</div>
                    <div class="nav-item" data-tab="process-dev">Process Development</div>
                    <div class="nav-item" data-tab="discovery">Drug Discovery</div>
                    <div class="nav-item" data-tab="principal-inv">Principal Investigator</div>
                    <div class="nav-item" data-tab="research-associate">Research Associate</div>
                    <div class="nav-item" data-tab="study-director">Study Director</div>
                    <div class="nav-item" data-tab="tech-transfer">Tech Transfer Specialist</div>
                </div>
            </div>

            <div class="nav-header">Other Libraries</div>
            <a href="education/index.html" class="nav-item">Education Hub</a>
            <a href="business/index.html" class="nav-item">Business Sectors</a>
            <a href="services/index.html" class="nav-item">Service Industries</a>
        </div>
    </nav>

    <main id="main-content" class="main-wrapper">
        <div class="top-header">
            <div class="page-title"><strong>Structured</strong> Prompt Engineering</div>
        </div>

        <div class="content-scroll">
            <div class="container">

                <div class="disclaimer-banner">
                    <div class="disclaimer-icon"><img src="assets/icons/SVG/shield.svg" alt="" class="local-icon icon-red"></div>
                    <div class="disclaimer-text">
                        <strong>Templates, Not Scripts:</strong> These prompts are starting points—customize them for your specific context, industry, and needs. Always verify AI outputs before use. Never input confidential or sensitive information into AI systems without proper authorization.
                    </div>
                </div>

                <div id="foundation" class="tab-content active">
                    <p class="lead">Using structured prompting methods is proven to reduce AI hallucinations by up to 60%. However, better prompts do not guarantee accuracy; you must verify the AI's output before using it.</p>

                    <!-- IT Industry Statistics Section -->
                    <div class="sec-section">
                        <h3><img src="assets/icons/SVG/chart.svg" class="local-icon icon-red" alt=""> AI in IT: The Impact Data</h3>
                        <p class="lead">Research shows AI is transforming IT workflows—from code completion to infrastructure management.</p>

                        <!-- Metrics Grid -->
                        <div class="metrics-grid">
                            <div class="metric-card">
                                <div class="metric-value green">55%</div>
                                <div class="metric-label">faster task completion with AI coding assistants</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-value blue">70%</div>
                                <div class="metric-label">of developers using AI tools in 2024</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-value purple">46%</div>
                                <div class="metric-label">of new code now AI-assisted at enterprises</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-value orange">3x</div>
                                <div class="metric-label">faster code review with AI analysis</div>
                            </div>
                        </div>

                        <!-- Bar Chart: AI Adoption by IT Role -->
                        <div class="chart-section">
                            <h4 class="chart-title">AI Tool Adoption by IT Role</h4>
                            <div class="bar-chart">
                                <div class="bar-item">
                                    <div class="bar-label">Software Engineers</div>
                                    <div class="bar-container">
                                        <div class="bar-fill" style="--bar-width: 82%;" data-value="82%"></div>
                                    </div>
                                </div>
                                <div class="bar-item">
                                    <div class="bar-label">DevOps/Cloud</div>
                                    <div class="bar-container">
                                        <div class="bar-fill" style="--bar-width: 68%;" data-value="68%"></div>
                                    </div>
                                </div>
                                <div class="bar-item">
                                    <div class="bar-label">Data Analysts</div>
                                    <div class="bar-container">
                                        <div class="bar-fill" style="--bar-width: 74%;" data-value="74%"></div>
                                    </div>
                                </div>
                                <div class="bar-item">
                                    <div class="bar-label">Cybersecurity</div>
                                    <div class="bar-container">
                                        <div class="bar-fill" style="--bar-width: 52%;" data-value="52%"></div>
                                    </div>
                                </div>
                                <div class="bar-item">
                                    <div class="bar-label">IT Support</div>
                                    <div class="bar-container">
                                        <div class="bar-fill" style="--bar-width: 61%;" data-value="61%"></div>
                                    </div>
                                </div>
                            </div>
                        </div>

                        <!-- Circular Progress Charts -->
                        <div class="circular-charts">
                            <div class="circular-chart-item">
                                <div class="circular-progress">
                                    <svg viewBox="0 0 120 120">
                                        <circle class="bg" cx="60" cy="60" r="50"></circle>
                                        <circle class="progress green" cx="60" cy="60" r="50"
                                                style="--progress-offset: calc(314 - (314 * 40 / 100));"></circle>
                                    </svg>
                                    <div class="circular-value">40%</div>
                                </div>
                                <div class="circular-label">Less Debug Time</div>
                            </div>
                            <div class="circular-chart-item">
                                <div class="circular-progress">
                                    <svg viewBox="0 0 120 120">
                                        <circle class="bg" cx="60" cy="60" r="50"></circle>
                                        <circle class="progress blue" cx="60" cy="60" r="50"
                                                style="--progress-offset: calc(314 - (314 * 75 / 100));"></circle>
                                    </svg>
                                    <div class="circular-value">75%</div>
                                </div>
                                <div class="circular-label">Code Suggestions Accepted</div>
                            </div>
                            <div class="circular-chart-item">
                                <div class="circular-progress">
                                    <svg viewBox="0 0 120 120">
                                        <circle class="bg" cx="60" cy="60" r="50"></circle>
                                        <circle class="progress purple" cx="60" cy="60" r="50"
                                                style="--progress-offset: calc(314 - (314 * 26 / 100));"></circle>
                                    </svg>
                                    <div class="circular-value">26%</div>
                                </div>
                                <div class="circular-label">More Developer Satisfaction</div>
                            </div>
                            <div class="circular-chart-item">
                                <div class="circular-progress">
                                    <svg viewBox="0 0 120 120">
                                        <circle class="bg" cx="60" cy="60" r="50"></circle>
                                        <circle class="progress orange" cx="60" cy="60" r="50"
                                                style="--progress-offset: calc(314 - (314 * 88 / 100));"></circle>
                                    </svg>
                                    <div class="circular-value">88%</div>
                                </div>
                                <div class="circular-label">Say AI Improves Productivity</div>
                            </div>
                        </div>

                        <p class="citation-note">Sources: GitHub Copilot Research 2024, Stack Overflow Developer Survey 2024, McKinsey Technology Trends 2024, Gartner IT Spending Forecast 2024</p>
                    </div>

                    <div class="section-divider"></div>

                    <h2>
                        <img src="assets/icons/SVG/cube.svg" class="local-icon icon-red" alt="CRISP"> CRISP Methodology
                    </h2>
                    <p><strong>Operational Focus:</strong> Speed & Efficiency. Ideal for daily communications.</p>
                    <div class="framework-grid cols-5">
                        <div class="def-cell"><span class="def-letter">C</span><span class="def-word">Context</span><div class="def-desc">Provides background info necessary to ground response. Limits search scope and reduces ambiguity.</div></div>
                        <div class="def-cell"><span class="def-letter">R</span><span class="def-word">Role</span><div class="def-desc">Defines persona or expertise. Anchors vocabulary and professional perspective.</div></div>
                        <div class="def-cell"><span class="def-letter">I</span><span class="def-word">Instruction</span><div class="def-desc">Specific directive using active verbs to determine the primary output action.</div></div>
                        <div class="def-cell"><span class="def-letter">S</span><span class="def-word">Style</span><div class="def-desc">Dictates voice and formatting. Aligns output with corporate or brand standards.</div></div>
                        <div class="def-cell"><span class="def-letter">P</span><span class="def-word">Parameters</span><div class="def-desc">Sets strict boundaries (length, format) to prevent rambling.</div></div>
                    </div>
                    <div class="method-explanation"><strong>Overview:</strong> The streamlined workhorse. Use for quick emails, summaries, and general queries where speed is paramount but guardrails are necessary.</div>

                    <div class="section-divider"></div>
                    
                    <h2>
                        <img src="assets/icons/SVG/layers.svg" class="local-icon icon-red" alt="CRISPE"> CRISPE Methodology
                    </h2>
                    <p><strong>Operational Focus:</strong> Accuracy & Formatting. Used for strict pattern matching.</p>
                    <div class="framework-grid cols-6">
                        <div class="def-cell"><span class="def-letter">C</span><span class="def-word">Context</span><div class="def-desc">Background info to limit search scope and reduce ambiguity.</div></div>
                        <div class="def-cell"><span class="def-letter">R</span><span class="def-word">Role</span><div class="def-desc">Defines persona to anchor vocabulary and perspective.</div></div>
                        <div class="def-cell"><span class="def-letter">I</span><span class="def-word">Instruction</span><div class="def-desc">Primary directive using active verbs to drive action.</div></div>
                        <div class="def-cell"><span class="def-letter">S</span><span class="def-word">Style</span><div class="def-desc">Dictates voice and formatting for brand consistency.</div></div>
                        <div class="def-cell"><span class="def-letter">P</span><span class="def-word">Parameters</span><div class="def-desc">Sets boundaries (length, format) to prevent rambling.</div></div>
                        
                        <div class="def-cell cell-accent">
                            <span class="def-letter text-white">E</span>
                            <span class="def-word text-white">Example</span>
                            <div class="def-desc text-white">Concrete input/output pairs. Reduces hallucination significantly.</div>
                        </div>
                    </div>
                    <div class="method-explanation"><strong>Overview:</strong> Adds "Example" (Few-Shot Prompting). Essential for code conversion, log parsing, or data restructuring where the AI must mimic a specific template.</div>

                    <div class="section-divider"></div>
                    
                    <h2>
                        <img src="assets/icons/SVG/bullseye.svg" class="local-icon icon-red" alt="COSTAR"> COSTAR Methodology
                    </h2>
                    <p><strong>Operational Focus:</strong> Strategy & Nuance. Separates Tone and Audience.</p>
                    <div class="framework-grid cols-6">
                        <div class="def-cell"><span class="def-letter">C</span><span class="def-word">Context</span><div class="def-desc">Background info to frame complex business scenarios.</div></div>
                        <div class="def-cell"><span class="def-letter">O</span><span class="def-word">Objective</span><div class="def-desc">Defines ultimate goal. Aligns output with strategic intent.</div></div>
                        <div class="def-cell"><span class="def-letter">S</span><span class="def-word">Style</span><div class="def-desc">Specifies professional standards (e.g., AP Style).</div></div>
                        <div class="def-cell"><span class="def-letter">T</span><span class="def-word">Tone</span><div class="def-desc">Adjusts sentiment (Empathetic, Stern) for impact.</div></div>
                        <div class="def-cell"><span class="def-letter">A</span><span class="def-word">Audience</span><div class="def-desc">Adjusts complexity/vocab to match stakeholder level.</div></div>
                        <div class="def-cell"><span class="def-letter">R</span><span class="def-word">Response</span><div class="def-desc">Strict structural output requirement (JSON, Table).</div></div>
                    </div>
                    <div class="method-explanation"><strong>Overview:</strong> Designed for high-stakes communication. Separates 'Tone' from 'Audience'. Crucial for executive strategy and negotiation.</div>

                    <div class="section-divider"></div>

                    <h2>
                        <img src="assets/icons/SVG/boltz.svg" class="local-icon icon-red" alt="ReAct"> ReAct Methodology - (Reasoning + Acting Loop)
                    </h2>
                    <p><strong>Operational Focus:</strong> Reasoning + Acting. Interactive troubleshooting and automation.</p>
                    <div class="framework-grid cols-3">
                        <div class="def-cell">
                            <span class="def-letter">1</span>
                            <span class="def-word">Thought</span>
                            <div class="def-desc">Analyze situation. Form hypothesis.</div>
                        </div>
                        <div class="def-cell">
                            <span class="def-letter">2</span>
                            <span class="def-word">Action</span>
                            <div class="def-desc">Execute tool to gather real data.</div>
                        </div>
                        <div class="def-cell cell-accent">
                            <span class="def-letter text-white">3</span>
                            <span class="def-word text-white">Observation</span>
                            <div class="def-desc text-white">Review results. Refine. Repeat loop.</div>
                        </div>
                    </div>
                    <div class="method-explanation"><strong>Overview:</strong> ReAct prevents "hallucination" by forcing the AI to request real data before drawing conclusions. Unlike standard chat that guesses solutions based on training data, ReAct creates an interactive loop where the AI stops and waits for your input before continuing.</div>

                </div>

                <div id="ea" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/calendar.svg" class="local-icon icon-red" alt="EA"> Executive Assistant (EA)
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Logistics & Scheduling</span><span class="level-desc">Focus: Speed (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Vendor Decline Email</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The CEO received a lunch invitation from a key vendor for next Friday. While we value this partnership and have contract renewals coming next quarter, the CEO is prioritizing internal quarterly reviews this month and cannot attend external events. We need to decline while preserving the relationship.<br><span class="key">[Role]</span> Senior Executive Assistant with expertise in diplomatic corporate communication.<br><span class="key">[Instruction]</span> Write a polite but firm decline email to the vendor contact.<br><span class="key">[Style]</span> Professional, appreciative, yet definitive.<br><span class="key">[Parameters]</span> Keep the email under 75 words. Do not propose a specific alternative date—suggest reconnecting "after our quarterly cycle concludes."<br><span class="key">[Constraints]</span> RAI: No real names, companies, or confidential details. Privacy: Use generic placeholders for any specific entities. Output: Professional tone appropriate for external business communication.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Data Organization</span><span class="level-desc">Focus: Formatting (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Meeting Minutes to Action Items</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I have a raw, unstructured transcript from the weekly Leadership Team meeting. It contains 45 minutes of dialogue, tangents, and side conversations. I need to distill this down to actionable tasks so department heads know exactly what is due next week.<br><span class="key">[Role]</span> Operations Efficiency Manager.<br><span class="key">[Instruction]</span> Extract only the concrete "Action Items" from the text and assign them to the correct owner mentioned in the transcript.<br><span class="key">[Style]</span> Corporate, Direct, and Action-Oriented.<br><span class="key">[Parameters]</span> Format strictly as a Markdown Table with columns for Owner, Action Item, and Due Date.<br><span class="key">[Example]</span> | Owner | Action Item | Due Date |<br>|-------|-------------|----------|<br>| Director1 | Finalize Q2 headcount proposal | Friday |<br><span class="key">[Constraints]</span> RAI: Remove any PII from transcript before processing. Data Accuracy: Only extract explicitly stated action items—do not infer tasks. Privacy: Replace real names with role-based identifiers in output.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Strategic Communication</span><span class="level-desc">Focus: Nuance (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Policy Rollout Announcement</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company is implementing a new hybrid work policy requiring staff to be in the office 3 days per week starting next quarter. This is a significant change from the current fully-remote arrangement. Leadership supports this decision for collaboration reasons, but we anticipate resistance from employees who have relocated or adjusted their lives around remote work.<br><span class="key">[Objective]</span> Announce the new policy in a way that minimizes backlash and maintains morale while being clear about the non-negotiable nature of the decision.<br><span class="key">[Style]</span> Executive Announcement / Change Management.<br><span class="key">[Tone]</span> Empathetic to employee concerns, but confident and clear about the business rationale.<br><span class="key">[Audience]</span> All company employees (diverse mix of roles, tenure, and personal circumstances).<br><span class="key">[Response]</span> A draft company-wide email from the CEO announcing the new hybrid work policy.<br><span class="key">[Constraints]</span> RAI: No employee-specific data or individual circumstances. Bias: Present policy rationale balanced with acknowledgment of employee impact. Perspective: Consider diverse stakeholder reactions. Transparency: Be honest about policy scope and limitations.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Executive Travel Disruption</span>
                        <span class="level-desc">Interactive Problem Solving</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Flight Cancellation Recovery</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Senior Executive Assistant using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to recover the CEO's travel itinerary after a flight cancellation by systematically gathering information before proposing solutions.<br>
<span class="key">[Tools]</span> You have access to: [FlightStatus], [CalendarView], [HotelBooking], [ContactDirectory]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> It is 6:15 AM. The CEO's 8:00 AM flight was just cancelled due to mechanical issues. She has a 1:00 PM contract signing at the client's headquarters, followed by a 4:00 PM board dinner. The contract signing cannot be virtual—the client's legal team requires wet signatures. The CEO is currently at her hotel near the departure airport.<br>
<span class="key">[Constraints]</span> RAI: No real executive names, travel details, or client information. Data Accuracy: Base all solutions on verified tool outputs—do not assume flight availability. Human Oversight: Flag any solution requiring executive approval before booking.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        A rushed response might book the first available flight without checking connection times, or suggest a virtual meeting that violates the client's legal requirements. ReAct forces you to verify actual flight availability, calculate realistic arrival times with ground transport, and confirm stakeholder constraints before committing to a solution that affects a critical contract signing.
                    </div>
                </div>

                <div id="engineer" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/codes.svg" class="local-icon icon-red" alt="Code"> IT Engineer
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Code Assistance</span><span class="level-desc">Focus: Explanation (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Explain Regex Pattern</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I am debugging a legacy validation script and found this Regular Expression: ^(?=.*[A-Za-z])(?=.*\d)[A-Za-z\d]{8,}$. It is being used for password validation, but users are complaining that their passwords are being rejected. I need to understand exactly what this pattern allows and forbids.<br><span class="key">[Role]</span> Senior Software Developer and Technical Educator.<br><span class="key">[Instruction]</span> Explain the logic of this Regex step-by-step in plain English.<br><span class="key">[Style]</span> Technical but accessible to intermediate developers.<br><span class="key">[Parameters]</span> Provide 3 examples of strings that would MATCH and 3 examples that would FAIL, explaining why for each.<br><span class="key">[Constraints]</span> RAI: No actual user passwords or credentials. Data Accuracy: Test examples against the actual regex pattern—do not fabricate match/fail results. Security: Never include real authentication patterns from production systems.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Code Transformation</span><span class="level-desc">Focus: Syntax Patterns (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Unit Test Generation</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I have a function called 'validate_transaction()' that handles financial record validation. We are moving to a Test Driven Development (TDD) model and I need to generate a standardized test suite for this function before refactoring it.<br><span class="key">[Role]</span> QA Automation Engineer specializing in unit testing frameworks.<br><span class="key">[Instruction]</span> Write 3 unit tests for this function covering success, failure, and edge cases.<br><span class="key">[Style]</span> Defensive Programming with clear test isolation.<br><span class="key">[Parameters]</span> You must use the 'Given-When-Then' comment structure for every test function.<br><span class="key">[Example]</span> def test_transaction_invalid_amount():<br> # Given: A transaction with negative amount<br> # When: validate_transaction is called<br> # Then: Raise ValidationError with message "Amount must be positive"<br><span class="key">[Constraints]</span> RAI: No real financial data, account numbers, or transaction records. Data Accuracy: Test values must be synthetic placeholders. Security: Never include actual business logic that could expose validation rules to attackers.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Architecture</span><span class="level-desc">Focus: Reasoning (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Database Architecture Trade-off</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are architecting a new user activity logging system that needs to ingest 1 million writes per minute. The team is debating whether to stick with our existing relational database or migrate to a NoSQL solution optimized for high write throughput. We need a neutral analysis to break the deadlock.<br><span class="key">[Objective]</span> Analyze the technical trade-offs to support a final architectural decision.<br><span class="key">[Style]</span> Technical Whitepaper / Architecture Review.<br><span class="key">[Tone]</span> Unbiased, Analytical, and Fact-based.<br><span class="key">[Audience]</span> The Chief Technology Officer and Principal Architects.<br><span class="key">[Response]</span> A comparison matrix evaluating: write performance, query flexibility, operational complexity, and cost. Include a final recommendation justified by the high write volume requirements.<br><span class="key">[Constraints]</span> RAI: No vendor-specific pricing or proprietary benchmarks. Source Accuracy: Base performance claims on documented specifications. Bias: Present balanced pros/cons for each approach. Uncertainty: Flag any assumptions about specific use case requirements.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Production API Degradation</span>
                        <span class="level-desc">Interactive Troubleshooting</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Response Time Spike Investigation</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Senior Backend Engineer using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to diagnose the root cause of API performance degradation by systematically gathering evidence before making changes.<br>
<span class="key">[Tools]</span> You have access to: [APM_Dashboard], [DatabaseMetrics], [RecentDeployments], [ErrorLogs]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> The /api/v2/orders endpoint p95 response time spiked from 180ms to 2,400ms starting at 10:47 AM today. The support team is reporting that enterprise clients are experiencing checkout timeouts. No deployments were made this morning. The database team says DB-Server-1 CPU looks normal. There are over 800 open support tickets tagged "checkout-slow" in the ticketing system.<br>
<span class="key">[Constraints]</span> RAI: No customer names, order IDs, or production credentials. Data Accuracy: Only draw conclusions from verified tool outputs—do not assume root causes. Human Oversight: Flag any proposed fix for review before implementation. Security: Never expose actual error messages or stack traces externally.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately scale up servers or restart services. ReAct forces you to first verify the actual bottleneck—is it the application, database queries, external API calls, or network? By checking APM traces and correlating with the exact timestamp, you might discover that a third-party service started timing out, not your own infrastructure. This prevents costly over-provisioning and identifies the true root cause.
                    </div>
                </div>

                <div id="manager" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/user-tie.svg" class="local-icon icon-red" alt="Manager"> IT Manager
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Status Reporting</span><span class="level-desc">Focus: Clarity (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Weekly Status Update</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The infrastructure migration project has completed the "Data Transfer" phase successfully ahead of schedule. However, we are encountering some minor latency issues in the reporting dashboard that are delaying the final sign-off. Stakeholders are anxious about the timeline.<br><span class="key">[Role]</span> IT Project Manager.<br><span class="key">[Instruction]</span> Write a weekly status update email to the department head.<br><span class="key">[Style]</span> Positive, Transparent, and Solution-Focused.<br><span class="key">[Parameters]</span> Use a "Green/Yellow/Red" status format. Keep the email under 150 words. Focus on the success of the transfer while addressing the latency issues constructively.<br><span class="key">[Constraints]</span> RAI: No specific project names, budget figures, or stakeholder identities. Data Accuracy: Status indicators must reflect actual project state. Transparency: Acknowledge issues without downplaying or exaggerating.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Documentation</span><span class="level-desc">Focus: Structure (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Project Milestone Documentation</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are kicking off a new infrastructure migration project and need to define clear success criteria for each phase. The documentation will be reviewed by stakeholders from Engineering, Operations, and Finance departments to ensure alignment.<br><span class="key">[Role]</span> Technical Project Manager.<br><span class="key">[Instruction]</span> Draft the "Project Milestones" section with measurable outcomes for the first quarter.<br><span class="key">[Style]</span> Formal, Measurable, and Professional.<br><span class="key">[Parameters]</span> Every milestone must strictly follow the SMART framework (Specific, Measurable, Achievable, Relevant, Time-bound).<br><span class="key">[Example]</span> Input: "Migrate servers faster."<br>Output: "Complete migration of at least 15 production servers to the new environment with 99.9% uptime maintained and zero data loss by the end of Q1."<br><span class="key">[Constraints]</span> RAI: No actual project budgets or proprietary infrastructure details. Data Accuracy: Milestones must be realistic and achievable—do not fabricate metrics. Source: Base targets on industry benchmarks where possible.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Strategic Influence</span><span class="level-desc">Focus: Persuasion (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Budget Defense Presentation</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The Finance department has proposed a flat 20% cut to our infrastructure budget for next fiscal year. This cut would force us to shut down our development sandbox environment and delay the automation pilot project, which are critical for our 3-year growth strategy.<br><span class="key">[Objective]</span> Persuade the Finance Committee to keep the infrastructure budget flat instead of cutting it.<br><span class="key">[Style]</span> Business Case / Risk Analysis.<br><span class="key">[Tone]</span> Firm, Warning, yet Collaborative.<br><span class="key">[Audience]</span> The CFO, who cares about risk mitigation and future revenue growth, not technical specifications.<br><span class="key">[Response]</span> A list of 5 talking points for the meeting, specifically linking "Infrastructure Investment" to "Operational Efficiency" and "Competitive Advantage."<br><span class="key">[Constraints]</span> RAI: No actual budget figures, revenue numbers, or financial projections. Data Accuracy: Risk assessments must be realistic, not exaggerated. Perspective: Acknowledge Finance's concerns while presenting IT's position. Source: Base ROI claims on verifiable industry data.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Vendor Contract Renewal Decision</span>
                        <span class="level-desc">Interactive Analysis</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Software Platform Evaluation</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are an IT Operations Manager using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to make a data-driven recommendation on whether to renew, renegotiate, or replace a critical vendor contract by systematically gathering evidence.<br>
<span class="key">[Tools]</span> You have access to: [UsageAnalytics], [SupportTicketHistory], [FinanceRecords], [StakeholderSurvey]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> The 3-year contract with your project management software vendor expires in 90 days. Procurement is requesting a renewal decision by Friday. The vendor is proposing a 22% price increase citing "enhanced features." Meanwhile, the Engineering Director mentioned teams are frustrated with the platform's performance, and two department heads have asked about switching to alternative solutions. You need to present a recommendation to the CTO with supporting data.<br>
<span class="key">[Constraints]</span> RAI: No actual vendor names, contract values, or internal budget data. Data Accuracy: Base recommendations only on verified tool outputs. Bias: Present balanced analysis of renewal vs. replacement options. Human Oversight: Flag final recommendation for executive approval.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to either accept the renewal to avoid disruption or reject it based on vocal complaints. ReAct forces you to gather actual usage metrics (are we using all our licenses?), support ticket trends (are complaints increasing or isolated?), and stakeholder input (what features do teams actually need?) before committing to a significant multi-year decision. This prevents both unnecessary spending and disruptive migrations based on incomplete information.
                    </div>
                </div>

                <div id="support" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/headset.svg" class="local-icon icon-red" alt="Support"> IT Infrastructure Site Support
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Ticketing & Colleague Support</span><span class="level-desc">Focus: Empathy & Updates (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Ticket Update Communication</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I am working on a support ticket regarding a broken AV system in the main boardroom. The user is frustrated because they have a client meeting tomorrow. We have diagnosed the issue as a faulty HDMI switch, but the replacement part is on backorder and won't arrive for 2 days.<br><span class="key">[Role]</span> Tier 2 Site Support Technician.<br><span class="key">[Instruction]</span> Write a ticket update to the user explaining the delay.<br><span class="key">[Style]</span> Empathetic, Professional, and Transparent.<br><span class="key">[Parameters]</span> Acknowledge their frustration. Provide the estimated arrival date for the part. Offer a temporary workaround (e.g., a portable projector from inventory). Do not make false promises on timing.<br><span class="key">[Constraints]</span> RAI: No user names, ticket numbers, or room identifiers. Data Accuracy: Only promise timelines you can verify with suppliers. Transparency: Be honest about delays without over-explaining internal processes.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Labs & Infrastructure</span><span class="level-desc">Focus: Standards (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Infrastructure Cabling Standards</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are experiencing intermittent connectivity issues in Lab-01 because the previous vendors used poor cabling practices (zip ties, tight bends, no labels). We need to issue a new standard to the Facilities team for all future work in the network closets.<br><span class="key">[Role]</span> Tier 3 Infrastructure Lead.<br><span class="key">[Instruction]</span> Create a checklist of "Cabling Best Practices" that must be followed by all vendors.<br><span class="key">[Style]</span> Technical, Strict, and Safety-Focused.<br><span class="key">[Parameters]</span> Format as a bulleted checklist with clear, actionable requirements.<br><span class="key">[Example]</span> Input: "Make it look neat."<br>Output: "Use Velcro straps every 6 inches for cable management. Zip ties are strictly prohibited to prevent cable crimping and allow future modifications."<br><span class="key">[Constraints]</span> RAI: No facility-specific locations or vendor names. Source Accuracy: Standards must align with industry best practices (TIA/EIA). Data Accuracy: Specifications must be technically correct and verifiable.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Strategy & Development</span><span class="level-desc">Focus: KPI Improvement (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Training Budget Proposal</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Our team's "First Call Resolution" (FCR) KPI has dropped to 65% (target is 80%). The root cause is that the team lacks certification in the new ticketing system module we deployed last month. We need budget approval for official training, but the training budget is currently frozen.<br><span class="key">[Objective]</span> Secure special approval for the certification training budget.<br><span class="key">[Style]</span> Business Case / ROI Analysis.<br><span class="key">[Tone]</span> Professional, Data-driven, and Solution-focused.<br><span class="key">[Audience]</span> The IT Director (who is focused on meeting SLA targets and team performance metrics).<br><span class="key">[Response]</span> A 3-bullet executive summary linking the cost of training directly to the cost of low FCR (ticket re-opens, user downtime, team overtime).<br><span class="key">[Constraints]</span> RAI: No actual budget amounts or vendor pricing. Data Accuracy: KPI claims must be based on real metrics—do not fabricate percentages. Source: ROI calculations should use verifiable industry benchmarks.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Conference Room AV Failure</span>
                        <span class="level-desc">Interactive Troubleshooting</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Executive Presentation Emergency</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Tier 2 Site Support Technician using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to restore conference room functionality before a critical meeting by systematically diagnosing the issue.<br>
<span class="key">[Tools]</span> You have access to: [RoomControlPanel], [NetworkStatus], [DeviceInventory], [CablingDiagram]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> It is 8:47 AM. An executive assistant just called in a P1 ticket: Conference Room 1 display shows "No Signal" and the video conferencing touch panel is unresponsive. A critical all-hands meeting with remote participants starts at 9:30 AM. The room was working fine for a 4:00 PM meeting yesterday. Facilities confirmed no overnight maintenance. The presenter needs to share slides from their laptop to both the in-room display and 50+ remote attendees.<br>
<span class="key">[Constraints]</span> RAI: No actual room names, user names, or network credentials. Data Accuracy: Base diagnosis only on verified tool observations—do not assume causes. Human Oversight: Escalate if solution requires changes to production network configuration.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately swap cables or reboot everything—but with 43 minutes until a critical meeting, random troubleshooting wastes time. ReAct forces you to first identify what changed (was it the display, the room PC, the video matrix, or network?) by checking each component systematically. You might discover the room PC rebooted overnight for updates and failed to reconnect to the network—a 2-minute fix versus replacing hardware that isn't broken.
                    </div>
                </div>

                <div id="data-analyst" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/chart-bar.svg" class="local-icon icon-red" alt="Data"> Data Analyst / Business Intelligence
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Report Generation</span><span class="level-desc">Focus: Clarity (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Dashboard Requirements Gathering</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The Commercial Operations team has requested a new sales dashboard. They mentioned wanting to see "performance metrics" but haven't specified which ones. The current reporting system shows 47 different KPIs across 12 reports, and the team complains about "too much data." I need to facilitate a requirements gathering session to identify the 5-7 most critical metrics for their daily decision-making.<br><span class="key">[Role]</span> Business Intelligence Analyst specializing in stakeholder requirements.<br><span class="key">[Instruction]</span> Create a structured requirements questionnaire to send to the Commercial Operations director before our meeting.<br><span class="key">[Style]</span> Professional and concise—executives have limited time for questionnaires.<br><span class="key">[Parameters]</span> Maximum 10 questions. Focus on business outcomes, not technical specifications. Include questions about decision frequency (daily/weekly/monthly) and data freshness requirements.<br><span class="key">[Constraints]</span> RAI: No actual sales figures, customer names, or proprietary KPI definitions. Privacy: Questions should not elicit confidential business strategy. Data Accuracy: Focus on gathering requirements—do not assume metric definitions.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Data Transformation</span><span class="level-desc">Focus: Logic Documentation (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>ETL Logic Documentation</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I am building an ETL pipeline that consolidates sales data from 3 different regional ERP systems into our data warehouse. Each system uses different product codes, currency formats, and fiscal calendars. I need to document the transformation logic so that future analysts can maintain and troubleshoot the pipeline.<br><span class="key">[Role]</span> Senior Data Engineer responsible for data pipeline documentation.<br><span class="key">[Instruction]</span> Create a data transformation specification document for the product code harmonization step.<br><span class="key">[Style]</span> Technical documentation suitable for developer handoff.<br><span class="key">[Parameters]</span> Include: source field mapping, transformation rules, exception handling logic, and validation checks. Format as a structured specification with clear sections.<br><span class="key">[Example]</span> Source Field: EMEA.product_sku (VARCHAR 20)<br>Transformation: Strip leading zeros, map to global_product_id via lookup table PROD_XREF<br>Exception: If no match found, log to ETL_EXCEPTIONS table with error code 'PROD_UNMAPPED'<br><span class="key">[Constraints]</span> RAI: No actual database schemas, connection strings, or production table names. Data Accuracy: Transformation logic must be technically correct. Security: Never include actual credentials or sensitive system configurations.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Strategic Analytics</span><span class="level-desc">Focus: Insight Delivery (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Executive Analytics Presentation</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Analysis of our clinical trial portfolio shows that Phase 2 studies are taking 40% longer than industry benchmarks. The data suggests the primary driver is delayed site activation, but there are confounding factors including a recent change in our CRO partner and increased regulatory requirements in key markets. The Head of Clinical Operations has requested a data-driven presentation for the R&D Leadership Team.<br><span class="key">[Objective]</span> Present the analysis findings in a way that drives action without creating blame or defensiveness among stakeholders.<br><span class="key">[Style]</span> Executive presentation with data visualization recommendations.<br><span class="key">[Tone]</span> Constructive and solution-oriented. Present findings as opportunities for improvement, not failures.<br><span class="key">[Audience]</span> R&D Leadership Team (SVP R&D, VP Clinical Operations, VP Regulatory, CFO).<br><span class="key">[Response]</span> An executive summary with: (1) Key Finding headline, (2) Supporting data visualization recommendations, (3) Root cause analysis (multi-factor), (4) Recommended actions with expected impact, (5) Data limitations and caveats.<br><span class="key">[Constraints]</span> RAI: No actual study names, patient counts, or vendor identities. Data Accuracy: Benchmarks must be from verifiable industry sources. Uncertainty: Clearly state limitations and caveats. Perspective: Present balanced multi-factor analysis without assigning blame.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Data Quality Investigation</span>
                        <span class="level-desc">Interactive Analysis</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Anomaly Root Cause Analysis</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Senior Data Analyst using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to investigate a data anomaly identified in a critical business report and determine whether it represents a real business change or a data quality issue.<br>
<span class="key">[Tools]</span> You have access to: [DataWarehouse], [SourceSystemLogs], [ETL_JobHistory], [DataLineage], [BusinessCalendar]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> The monthly revenue report shows a 35% spike in Product-A sales for the APAC region last week. The Commercial team says they had no promotions or major deals close. Finance is concerned this might be a duplicate booking or currency conversion error. The CFO needs an explanation before the board meeting tomorrow.<br>
<span class="key">[Constraints]</span> RAI: No actual revenue figures, customer names, or product identifiers. Data Accuracy: Conclusions must be based on verified tool outputs only. Uncertainty: Clearly distinguish between confirmed facts and hypotheses. Human Oversight: Flag conclusions for business validation before reporting.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately check the raw data and make a quick determination. ReAct forces you to systematically verify the data pipeline (did ETL run correctly?), check source system integrity, validate currency conversion rates for that period, and review the business calendar for any regional events before concluding. This prevents embarrassing retractions and ensures confident reporting to leadership.
                    </div>
                </div>

                <div id="cybersecurity" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/shield.svg" class="local-icon icon-red" alt="Security"> Cybersecurity Analyst
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Security Awareness</span><span class="level-desc">Focus: Communication (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Phishing Alert Communication</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We detected a targeted phishing campaign hitting employees in our Finance department. The emails appear to come from a known vendor and request urgent invoice payment via a spoofed link. Three employees have already clicked the link, though our web filter blocked the malicious payload. We need to alert all employees quickly while avoiding panic.<br><span class="key">[Role]</span> Security Operations Analyst responsible for security communications.<br><span class="key">[Instruction]</span> Draft an urgent security alert email to all employees about this phishing campaign.<br><span class="key">[Style]</span> Urgent but calm—create awareness without causing panic or blame.<br><span class="key">[Parameters]</span> Include: what to look for (specific indicators), what to do if they receive the email, what to do if they already clicked, and who to contact. Keep under 200 words. Do not name the employees who clicked.<br><span class="key">[Constraints]</span> RAI: No employee names, vendor names, or specific URL indicators that could aid attackers. Privacy: Protect identity of affected employees. Data Accuracy: Only include verified threat indicators. Perspective: Balance urgency with calm—avoid panic-inducing language.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Vulnerability Assessment</span><span class="level-desc">Focus: Risk Prioritization (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Vulnerability Remediation Report</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Our quarterly vulnerability scan identified 847 vulnerabilities across 200+ systems. The IT Operations team is overwhelmed and asking for prioritization guidance. We need to identify the critical vulnerabilities that require immediate remediation versus those that can be addressed in regular patch cycles.<br><span class="key">[Role]</span> Vulnerability Management Analyst responsible for risk-based prioritization.<br><span class="key">[Instruction]</span> Create a vulnerability prioritization framework and apply it to categorize vulnerabilities into remediation tiers.<br><span class="key">[Style]</span> Technical risk assessment with clear action items.<br><span class="key">[Parameters]</span> Define 4 tiers (Critical/High/Medium/Low) with specific criteria including CVSS score, exploitability, asset criticality, and exposure. Format as a decision matrix with remediation SLAs for each tier.<br><span class="key">[Example]</span> Tier 1 (Critical): CVSS 9.0+ AND publicly exploited AND internet-facing = Remediate within 24 hours<br>Tier 2 (High): CVSS 7.0-8.9 OR internal system with sensitive data = Remediate within 7 days<br><span class="key">[Constraints]</span> RAI: No actual CVE numbers, system names, or IP addresses. Data Accuracy: CVSS scores and SLAs must align with industry standards. Source: Base framework on recognized standards (NIST, CISA KEV). Security: Never expose actual vulnerability details externally.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Security Architecture</span><span class="level-desc">Focus: Risk Management (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Cloud Security Assessment</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company is planning to migrate our clinical trial management system to a cloud-based SaaS platform. The vendor has provided their SOC 2 Type II report and security documentation. However, the system will process sensitive patient data and is subject to FDA 21 CFR Part 11 requirements. The project team is eager to proceed, but Security has not completed the risk assessment.<br><span class="key">[Objective]</span> Conduct a security risk assessment that identifies gaps and provides actionable recommendations for secure implementation.<br><span class="key">[Style]</span> Security risk assessment memo with compliance mapping.<br><span class="key">[Tone]</span> Thorough but constructive—identify risks without blocking progress. Focus on mitigation, not rejection.<br><span class="key">[Audience]</span> IT Steering Committee (CIO, CISO, VP Clinical Operations, Compliance Officer).<br><span class="key">[Response]</span> A risk assessment including: (1) Vendor Security Posture Summary, (2) Gap Analysis against 21 CFR Part 11 requirements, (3) Data Flow and Boundary Analysis, (4) Identified Risks with Likelihood and Impact, (5) Recommended Controls and Mitigations, (6) Residual Risk Acceptance Criteria.<br><span class="key">[Constraints]</span> RAI: No PHI, vendor names, or proprietary system details. Source Accuracy: Regulatory requirements must be accurately cited. Perspective: Balance security concerns with business objectives. Human Oversight: Flag risk acceptance decisions for leadership approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Security Incident Response</span>
                        <span class="level-desc">Interactive Investigation</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Suspicious Activity Investigation</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Security Operations Analyst using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to investigate a potential security incident and determine the scope and severity before escalating to incident response.<br>
<span class="key">[Tools]</span> You have access to: [SIEM], [EDR_Console], [ActiveDirectory], [NetworkLogs], [ThreatIntelligence]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> The SIEM generated an alert for "Anomalous PowerShell Activity" on a workstation belonging to a Finance department employee. The alert shows encoded PowerShell commands executed at 2:47 AM local time. The employee claims they were not at work at that time. The workstation has access to financial systems and shared drives containing sensitive data.<br>
<span class="key">[Constraints]</span> RAI: No employee names, hostnames, or actual malware indicators. Data Accuracy: Base conclusions only on verified evidence from tools. Security: Do not share IOCs externally without authorization. Human Oversight: Escalate confirmed incidents to IR team before containment actions.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately isolate the machine and declare an incident. ReAct forces you to first verify the activity (was it legitimate automation or scheduled task?), check for lateral movement indicators, review the user's recent authentication patterns, and correlate with threat intelligence before determining severity. This prevents both over-reaction (disrupting business for a false positive) and under-reaction (missing actual compromise indicators).
                    </div>
                </div>

                <div id="sysadmin" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/cube.svg" class="local-icon icon-red" alt="Server"> Systems Administrator
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">System Maintenance</span><span class="level-desc">Focus: Documentation (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Change Request Documentation</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We need to apply critical security patches to 15 Windows servers in the production environment. The change requires a 30-minute maintenance window and server reboots. The Change Advisory Board meets tomorrow and requires detailed documentation before approving any production changes.<br><span class="key">[Role]</span> Systems Administrator responsible for change management documentation.<br><span class="key">[Instruction]</span> Draft a Change Request document for the patch deployment.<br><span class="key">[Style]</span> Formal change management format—structured, thorough, and risk-aware.<br><span class="key">[Parameters]</span> Include: change description, business justification, risk assessment (what could go wrong), rollback plan, testing approach, and required approvals. Follow ITIL change management best practices.<br><span class="key">[Constraints]</span> RAI: No actual server names, IP addresses, or patch KB numbers. Data Accuracy: Risk assessments must be realistic and complete. Source: Follow ITIL best practices for change management. Human Oversight: All production changes require CAB approval.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Automation Scripting</span><span class="level-desc">Focus: Code Quality (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Server Health Check Script</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I need to automate daily health checks across 50 Windows servers. Currently, this is done manually by checking disk space, memory usage, service status, and event logs. The script should generate a summary report and alert on any critical issues found.<br><span class="key">[Role]</span> Senior Systems Administrator with PowerShell expertise.<br><span class="key">[Instruction]</span> Write a PowerShell script that performs automated health checks and generates a summary report.<br><span class="key">[Style]</span> Production-quality code with proper error handling and logging.<br><span class="key">[Parameters]</span> Check: disk space (alert if below 10%), memory usage (alert if above 90%), critical Windows services status, and critical/error events in the last 24 hours. Output results to both console and CSV file.<br><span class="key">[Example]</span> # Expected output format:<br>Server: SRV-PROD-01<br>Disk C: 45% free - OK<br>Memory: 72% used - OK<br>Services: All critical services running<br>Events: 2 errors found (see details)<br><span class="key">[Constraints]</span> RAI: No hardcoded credentials or actual server names. Security: Script must not store or log passwords. Data Accuracy: Thresholds must match actual monitoring standards. Source: Follow PowerShell best practices for production scripts.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Infrastructure Planning</span><span class="level-desc">Focus: Capacity Management (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Infrastructure Capacity Assessment</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Our data center is approaching capacity limits. Current utilization is at 78% for compute, 85% for storage, and 70% for network bandwidth. A new business initiative will deploy 3 new applications over the next 18 months, each with significant infrastructure requirements. Leadership needs to decide between expanding on-premises capacity or accelerating cloud migration.<br><span class="key">[Objective]</span> Provide a capacity analysis that quantifies the gap and evaluates options for addressing future growth.<br><span class="key">[Style]</span> Technical capacity planning document with financial analysis.<br><span class="key">[Tone]</span> Data-driven and objective. Present both options fairly without predetermined bias.<br><span class="key">[Audience]</span> IT Leadership Team (CIO, Director of Infrastructure, Finance Business Partner).<br><span class="key">[Response]</span> A capacity assessment including: (1) Current State Analysis, (2) Projected Demand (18-month forecast), (3) Gap Analysis, (4) Option 1: On-Premises Expansion (scope, timeline, cost), (5) Option 2: Cloud Migration (scope, timeline, cost), (6) Hybrid Option Analysis, (7) Recommendation with Rationale.<br><span class="key">[Constraints]</span> RAI: No actual pricing, vendor quotes, or proprietary capacity data. Data Accuracy: Projections must be based on stated assumptions—not fabricated. Bias: Present balanced analysis of all options. Uncertainty: Clearly state assumptions and limitations in forecasts.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Production Server Issue</span>
                        <span class="level-desc">Interactive Troubleshooting</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Server Performance Degradation</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Senior Systems Administrator using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to diagnose and resolve a production server performance issue while minimizing business disruption.<br>
<span class="key">[Tools]</span> You have access to: [PerformanceMonitor], [EventViewer], [TaskManager], [ResourceMonitor], [ServiceControl]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> Users are reporting that the document management application is extremely slow this morning. The application runs on a dedicated Windows Server. Initial reports show the server has been up for 47 days, and performance was fine until this morning. No changes were deployed over the weekend. CPU is showing 95% utilization but memory and disk I/O appear normal.<br>
<span class="key">[Constraints]</span> RAI: No actual server names, user names, or application identifiers. Data Accuracy: Base diagnosis only on verified tool outputs. Human Oversight: Restart decisions require impact assessment first. Security: Do not expose actual performance data externally.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to restart the server immediately since it's been up for 47 days. ReAct forces you to first identify what process is consuming CPU (legitimate workload or runaway process?), check if scheduled tasks or antivirus scans are running, and verify there's no memory leak building before taking disruptive action. You might discover a scheduled index rebuild that's legitimate but was misconfigured to run during business hours.
                    </div>
                </div>

                <div id="dba" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/layers.svg" class="local-icon icon-red" alt="Database"> Database Administrator
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Query Optimization</span><span class="level-desc">Focus: Performance (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Slow Query Analysis</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A report query that normally runs in 3 seconds is now taking over 2 minutes. The query pulls sales data for the past 12 months with multiple joins across product, customer, and transaction tables. No schema changes were made, but the database has grown by 40% since the query was originally written.<br><span class="key">[Role]</span> Database Administrator specializing in query performance tuning.<br><span class="key">[Instruction]</span> Analyze the query execution plan and recommend optimization strategies.<br><span class="key">[Style]</span> Technical analysis with actionable recommendations.<br><span class="key">[Parameters]</span> Focus on: index analysis, join optimization, and statistics freshness. Provide specific recommendations ranked by expected impact. Do not rewrite the entire query—suggest targeted improvements.<br><span class="key">[Constraints]</span> RAI: No actual table names, column names, or customer data. Data Accuracy: Recommendations must be technically sound. Source: Base advice on established SQL optimization principles. Security: Never expose actual query logic or schema details.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Backup & Recovery</span><span class="level-desc">Focus: Procedures (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Disaster Recovery Runbook</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We need to document the disaster recovery procedure for our primary clinical database. The database is SQL Server with a 2TB dataset. Our RPO is 1 hour and RTO is 4 hours. We have log shipping to a secondary site and daily full backups to tape. The procedure must be executable by an on-call DBA who may not be familiar with this specific database.<br><span class="key">[Role]</span> Senior Database Administrator responsible for disaster recovery planning.<br><span class="key">[Instruction]</span> Create a step-by-step disaster recovery runbook for database failover and recovery.<br><span class="key">[Style]</span> Operational runbook format—clear, sequential, and idiot-proof.<br><span class="key">[Parameters]</span> Include: pre-requisites checklist, decision tree for failover scenarios, step-by-step commands with expected outputs, verification steps, and rollback procedures. Format with numbered steps and command blocks.<br><span class="key">[Example]</span> Step 1: Verify primary server status<br>Command: Test-Connection -ComputerName SQLPROD01<br>Expected: Request timed out (confirms primary is down)<br>If successful: STOP - Primary is online, do not proceed with failover<br><span class="key">[Constraints]</span> RAI: No actual server names, connection strings, or credentials. Data Accuracy: Procedures must be technically accurate and tested. Security: Never include actual passwords or authentication details. Human Oversight: Critical failover decisions require management notification.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Architecture Design</span><span class="level-desc">Focus: Scalability (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Database Migration Strategy</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company is consolidating 5 legacy Oracle databases onto a modern SQL Server platform as part of a broader infrastructure modernization initiative. The databases support critical manufacturing and quality systems. Total data volume is approximately 8TB with complex interdependencies and custom stored procedures. The project has a 12-month timeline and zero-tolerance for data loss.<br><span class="key">[Objective]</span> Design a migration strategy that minimizes risk and business disruption while meeting the timeline.<br><span class="key">[Style]</span> Technical migration strategy document.<br><span class="key">[Tone]</span> Thorough and risk-aware. Acknowledge complexity without being pessimistic.<br><span class="key">[Audience]</span> IT Steering Committee and Application Owners.<br><span class="key">[Response]</span> A migration strategy including: (1) Assessment Methodology, (2) Database Prioritization and Sequencing, (3) Data Migration Approach (big bang vs. phased), (4) Schema Conversion Considerations, (5) Testing Strategy, (6) Cutover Planning, (7) Risk Register with Mitigations, (8) Resource and Timeline Estimates.<br><span class="key">[Constraints]</span> RAI: No actual system names, data volumes, or proprietary schemas. Data Accuracy: Migration approaches must be technically sound. Bias: Present balanced risk/benefit analysis. Human Oversight: Major cutover decisions require business sign-off.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Database Performance Crisis</span>
                        <span class="level-desc">Interactive Diagnosis</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Production Database Slowdown</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Senior Database Administrator using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to diagnose and resolve a critical production database performance issue affecting multiple applications.<br>
<span class="key">[Tools]</span> You have access to: [DMV_Queries], [ExecutionPlans], [WaitStatistics], [BlockingAnalysis], [TempDBUsage]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> Multiple applications are reporting database timeouts starting at 9:15 AM. The database server CPU is at 45% and memory is normal. The application teams say nothing changed on their end. However, the batch processing team mentions they started a new monthly report job at 9:00 AM that they've never run before. Hundreds of users are affected and the Service Desk is overwhelmed with tickets.<br>
<span class="key">[Constraints]</span> RAI: No actual query text, database names, or user identifiers. Data Accuracy: Conclusions must be based on verified DMV/tool outputs only. Human Oversight: Terminating batch jobs requires business impact assessment. Security: Do not expose execution plans or performance data externally.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately kill the new batch job since it correlates with the issue. ReAct forces you to first verify the actual bottleneck (is it blocking, waits, tempdb contention?), understand what the batch job is doing and whether killing it mid-transaction could cause data integrity issues, and identify if there are other contributing factors. This prevents making the situation worse by creating orphaned transactions or incomplete data states.
                    </div>
                </div>

                <div id="devops" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/codes.svg" class="local-icon icon-red" alt="DevOps"> Cloud / DevOps Engineer
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Pipeline Maintenance</span><span class="level-desc">Focus: Troubleshooting (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>CI/CD Pipeline Failure Analysis</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The nightly build pipeline has failed for the third consecutive night. The error message indicates a test timeout, but the same tests pass when developers run them locally. The pipeline runs in a containerized environment and was working fine until a week ago when we updated the base Docker image.<br><span class="key">[Role]</span> DevOps Engineer responsible for CI/CD pipeline maintenance.<br><span class="key">[Instruction]</span> Create a troubleshooting checklist to diagnose the pipeline failure.<br><span class="key">[Style]</span> Systematic troubleshooting guide with specific commands to run.<br><span class="key">[Parameters]</span> Focus on: environment differences (local vs. pipeline), resource constraints, timing issues, and recent changes. Include specific diagnostic commands for each check.<br><span class="key">[Constraints]</span> RAI: No actual pipeline names, repository URLs, or credentials. Security: Never include secrets, tokens, or API keys in diagnostics. Data Accuracy: Commands must be technically correct. Source: Follow CI/CD troubleshooting best practices.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Infrastructure as Code</span><span class="level-desc">Focus: Best Practices (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Terraform Module Development</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We need to create a reusable Terraform module for provisioning application environments in AWS. Each environment needs: a VPC with public/private subnets, an Application Load Balancer, an ECS cluster with Fargate, and RDS PostgreSQL. The module must support multiple environments (dev, staging, prod) with appropriate sizing for each.<br><span class="key">[Role]</span> Senior DevOps Engineer specializing in Infrastructure as Code.<br><span class="key">[Instruction]</span> Design the Terraform module structure with variable definitions and outputs.<br><span class="key">[Style]</span> Production-quality IaC following Terraform best practices.<br><span class="key">[Parameters]</span> Include: module structure, input variables with sensible defaults, output values, and environment-specific sizing. Follow DRY principles and support flexible configuration.<br><span class="key">[Example]</span> variable "environment" {<br>  type = string<br>  description = "Environment name (dev/staging/prod)"<br>  validation {<br>    condition = contains(["dev", "staging", "prod"], var.environment)<br>    error_message = "Environment must be dev, staging, or prod."<br>  }<br>}<br><span class="key">[Constraints]</span> RAI: No actual AWS account IDs, VPC CIDRs, or resource ARNs. Security: Never hardcode credentials or secrets—use variables. Data Accuracy: Code must be syntactically correct Terraform. Source: Follow HashiCorp Terraform best practices.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Platform Strategy</span><span class="level-desc">Focus: Architecture (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Container Platform Selection</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company is standardizing on container-based deployment for all new applications. We need to select between managing our own Kubernetes clusters (EKS) versus using a fully managed platform (AWS App Runner or ECS Fargate). We have 15 applications to migrate over 18 months. The team has limited Kubernetes experience but strong AWS skills. Compliance requires we maintain audit logs and implement specific security controls.<br><span class="key">[Objective]</span> Provide a platform recommendation that balances operational complexity, cost, and compliance requirements.<br><span class="key">[Style]</span> Technical architecture decision document.<br><span class="key">[Tone]</span> Balanced and practical. Acknowledge trade-offs honestly.<br><span class="key">[Audience]</span> CTO, Director of Engineering, and Security Architect.<br><span class="key">[Response]</span> A platform analysis including: (1) Requirements Summary, (2) Option Analysis (EKS vs. ECS Fargate vs. App Runner), (3) Compliance Mapping, (4) Operational Complexity Assessment, (5) Cost Comparison (3-year TCO), (6) Team Skill Gap Analysis, (7) Migration Approach per Option, (8) Final Recommendation with Rationale.<br><span class="key">[Constraints]</span> RAI: No actual pricing quotes or proprietary architecture details. Data Accuracy: TCO estimates must use published pricing models. Bias: Present balanced analysis of all options. Source: Base recommendations on documented platform capabilities.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Deployment Rollback Decision</span>
                        <span class="level-desc">Interactive Assessment</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Production Deployment Issue</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Senior DevOps Engineer using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to assess a problematic production deployment and decide whether to proceed, fix forward, or rollback.<br>
<span class="key">[Tools]</span> You have access to: [DeploymentLogs], [ApplicationMetrics], [ErrorTracking], [FeatureFlags], [RollbackProcedure]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> A deployment completed 15 minutes ago. Error rates have increased from 0.1% to 2.3%. The deployment included both a database schema change and application code changes. The schema migration added a new column and modified an index. 85% of users appear unaffected based on successful transaction metrics, but customer support is receiving complaints about checkout failures.<br>
<span class="key">[Constraints]</span> RAI: No actual error messages, user data, or transaction details. Data Accuracy: Decisions must be based on verified metrics only. Human Oversight: Rollback decisions with data implications require approval. Security: Do not expose production metrics externally.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately rollback given the error spike. ReAct forces you to first determine if rollback is even safe (can we reverse the schema change without data loss?), identify which specific functionality is failing (is it the new code or existing code affected by the schema?), and assess whether feature flags could disable the problematic feature without full rollback. This prevents making the situation worse with a botched rollback of irreversible database changes.
                    </div>
                </div>

                <div id="it-pm" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/calendar.svg" class="local-icon icon-red" alt="PM"> IT Project Manager
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Status Reporting</span><span class="level-desc">Focus: Communication (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Stakeholder Status Update</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The ERP implementation project is in Week 8 of a 24-week timeline. We completed the design phase on schedule, but the build phase is 1 week behind due to delayed vendor resource allocation. The vendor has committed additional resources starting next week. The project sponsor is asking for a status update before the steering committee meeting.<br><span class="key">[Role]</span> IT Project Manager responsible for executive stakeholder communication.<br><span class="key">[Instruction]</span> Write a concise status update email for the project sponsor.<br><span class="key">[Style]</span> Executive summary format—lead with the headline, then details.<br><span class="key">[Parameters]</span> Use RAG status (Red/Amber/Green) format. Include: overall status, key accomplishments, current risks, and mitigation actions. Keep under 200 words. Be transparent about the delay but confident about recovery.<br><span class="key">[Constraints]</span> RAI: No actual project names, budget figures, or vendor identities. Data Accuracy: Status must accurately reflect real project state—no sugar-coating. Transparency: Be honest about delays and risks. Human Oversight: Critical status changes require sponsor acknowledgment.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Risk Management</span><span class="level-desc">Focus: Assessment (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Project Risk Register</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are initiating a new project to implement a laboratory information management system (LIMS) across 5 manufacturing sites. The project has a 12-month timeline and $2M budget. Key dependencies include vendor selection (in progress), site infrastructure upgrades, and regulatory validation requirements. I need to establish the initial risk register for the project kick-off meeting.<br><span class="key">[Role]</span> Senior IT Project Manager specializing in GxP system implementations.<br><span class="key">[Instruction]</span> Create an initial risk register with the top 10 project risks.<br><span class="key">[Style]</span> Formal project management documentation following PMI standards.<br><span class="key">[Parameters]</span> Format as a table with columns: Risk ID, Description, Category, Probability (H/M/L), Impact (H/M/L), Risk Score, Mitigation Strategy, Owner, Status. Focus on risks specific to pharmaceutical manufacturing system implementations.<br><span class="key">[Example]</span> | R001 | Vendor delays validation documentation delivery | Vendor | M | H | 6 | Include documentation SLA in contract with penalty clause | PM | Open |<br><span class="key">[Constraints]</span> RAI: No actual project names, budgets, or vendor names. Data Accuracy: Risk assessments must be realistic for pharma implementations. Source: Follow PMI and GxP risk management best practices. Perspective: Include both technical and regulatory risks.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Program Recovery</span><span class="level-desc">Focus: Turnaround Strategy (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Troubled Project Recovery Plan</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A critical data center migration project is severely off-track. Original timeline was 9 months; we are now at month 11 with approximately 60% completion. Budget has been exceeded by 35%. Root causes include scope creep, resource turnover, and vendor underperformance. Executive leadership is considering canceling the project, but we have already decommissioned 40% of the legacy infrastructure with no rollback option.<br><span class="key">[Objective]</span> Develop a recovery plan that gets the project back on track with realistic expectations and appropriate governance.<br><span class="key">[Style]</span> Project recovery assessment and plan.<br><span class="key">[Tone]</span> Honest about past failures but forward-looking. Take accountability without dwelling on blame.<br><span class="key">[Audience]</span> Executive Steering Committee (CIO, CFO, VP Operations) who are frustrated and skeptical.<br><span class="key">[Response]</span> A recovery plan including: (1) Honest Assessment of Current State, (2) Root Cause Analysis (categorized), (3) Revised Scope (what's in, what's deferred), (4) Realistic Timeline to Completion, (5) Additional Resource/Budget Requirements, (6) Enhanced Governance Model, (7) Key Milestones with Go/No-Go Decision Points, (8) Risk of Cancellation vs. Continuation.<br><span class="key">[Constraints]</span> RAI: No actual project names, budget figures, or vendor identities. Data Accuracy: Timelines and estimates must be realistic. Transparency: Be honest about failures and challenges. Bias: Present balanced cancellation vs. continuation analysis. Human Oversight: Major recovery decisions require executive approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Resource Conflict Resolution</span>
                        <span class="level-desc">Interactive Problem Solving</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Critical Resource Shortage</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are an IT Project Manager using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to resolve a critical resource conflict that threatens your project timeline by gathering information and negotiating solutions.<br>
<span class="key">[Tools]</span> You have access to: [ResourceSchedule], [ProjectPortfolio], [SkillsInventory], [StakeholderDirectory], [BudgetTracker]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> Your lead developer just informed you they've been assigned to another "higher priority" project starting next week. They are the only person with expertise in the legacy system integration that is on your critical path. The work cannot be delayed without pushing your go-live date, which has contractual implications with an external partner. You have 3 days to find a solution.<br><span class="key">[Constraints]</span> RAI: No actual employee names, project names, or partner identities. Data Accuracy: Resource availability must reflect real allocation. Transparency: Be honest about timeline impacts. Human Oversight: Escalation decisions require management approval.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately escalate to leadership demanding resource priority. ReAct forces you to first understand the other project's constraints (is the "higher priority" assignment negotiable?), identify alternative resources or contractors, assess whether the critical path work can be restructured, and prepare a business case with quantified impact before escalating. This positions you for a productive negotiation rather than a conflict.
                    </div>
                </div>

                <div id="network" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/cube.svg" class="local-icon icon-red" alt="Network"> Network Engineer
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Network Troubleshooting</span><span class="level-desc">Focus: Methodology (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Connectivity Issue Diagnosis</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Users in Building B are reporting intermittent connectivity issues to the file server located in Building A. The issues started after a power outage last night. Building B has its own network closet with a core switch that connects via fiber to the main data center in Building A. Ping tests show 15% packet loss to the file server from affected workstations.<br><span class="key">[Role]</span> Network Engineer responsible for campus network support.<br><span class="key">[Instruction]</span> Create a structured troubleshooting approach to diagnose this connectivity issue.<br><span class="key">[Style]</span> Systematic troubleshooting methodology—OSI layer approach.<br><span class="key">[Parameters]</span> Work from Layer 1 up. Include specific commands to run at each step, expected outputs for success/failure, and decision points for escalation. Focus on the most likely causes given the power outage context.<br><span class="key">[Constraints]</span> RAI: No actual IP addresses, hostnames, or site identifiers. Data Accuracy: Commands must be valid for the described equipment. Security: Do not expose network topology details. Human Oversight: Physical layer changes require on-site verification.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Network Configuration</span><span class="level-desc">Focus: Security (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Firewall Rule Documentation</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are deploying a new application that requires connectivity between the corporate network and a cloud-hosted service. The security team requires detailed documentation of all firewall rules before approval. The application needs outbound HTTPS to the vendor API, inbound webhook callbacks from the vendor to our application server, and database replication between on-premises and cloud.<br><span class="key">[Role]</span> Network Engineer responsible for firewall change requests.<br><span class="key">[Instruction]</span> Document the required firewall rules for security team review.<br><span class="key">[Style]</span> Formal firewall change request format with security justification.<br><span class="key">[Parameters]</span> Format as a table with: Rule Name, Source, Destination, Port/Protocol, Direction, Business Justification, Expiration (if temporary). Apply principle of least privilege—be as specific as possible with IPs and ports.<br><span class="key">[Example]</span> | Rule Name | Source | Destination | Port/Protocol | Direction | Justification | Expiration |<br>|-----------|--------|-------------|---------------|-----------|---------------|------------|<br>| APP-API-OUT | 10.1.50.25/32 | api.vendor.com | 443/TCP | Outbound | Application API calls | Permanent |<br><span class="key">[Constraints]</span> RAI: Use example IPs only—no production addresses. Security: Apply least privilege principle. Data Accuracy: Port/protocol must match actual application requirements. Human Oversight: All firewall changes require security team approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Network Architecture</span><span class="level-desc">Focus: Design (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Network Segmentation Strategy</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Following a security assessment, we need to implement network segmentation to isolate our manufacturing systems (OT network) from the corporate IT network. Currently, everything is on a flat network with minimal segmentation. The manufacturing systems include PLCs, SCADA systems, and lab instruments that cannot tolerate network latency. Some systems require connectivity to corporate systems for data transfer.<br><span class="key">[Objective]</span> Design a network segmentation architecture that improves security posture while maintaining operational requirements.<br><span class="key">[Style]</span> Network architecture design document.<br><span class="key">[Tone]</span> Security-conscious but pragmatic about operational constraints.<br><span class="key">[Audience]</span> CISO, Director of Manufacturing, and IT Leadership.<br><span class="key">[Response]</span> A segmentation design including: (1) Current State Network Diagram, (2) Proposed Segmentation Zones, (3) Traffic Flow Matrix, (4) Security Controls per Zone, (5) Data Diode/DMZ Requirements for OT-IT Connectivity, (6) Implementation Phases, (7) Risk Assessment (security improvement vs. operational risk), (8) Testing and Validation Approach.<br><span class="key">[Constraints]</span> RAI: No actual IP ranges, vendor names, or site identifiers. Security: Follow IEC 62443 and NIST guidelines for OT segmentation. Bias: Present balanced operational vs. security trade-offs. Human Oversight: OT changes require manufacturing and safety team approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Network Outage Response</span>
                        <span class="level-desc">Interactive Troubleshooting</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Site Connectivity Loss</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Senior Network Engineer using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to diagnose and restore connectivity to a remote site that has lost network access to headquarters.<br>
<span class="key">[Tools]</span> You have access to: [NetworkMonitoring], [RouterCLI], [CircuitProvider_Portal], [BGP_Status], [SiteContactDirectory]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> At 7:15 AM, monitoring alerts indicated complete loss of connectivity to Site-005, a manufacturing facility with 150 users. The site has a primary MPLS circuit and a backup internet VPN connection—both appear down. A user at the site called the help desk using their cell phone and confirmed "nothing is working." The site is 200 miles away and the nearest field technician is 2 hours out.<br><span class="key">[Constraints]</span> RAI: No actual site names, circuit IDs, or provider details. Data Accuracy: Troubleshooting steps must follow logical diagnostic sequence. Security: Do not expose monitoring credentials or network topology. Human Oversight: Dispatch decisions require manager approval for cost implications.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately dispatch a technician. ReAct forces you to first verify the scope (is it the circuits, the site equipment, or a local power issue?), check with the circuit provider for outage reports, attempt remote access via alternate paths (4G backup?), and gather information from on-site personnel before committing to a 4-hour round trip. You might discover it's a provider outage with a 30-minute ETA for restoration, saving unnecessary travel.
                    </div>
                </div>

                <div id="regulatory" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/clipboard.svg" class="local-icon icon-red" alt="Regulatory"> Regulatory Affairs Specialist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Regulatory Intelligence</span><span class="level-desc">Focus: Summarization (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Guidance Document Summary</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The FDA just released a new draft guidance on post-market surveillance requirements for medical devices. The document is 47 pages. Our regulatory team needs a concise summary highlighting what has changed from the previous guidance and what actions our company may need to take.<br><span class="key">[Role]</span> Senior Regulatory Affairs Specialist with expertise in FDA medical device regulations.<br><span class="key">[Instruction]</span> Summarize the key changes in this guidance document and identify potential compliance gaps for a mid-sized device manufacturer.<br><span class="key">[Style]</span> Executive briefing format—clear, factual, and action-oriented.<br><span class="key">[Parameters]</span> Limit to 300 words. Structure as: (1) Key Changes, (2) Timeline Implications, (3) Recommended Actions.<br><span class="key">[Constraints]</span> Source Accuracy: Reference only official FDA guidance documents. Temporal Accuracy: Note guidance publication date and comment period deadlines. Data Accuracy: Do not speculate on final rule requirements. Human Oversight: Regulatory interpretations require legal/regulatory leadership review.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Submission Preparation</span><span class="level-desc">Focus: Checklists (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Regulatory Submission Checklist</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are preparing a regulatory submission for Product-A, a combination product with both drug and device components. The submission is due in 60 days. Multiple departments (CMC, Nonclinical, Clinical, Regulatory) must contribute sections, and we need a master checklist to track deliverables.<br><span class="key">[Role]</span> Regulatory Project Manager responsible for submission coordination.<br><span class="key">[Instruction]</span> Create a comprehensive submission checklist with all required modules and their dependencies.<br><span class="key">[Style]</span> Project management format with clear ownership assignments.<br><span class="key">[Parameters]</span> Format as a Markdown Table with columns: Module, Description, Owner, Dependency, Due Date (relative to submission).<br><span class="key">[Example]</span> | Module | Description | Owner | Dependency | Due Date |<br>|--------|-------------|-------|------------|----------|<br>| 2.7.1 | Summary of Biopharmaceutic Studies | CMC | Bioanalytical reports | D-45 |<br><span class="key">[Constraints]</span> RAI: Use generic product names and placeholder dates. Source Accuracy: Module requirements per ICH CTD format. Data Accuracy: Dependencies must reflect actual workflow. Human Oversight: Final checklist requires regulatory lead approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Regulatory Strategy</span><span class="level-desc">Focus: Pathway Analysis (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Regulatory Pathway Recommendation</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are developing Product-B, a novel therapeutic with a mechanism of action similar to an existing approved drug but targeting a different indication. The commercial team is pushing for the fastest path to market. However, the clinical team has concerns about the data package required. We need to evaluate whether to pursue the standard approval pathway or seek expedited designation.<br><span class="key">[Objective]</span> Provide a regulatory pathway analysis comparing standard vs. expedited options with a clear recommendation.<br><span class="key">[Style]</span> Strategic regulatory assessment memo.<br><span class="key">[Tone]</span> Analytical, balanced, and risk-aware. Acknowledge commercial pressures while being honest about regulatory realities.<br><span class="key">[Audience]</span> The Regulatory Strategy Committee (VP Regulatory, VP Clinical, VP Commercial).<br><span class="key">[Response]</span> A 2-page analysis covering: (1) Pathway options with pros/cons, (2) Precedent analysis from similar products, (3) Risk assessment for each pathway, (4) Final recommendation with rationale.<br><span class="key">[Constraints]</span> RAI: No actual product names, competitor names, or clinical data. Source Accuracy: Pathway criteria per current FDA guidance. Bias: Present balanced analysis of expedited vs. standard pathways. Human Oversight: Strategic decisions require regulatory committee approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Health Authority Query Response</span>
                        <span class="level-desc">Interactive Problem Solving</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Information Request Triage</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Senior Regulatory Affairs Specialist using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to coordinate a response to a health authority Information Request (IR) by systematically gathering input from cross-functional teams before drafting the response.<br>
<span class="key">[Tools]</span> You have access to: [SubmissionArchive], [SME_Directory], [ResponseTemplates], [TimelineCalculator]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> The health authority has issued an IR with 5 questions regarding the CMC section of our Product-A submission. The response is due in 30 calendar days. Question 3 references data that was generated by a CRO that has since been acquired by another company. Question 5 asks for a comparison to a competitor product that we did not include in our original submission.<br><span class="key">[Constraints]</span> RAI: No actual submission numbers, CRO names, or competitor products. Data Accuracy: Response timelines must reflect actual regulatory deadlines. Source Accuracy: Data references must be traceable. Human Oversight: IR responses require regulatory and legal review before submission.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately assign questions to SMEs and start drafting. ReAct forces you to first assess the complexity of each question, identify data availability issues (like the CRO acquisition), and flag strategic concerns (like the competitor comparison request) before committing to a timeline. This prevents last-minute surprises and ensures the response strategy is aligned across functions.
                    </div>
                </div>

                <div id="qa" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/shield.svg" class="local-icon icon-red" alt="QA"> Quality Assurance Manager
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Audit Response</span><span class="level-desc">Focus: Clarity (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Audit Observation Response</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> During a recent internal audit of our Batch Record Review process, the auditor noted that 3 out of 15 sampled batch records had review signatures dated more than 5 business days after batch completion, which exceeds our SOP requirement of 3 business days. This is classified as a minor observation. We need to draft a response acknowledging the finding and proposing immediate corrective action.<br><span class="key">[Role]</span> Quality Assurance Manager responsible for batch record compliance.<br><span class="key">[Instruction]</span> Draft a formal response to this audit observation that acknowledges the gap, explains the root cause, and commits to corrective action.<br><span class="key">[Style]</span> Formal audit response format—factual, non-defensive, and solution-focused.<br><span class="key">[Parameters]</span> Keep under 150 words. Do not make excuses. Focus on facts and actions.<br><span class="key">[Constraints]</span> RAI: No actual batch numbers, product names, or employee identifiers. Data Accuracy: Observation details must accurately reflect audit findings. Transparency: Acknowledge gaps without minimizing. Human Oversight: CAPA commitments require QA leadership approval.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">CAPA Documentation</span><span class="level-desc">Focus: Structure (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>CAPA Root Cause Analysis</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are documenting a Corrective and Preventive Action (CAPA) for a recurring deviation in our packaging line. Over the past quarter, there have been 4 instances where labels were applied with incorrect lot numbers. Initial investigation suggests the issue is related to the manual changeover process between batches.<br><span class="key">[Role]</span> Quality Systems Specialist responsible for CAPA management.<br><span class="key">[Instruction]</span> Document the root cause analysis section of the CAPA using the 5-Why methodology.<br><span class="key">[Style]</span> GxP-compliant documentation format.<br><span class="key">[Parameters]</span> Structure as a formal 5-Why analysis with each level clearly labeled. End with the identified root cause and a brief statement of the proposed corrective action category (procedural, training, or engineering control).<br><span class="key">[Example]</span> Why 1: Labels had incorrect lot numbers → Because the label printer was not reset after the previous batch.<br>Why 2: Printer was not reset → Because...<br><span class="key">[Constraints]</span> RAI: No actual lot numbers, equipment IDs, or operator names. Data Accuracy: Root cause analysis must follow logical sequence. Source Accuracy: Reference applicable GxP requirements. Human Oversight: CAPA determination requires quality board review.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Deviation Investigation</span><span class="level-desc">Focus: Risk Assessment (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Critical Deviation Summary</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A temperature excursion occurred in Cold Storage Unit 2 over the weekend. The temperature rose to 12°C for approximately 4 hours before the alarm was acknowledged and corrective action taken. The unit contained 15 batches of Product-C, a temperature-sensitive biologic with a storage requirement of 2-8°C. Stability data suggests the product can tolerate up to 15°C for 24 hours without impact, but this has not been formally validated.<br><span class="key">[Objective]</span> Prepare a deviation investigation summary that assesses product impact, determines batch disposition, and recommends preventive measures.<br><span class="key">[Style]</span> Quality Review Board presentation format.<br><span class="key">[Tone]</span> Objective, data-driven, and appropriately cautious about patient safety.<br><span class="key">[Audience]</span> Quality Review Board (Head of QA, Head of Manufacturing, Qualified Person).<br><span class="key">[Response]</span> A structured summary including: (1) Deviation Description, (2) Impact Assessment with supporting data, (3) Batch Disposition Recommendation (release, reject, or additional testing), (4) Root Cause, (5) CAPA Recommendations.<br><span class="key">[Constraints]</span> RAI: No actual batch numbers, product names, or patient data. Data Accuracy: Temperature data and stability references must be accurate. Bias: Present balanced disposition options. Human Oversight: Batch disposition requires QP/QA Director approval. Patient Safety: When in doubt, recommend additional testing.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Regulatory Inspection Preparation</span>
                        <span class="level-desc">Interactive Planning</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Inspection Readiness Assessment</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Quality Assurance Manager using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to systematically assess inspection readiness and identify gaps before a scheduled regulatory inspection.<br>
<span class="key">[Tools]</span> You have access to: [CAPA_Tracker], [TrainingRecords], [DeviationLog], [DocumentManagement], [PreviousInspectionFindings]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> The site has received notification of a regulatory inspection scheduled in 6 weeks. The last inspection was 3 years ago and resulted in 2 major observations related to training documentation and deviation trending. You need to assess current readiness and develop a preparation plan. The CAPA from the previous inspection was closed 18 months ago.<br><span class="key">[Constraints]</span> RAI: No actual site names, inspection dates, or employee identifiers. Data Accuracy: CAPA status must reflect actual completion state. Source Accuracy: Reference applicable GxP regulations. Human Oversight: Readiness assessment requires QA Director approval before submission.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately start a documentation review marathon. ReAct forces you to first check the status of previous inspection CAPAs (are they truly effective?), assess current deviation and training metrics, and identify patterns that an inspector might query. This systematic approach ensures you address root issues rather than just tidying up paperwork.
                    </div>
                </div>

                <div id="msl" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/search.svg" class="local-icon icon-red" alt="MSL"> Medical Science Liaison (MSL)
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Medical Inquiry Response</span><span class="level-desc">Focus: Compliance (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Unsolicited Medical Inquiry</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A healthcare professional contacted our Medical Information team with a question about dosing adjustments for Product-D in patients with moderate renal impairment. This information is included in the approved prescribing information, but the HCP is asking for additional context about the clinical trial population that informed this recommendation.<br><span class="key">[Role]</span> Medical Information Specialist responsible for responding to unsolicited medical inquiries.<br><span class="key">[Instruction]</span> Draft a compliant response that addresses the HCP's question using only approved and published sources.<br><span class="key">[Style]</span> Medical letter format—scientific, accurate, and appropriately referenced.<br><span class="key">[Parameters]</span> Reference only the approved label and published clinical trial data. Do not include any off-label information. Include standard medical information disclaimer language at the end.<br><span class="key">[Constraints]</span> RAI: No actual HCP names, institutions, or patient identifiers. Source Accuracy: Reference only approved labeling and peer-reviewed publications. Regulatory: Strictly on-label information only. Human Oversight: All medical responses require Medical Affairs review before sending.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">KOL Engagement</span><span class="level-desc">Focus: Documentation (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>KOL Meeting Summary</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I just completed a scientific exchange meeting with a Key Opinion Leader (KOL) who is a principal investigator at a major academic medical center. We discussed the latest Phase 3 data for Product-E, the KOL's ongoing investigator-initiated study, and their perspectives on the competitive landscape in this therapeutic area. I need to document this interaction for our CRM system.<br><span class="key">[Role]</span> Medical Science Liaison responsible for KOL relationship documentation.<br><span class="key">[Instruction]</span> Create a structured meeting summary suitable for entry into the MSL CRM system.<br><span class="key">[Style]</span> Compliant field documentation format—factual, concise, and focused on scientific exchange.<br><span class="key">[Parameters]</span> Format with clear sections: Meeting Objective, Key Discussion Points (bulleted), KOL Insights, Follow-up Actions. Do not include any promotional language or characterize the KOL's sentiment toward our products.<br><span class="key">[Example]</span> Meeting Objective: Scientific exchange regarding Phase 3 data presentation at recent congress.<br>Key Discussion Points:<br>• Discussed methodology of the primary endpoint analysis<br>• KOL inquired about subgroup analysis plans<br><span class="key">[Constraints]</span> RAI: No actual KOL names, institutions, or study identifiers. Regulatory: No promotional language or sentiment characterization. Data Accuracy: Document only factual scientific exchanges. Human Oversight: Documentation reviewed by Medical Affairs compliance.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Scientific Communication Strategy</span><span class="level-desc">Focus: Stakeholder Alignment (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Publication Dissemination Plan</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A pivotal Phase 3 study for Product-F has just been published in a top-tier medical journal. This is the first head-to-head comparison data against the current standard of care. The results show a statistically significant but modest improvement in the primary endpoint. The MSL team needs to develop a scientific engagement strategy for discussing this data with KOLs in a balanced, compliant manner.<br><span class="key">[Objective]</span> Develop a field communication strategy that enables scientifically accurate, balanced discussion of the new data.<br><span class="key">[Style]</span> Medical Affairs strategic planning document.<br><span class="key">[Tone]</span> Scientific, balanced, and compliance-conscious. Acknowledge both the strengths and limitations of the data.<br><span class="key">[Audience]</span> MSL Leadership Team and Medical Affairs Compliance.<br><span class="key">[Response]</span> A strategy document including: (1) Key Scientific Messages (balanced), (2) Anticipated KOL Questions and Suggested Responses, (3) Data Limitations to Proactively Address, (4) Competitive Context (factual only), (5) Compliance Guardrails.<br><span class="key">[Constraints]</span> RAI: No actual product names, competitor names, or study identifiers. Bias: Present balanced view of data strengths and limitations. Source Accuracy: Reference only published, peer-reviewed data. Human Oversight: Strategy requires Medical Affairs and Legal/Compliance review.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Congress Engagement Planning</span>
                        <span class="level-desc">Interactive Strategy</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Medical Congress Preparation</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Medical Science Liaison using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to prepare a comprehensive engagement plan for an upcoming major medical congress by systematically gathering information and coordinating with stakeholders.<br>
<span class="key">[Tools]</span> You have access to: [CongressAgenda], [KOL_Database], [AbstractDatabase], [CompetitorIntelligence], [TravelBooking]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> A major therapeutic area congress is scheduled in 8 weeks. Our company has 2 poster presentations and 1 oral presentation accepted. Three of your priority KOLs are presenting at the congress, including one who is chairing a session on a topic directly relevant to our pipeline. You need to develop your engagement plan and coordinate with 4 other MSLs who will also be attending.<br><span class="key">[Constraints]</span> RAI: No actual congress names, KOL names, or company identifiers. Regulatory: All engagement must be non-promotional scientific exchange. Data Accuracy: Congress schedule information must be verified. Human Oversight: Engagement plans require MSL Director approval.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately book meetings with as many KOLs as possible. ReAct forces you to first review the congress agenda for conflicts, check which KOLs are presenting and when, identify competitive presentations that may influence discussions, and coordinate with colleagues to avoid duplicate outreach. This ensures strategic, efficient use of limited congress time.
                    </div>
                </div>

                <div id="clinical" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/chart-bar.svg" class="local-icon icon-red" alt="Clinical"> Clinical Operations Coordinator
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Site Communication</span><span class="level-desc">Focus: Clarity (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Protocol Amendment Notification</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A protocol amendment for Study-001 has been approved by the IRB/EC. The amendment changes the inclusion criteria to allow patients with a slightly lower baseline score, and adds an additional safety assessment at Week 8. All 12 active sites need to be notified and must acknowledge receipt before implementing the changes.<br><span class="key">[Role]</span> Clinical Trial Coordinator responsible for site communications.<br><span class="key">[Instruction]</span> Draft a site notification letter announcing the protocol amendment.<br><span class="key">[Style]</span> Formal clinical trial communication—clear, actionable, and GCP-compliant.<br><span class="key">[Parameters]</span> Include: amendment number, effective date, summary of changes, required site actions, and acknowledgment deadline. Keep under 200 words.<br><span class="key">[Constraints]</span> RAI: No actual study numbers, site names, or patient data. Data Accuracy: Amendment details must accurately reflect approved changes. Source Accuracy: Reference IRB/EC approval documentation. Human Oversight: Site communications require Clinical Operations approval.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Enrollment Tracking</span><span class="level-desc">Focus: Data Presentation (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Enrollment Status Report</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are preparing the monthly enrollment status report for Study-002. The study target is 200 patients across 15 sites. We are currently at Week 24 of a 52-week enrollment period. Some sites are exceeding targets while others have not enrolled any patients. The sponsor is concerned about timeline and wants a clear picture of where we stand.<br><span class="key">[Role]</span> Clinical Operations Manager responsible for enrollment tracking.<br><span class="key">[Instruction]</span> Create an enrollment status summary that highlights site performance and identifies at-risk sites.<br><span class="key">[Style]</span> Executive dashboard format—visual, data-driven, and action-oriented.<br><span class="key">[Parameters]</span> Format as a Markdown Table with columns: Site ID, Target, Enrolled, % of Target, Status (On Track/At Risk/Critical). Include a summary section with overall enrollment rate and projected completion date based on current trajectory.<br><span class="key">[Example]</span> | Site ID | Target | Enrolled | % Target | Status |<br>|---------|--------|----------|----------|--------|<br>| Site-001 | 15 | 12 | 80% | On Track |<br><span class="key">[Constraints]</span> RAI: Use placeholder site IDs only—no actual site identifiers. Data Accuracy: Enrollment numbers must reflect verified CTMS data. Transparency: Honestly flag underperforming sites. Human Oversight: At-risk site escalations require Clinical Operations Manager review.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Site Remediation</span><span class="level-desc">Focus: Problem Resolution (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Site Performance Improvement Plan</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Site-007 in Study-003 has had 3 consecutive monitoring visits with major findings, including protocol deviations related to informed consent timing and incomplete source documentation. The site has enrolled 8 patients who are currently in follow-up. The sponsor is considering whether to close the site or implement a remediation plan. Closing the site would impact patients and delay study completion.<br><span class="key">[Objective]</span> Develop a site remediation plan that addresses compliance concerns while minimizing patient and study impact.<br><span class="key">[Style]</span> Formal remediation plan document.<br><span class="key">[Tone]</span> Firm but collaborative—clearly communicate expectations while supporting site improvement.<br><span class="key">[Audience]</span> Site Principal Investigator, Site Coordinator, and Sponsor Clinical Operations Leadership.<br><span class="key">[Response]</span> A remediation plan including: (1) Summary of Findings, (2) Required Corrective Actions with Deadlines, (3) Enhanced Monitoring Plan, (4) Success Criteria for Continuing Participation, (5) Escalation Path if Remediation Fails.<br><span class="key">[Constraints]</span> RAI: No actual site names, PI names, or patient identifiers. Data Accuracy: Findings must accurately reflect monitoring visit observations. Patient Safety: Enrolled patient welfare is primary consideration. Human Oversight: Site closure decisions require Sponsor Medical Director approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Protocol Deviation Assessment</span>
                        <span class="level-desc">Interactive Investigation</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Deviation Impact Analysis</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Clinical Operations Manager using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to assess a reported protocol deviation, determine its impact on patient safety and data integrity, and recommend appropriate follow-up actions.<br>
<span class="key">[Tools]</span> You have access to: [ProtocolDocument], [PatientRecord], [DeviationHistory], [RegulatoryRequirements], [MedicalMonitor]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> Site-012 reported that Patient 042 in Study-004 received the investigational product 3 days outside the dosing window specified in the protocol. The site coordinator states this occurred because the patient missed their scheduled visit due to a family emergency and the site did not want to discontinue the patient from the study. The patient has not reported any adverse events.<br><span class="key">[Constraints]</span> RAI: Use placeholder IDs only—no actual patient or site identifiers. Patient Safety: Safety assessment takes priority over data considerations. Source Accuracy: Reference protocol requirements exactly. Human Oversight: Major deviations require Medical Monitor review before final classification.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately classify the deviation and file the paperwork. ReAct forces you to first check whether this is part of a pattern at this site, review the protocol to understand the scientific rationale for the dosing window, assess whether patient safety was compromised, and consult the medical monitor before determining reportability. This ensures deviations are handled appropriately based on actual impact, not just procedurally.
                    </div>
                </div>

                <div id="cdm" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/layers.svg" class="local-icon icon-red" alt="CDM"> Clinical Data Manager
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Data Cleaning</span><span class="level-desc">Focus: Query Writing (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Data Query Communication</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> During routine data review of Study-006, I identified a discrepancy: Patient 087's adverse event start date (15-Mar-2024) is recorded as before the study drug start date (22-Mar-2024). This is logically impossible for treatment-emergent adverse events. I need to query the site to clarify the correct dates.<br><span class="key">[Role]</span> Clinical Data Manager responsible for data query generation.<br><span class="key">[Instruction]</span> Write a clear, specific data query to send to the site via the EDC system.<br><span class="key">[Style]</span> Concise and professional—site coordinators receive many queries and appreciate clarity.<br><span class="key">[Parameters]</span> Include: specific data point in question, the discrepancy identified, and what information is needed to resolve. Do not suggest the "correct" answer—let the site verify source documents. Keep under 50 words.<br><span class="key">[Constraints]</span> RAI: Use placeholder patient/study IDs only—no actual identifiers. Data Accuracy: Query must accurately describe the discrepancy. Bias: Do not lead the site toward a specific answer. Human Oversight: Complex queries may require Medical Monitor input.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Edit Check Programming</span><span class="level-desc">Focus: Logic Specification (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Edit Check Specification</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are building the EDC database for a new oncology study. The protocol requires that patients must have an ECOG Performance Status of 0-2 at screening to be eligible. I need to write the edit check specification that will fire a query if this criterion is not met.<br><span class="key">[Role]</span> Clinical Data Manager responsible for edit check specification.<br><span class="key">[Instruction]</span> Write a formal edit check specification for the ECOG eligibility criterion.<br><span class="key">[Style]</span> Technical specification format suitable for EDC programmer implementation.<br><span class="key">[Parameters]</span> Include: edit check ID, description, triggering condition (in Boolean logic), query text, affected forms/fields, and query priority. Follow standard edit check naming conventions.<br><span class="key">[Example]</span> Edit Check ID: ELIG_ECOG_001<br>Description: ECOG Performance Status must be 0, 1, or 2 at Screening<br>Condition: IF [Screening.ECOG] NOT IN (0, 1, 2) AND [Screening.ECOG] IS NOT NULL<br>Query Text: "ECOG Performance Status is [value]. Per protocol, eligible patients must have ECOG 0-2. Please verify."<br><span class="key">[Constraints]</span> RAI: No actual study or site identifiers in specifications. Data Accuracy: Boolean logic must exactly match protocol requirements. Source Accuracy: Reference specific protocol sections. Human Oversight: Edit checks require CDM Lead validation before implementation.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Database Lock Strategy</span><span class="level-desc">Focus: Planning (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Database Lock Plan</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Study-007 is approaching database lock with 450 patients across 35 sites. Current open query rate is 8% (target is below 2%). The lock is scheduled in 6 weeks to meet the regulatory submission timeline. Several sites have high query volumes and slow response times. The medical monitor has flagged 12 patients requiring additional medical review before lock.<br><span class="key">[Objective]</span> Develop a database lock plan that ensures data quality while meeting the timeline.<br><span class="key">[Style]</span> Clinical data management planning document.<br><span class="key">[Tone]</span> Action-oriented and realistic about challenges.<br><span class="key">[Audience]</span> Clinical Operations Lead, Biostatistics, and Medical Monitor.<br><span class="key">[Response]</span> A lock plan including: (1) Current State Assessment (query metrics by site), (2) Site-Specific Action Plans for High-Query Sites, (3) Query Resolution Timeline with Milestones, (4) Medical Review Coordination, (5) Soft Lock and Hard Lock Criteria, (6) Exception Handling Process, (7) Risk Assessment and Contingency.<br><span class="key">[Constraints]</span> RAI: Use placeholder site IDs—no actual identifiers. Data Accuracy: Query metrics must reflect current EDC data. Transparency: Honestly assess timeline risks. Human Oversight: Lock criteria require Clinical Operations and Biostatistics sign-off.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Data Discrepancy Resolution</span>
                        <span class="level-desc">Interactive Investigation</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Complex Query Investigation</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Clinical Data Manager using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to investigate a complex data discrepancy that has not been resolved through standard queries and determine the correct data handling approach.<br>
<span class="key">[Tools]</span> You have access to: [EDC_Database], [QueryHistory], [ProtocolDocument], [SiteContact], [MedicalMonitor]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> Patient 142 has conflicting information about a prior cancer diagnosis. The medical history form indicates "No prior malignancy," but the concomitant medication form lists a drug that is only indicated for cancer treatment. The site has responded to two queries stating the data is correct as entered. The discrepancy affects eligibility determination. Database lock is in 2 weeks.<br><span class="key">[Constraints]</span> RAI: Use placeholder patient IDs—no actual PHI. Data Integrity: Resolve discrepancy before lock—do not ignore. Patient Safety: Eligibility determination affects patient welfare. Human Oversight: Eligibility discrepancies require Medical Monitor adjudication.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to escalate to the site manager or force a data change. ReAct forces you to first review the complete patient record for context, check if the medication has any non-oncology indications, review query response details, and consult with the medical monitor on clinical plausibility before determining if this requires source document verification or is actually consistent data. This prevents unnecessary site friction while ensuring data integrity.
                    </div>
                </div>

                <div id="cta" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/calendar.svg" class="local-icon icon-red" alt="CTA"> Clinical Trial Associate
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Site Coordination</span><span class="level-desc">Focus: Communication (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Site Initiation Checklist Follow-up</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Site-015 was approved to participate in Study-008 three weeks ago. The Site Initiation Visit (SIV) is scheduled for next week, but several pre-SIV requirements are incomplete: the site has not returned the signed delegation log, and the pharmacy has not confirmed drug storage capability. The CRA needs these items completed before the SIV can proceed.<br><span class="key">[Role]</span> Clinical Trial Associate responsible for site start-up coordination.<br><span class="key">[Instruction]</span> Draft a professional follow-up email to the site coordinator requesting the outstanding items.<br><span class="key">[Style]</span> Friendly but firm—maintain positive relationship while emphasizing urgency.<br><span class="key">[Parameters]</span> List specific outstanding items. Provide clear deadline tied to the SIV date. Offer assistance if there are barriers. Keep under 150 words.<br><span class="key">[Constraints]</span> RAI: No actual site names, coordinator names, or study identifiers. Data Accuracy: Outstanding items must accurately reflect current status. Transparency: Be clear about SIV dependencies. Human Oversight: Site delays may require CRA/CTM escalation.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Essential Documents</span><span class="level-desc">Focus: Organization (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>TMF Review Checklist</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> An internal audit of the Trial Master File (TMF) for Study-009 is scheduled in 2 weeks. The study has 20 active sites across 5 countries. I need to conduct a pre-audit review to identify any missing or deficient essential documents before the auditors arrive.<br><span class="key">[Role]</span> Clinical Trial Associate responsible for TMF maintenance.<br><span class="key">[Instruction]</span> Create a TMF review checklist for the pre-audit assessment.<br><span class="key">[Style]</span> ICH E6 compliant document checklist.<br><span class="key">[Parameters]</span> Organize by TMF zone (Sponsor, Site, Country). For each essential document, include: document name, filing requirement (when required), common deficiencies to check for, and priority (Critical/Important/Supporting). Focus on high-audit-risk documents.<br><span class="key">[Example]</span> Zone 5 - Site Documents:<br>| Document | Required | Check For | Priority |<br>| Signed Protocol | Before first patient | Current version, all pages initialed | Critical |<br>| Delegation Log | Before SIV | All staff listed, signatures present, dates logical | Critical |<br><span class="key">[Constraints]</span> RAI: No actual study or site identifiers. Source Accuracy: Requirements per ICH E6(R2) and TMF Reference Model. Data Accuracy: Checklist must reflect current regulatory expectations. Human Oversight: Critical deficiencies require immediate escalation to Quality.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Site Issue Management</span><span class="level-desc">Focus: Problem Resolution (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Site Performance Improvement</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Site-022 in Study-010 has consistently underperformed: enrollment is at 30% of target, query response time averages 21 days (study average is 7 days), and the last monitoring visit identified 15 protocol deviations. The site's PI is a key opinion leader whose participation is important for the study's scientific credibility. The sponsor is considering whether to continue with this site.<br><span class="key">[Objective]</span> Develop a site performance improvement plan that addresses deficiencies while preserving the relationship.<br><span class="key">[Style]</span> Site management action plan.<br><span class="key">[Tone]</span> Constructive and collaborative—focus on support rather than blame.<br><span class="key">[Audience]</span> CRA, Clinical Operations Manager, and Medical Monitor.<br><span class="key">[Response]</span> An improvement plan including: (1) Current Performance Summary, (2) Root Cause Hypothesis (based on available information), (3) Site Support Actions, (4) Performance Milestones and Timelines, (5) Escalation Triggers, (6) Communication Strategy with PI, (7) Contingency if Improvement Not Achieved.<br><span class="key">[Constraints]</span> RAI: No actual site names, PI names, or study identifiers. Data Accuracy: Performance metrics must reflect verified data. Bias: Focus on support, not blame. Human Oversight: Site termination decisions require Medical Monitor and Legal review.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Urgent Document Recovery</span>
                        <span class="level-desc">Interactive Problem Solving</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Missing Essential Document</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Clinical Trial Associate using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to locate and file a critical missing document before a scheduled regulatory inspection.<br>
<span class="key">[Tools]</span> You have access to: [TMF_System], [EmailArchive], [SiteContactList], [VendorPortal], [InternalSharepoint]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> During inspection preparation, you discovered that the signed Clinical Trial Agreement for Site-030 is not in the TMF. The site was activated 18 months ago and has enrolled 12 patients. The previous CTA who managed this site has left the company. The regulatory inspection begins in 5 business days. Without this document, the site's participation may be questioned.<br><span class="key">[Constraints]</span> RAI: Use placeholder site IDs—no actual identifiers. Data Accuracy: Document status must reflect actual TMF state. Transparency: Be honest about filing gaps. Human Oversight: Missing critical documents require immediate QA and Legal notification.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately contact the site and request a copy of the signed agreement. ReAct forces you to first search all potential filing locations (was it misfiled?), check email archives for transmission records, verify the document was actually executed (vs. never signed), and determine if alternative documentation exists before creating panic at the site. This often locates documents that were simply misfiled rather than missing.
                    </div>
                </div>

                <div id="biostat" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/chart-bar.svg" class="local-icon icon-red" alt="Stats"> Biostatistician
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Statistical Programming</span><span class="level-desc">Focus: Code Documentation (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Analysis Code Comment Standards</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I am writing SAS code for the primary efficacy analysis of Study-011. The analysis involves a mixed-model repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit interaction, baseline value, and stratification factors. The code will be reviewed by senior biostatisticians and may be inspected by regulators.<br><span class="key">[Role]</span> Statistical Programmer responsible for analysis dataset and TFL production.<br><span class="key">[Instruction]</span> Write a header comment block for this analysis program following regulatory documentation standards.<br><span class="key">[Style]</span> GxP-compliant programming documentation.<br><span class="key">[Parameters]</span> Include: program name, purpose, author, creation date, modification history, input datasets, output datasets/tables, key assumptions, and SAP reference. Format for clear audit trail.<br><span class="key">[Constraints]</span> RAI: No actual study numbers or patient identifiers in code. Data Accuracy: Code logic must exactly match SAP methodology. Source Accuracy: Reference specific SAP sections. Human Oversight: Analysis programs require independent QC before production.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Analysis Specification</span><span class="level-desc">Focus: Precision (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>TFL Shell Specification</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The Statistical Analysis Plan for Study-012 specifies that a subgroup analysis of the primary endpoint will be performed by age group (under 65 vs. 65 and over). I need to create the mock table shell showing how the results will be presented.<br><span class="key">[Role]</span> Biostatistician responsible for TFL specification.<br><span class="key">[Instruction]</span> Create a mock table shell for the age subgroup analysis.<br><span class="key">[Style]</span> ICH E3 compliant table format.<br><span class="key">[Parameters]</span> Include: table number and title, column headers, row stubs, footnotes for statistical methodology, and programming notes. Use standard notation for statistics to be populated ([N], [Mean (SD)], [LS Mean], [95% CI], [p-value]).<br><span class="key">[Example]</span> Table 14.2.1.2: Primary Endpoint by Age Subgroup (ITT Population)<br>| Subgroup | Treatment A | Treatment B | Difference | 95% CI | p-value |<br>| Age < 65 years (n=X) | | | | | |<br>|   Baseline Mean (SD) | [XX.X (XX.X)] | | | | |<br><span class="key">[Constraints]</span> RAI: Use placeholder data—no actual results. Data Accuracy: Statistical notation must be precise and standard. Source Accuracy: Table format per ICH E3 requirements. Human Oversight: TFL shells require Biostatistics Lead approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Statistical Methodology</span><span class="level-desc">Focus: Scientific Rigor (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Missing Data Analysis Strategy</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Study-013 is a pivotal Phase 3 trial with a 12-month treatment period. The primary endpoint is change from baseline at Month 12. Projected dropout rate is 25%, primarily due to lack of efficacy and adverse events. The regulatory guidance emphasizes the need for robust handling of missing data with sensitivity analyses. We are developing the missing data strategy for the SAP.<br><span class="key">[Objective]</span> Develop a comprehensive missing data analysis strategy that will withstand regulatory scrutiny.<br><span class="key">[Style]</span> Statistical methodology section for SAP.<br><span class="key">[Tone]</span> Scientifically rigorous and anticipating regulatory questions.<br><span class="key">[Audience]</span> Regulatory agency statisticians and medical reviewers.<br><span class="key">[Response]</span> A missing data strategy including: (1) Anticipated Missing Data Patterns, (2) Primary Analysis Method with Missing Data Handling, (3) Sensitivity Analyses (MNAR, tipping point, pattern mixture), (4) Supportive Analyses, (5) Rationale for Each Approach, (6) Implementation Details (software, seeds, iterations).<br><span class="key">[Constraints]</span> RAI: No actual study data or patient counts. Source Accuracy: Reference ICH E9(R1) estimand framework and FDA guidance. Data Accuracy: Methodology must be scientifically defensible. Human Oversight: SAP methodology requires regulatory statistician review.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Results Anomaly Investigation</span>
                        <span class="level-desc">Interactive Analysis</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Unexpected Statistical Finding</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Biostatistician using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to investigate an unexpected statistical finding before results are finalized to ensure the analysis is correct.<br>
<span class="key">[Tools]</span> You have access to: [AnalysisDatasets], [ProgramCode], [DataListings], [ProtocolAmendments], [SAPHistory]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> The primary analysis of Study-014 shows an unexpected result: the treatment effect is statistically significant, but the direction of the effect is opposite to what was hypothesized (the control group performed better than the treatment group). This is the unblinded analysis for the Data Monitoring Committee. The study team is asking if there's a programming error.<br><span class="key">[Constraints]</span> RAI: No actual study results or patient data. Data Integrity: Verify programming before dismissing unexpected results. Transparency: Report findings accurately regardless of direction. Human Oversight: Unexpected results require senior statistician and DMC review.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately assume a programming error and start debugging code. ReAct forces you to first verify the programming (did signs get reversed?), then check if the unexpected direction is consistent across sensitivity analyses and subgroups, review if any protocol amendments changed outcome definitions, and assess whether the finding is biologically plausible before concluding. This ensures thorough investigation rather than premature dismissal of a potentially real finding.
                    </div>
                </div>

                <div id="med-writer" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/clipboard.svg" class="local-icon icon-red" alt="Writer"> Medical Writer
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Document Editing</span><span class="level-desc">Focus: Consistency (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Abbreviation List Compilation</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I am finalizing the Clinical Study Report for Study-015. Per ICH E3, the report requires a list of abbreviations and definitions. The document is 250 pages with contributions from multiple authors. Abbreviation usage is inconsistent—some are defined at first use, some are not, and some have multiple definitions.<br><span class="key">[Role]</span> Medical Writer responsible for document quality control.<br><span class="key">[Instruction]</span> Create a process for compiling and standardizing the abbreviation list.<br><span class="key">[Style]</span> Technical writing quality control checklist.<br><span class="key">[Parameters]</span> Include steps for: identification of all abbreviations, verification against source documents, standardization of definitions, and formatting per company style guide. Prioritize regulatory-critical abbreviations.<br><span class="key">[Constraints]</span> RAI: No actual study numbers or proprietary abbreviations. Data Accuracy: Definitions must match source documents exactly. Source Accuracy: Follow ICH E3 and company style guide requirements. Human Oversight: Final abbreviation list requires QC review.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Narrative Writing</span><span class="level-desc">Focus: Scientific Clarity (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Efficacy Results Narrative</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I am writing the efficacy results section for Study-016's Clinical Study Report. The primary endpoint showed statistical significance (p=0.023) with a treatment difference of 2.5 points on a 20-point scale. The clinical meaningfulness of this difference is debated. Secondary endpoints showed mixed results: 2 of 5 reached significance.<br><span class="key">[Role]</span> Medical Writer responsible for CSR authoring.<br><span class="key">[Instruction]</span> Write the opening paragraph of the efficacy results section summarizing the primary endpoint findings.<br><span class="key">[Style]</span> ICH E3 compliant scientific writing—objective, precise, and data-driven.<br><span class="key">[Parameters]</span> State the result factually without overinterpreting. Include the statistical test used, effect size, confidence interval, and p-value. Do not editorialize on clinical meaningfulness—that belongs in the discussion section. Reference the relevant table.<br><span class="key">[Example]</span> "The primary efficacy analysis demonstrated [statistical outcome] for [endpoint]. At Week X, the [treatment group] showed a [direction] of [X.X units] compared to [comparator] (95% CI: X.X to X.X; p=X.XXX; Table XX)."<br><span class="key">[Constraints]</span> RAI: Use placeholder data—no actual efficacy results. Data Accuracy: Narrative must match tables exactly. Bias: Present results factually without interpretation in results section. Human Oversight: Efficacy narrative requires Biostatistics and Medical review.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Strategic Document Planning</span><span class="level-desc">Focus: Regulatory Strategy (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Integrated Summary Planning</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are preparing the NDA submission for Product-I. The submission will include 4 pivotal studies, 8 supportive studies, and extensive non-clinical data. The Integrated Summary of Efficacy (ISE) must synthesize data across studies with different designs, endpoints, and populations. Regulatory feedback from the Type B meeting indicated concerns about one of the pivotal studies.<br><span class="key">[Objective]</span> Develop a strategic outline for the ISE that presents the totality of evidence compellingly while addressing known regulatory concerns.<br><span class="key">[Style]</span> Regulatory submission strategy document.<br><span class="key">[Tone]</span> Scientifically objective while strategically addressing weaknesses.<br><span class="key">[Audience]</span> Regulatory submission team and FDA reviewers.<br><span class="key">[Response]</span> An ISE outline including: (1) Key Messages Framework, (2) Section-by-Section Strategy (what to emphasize, what to acknowledge), (3) Data Integration Approach (meta-analysis, pooled analysis, qualitative synthesis), (4) Handling of Inconsistent Results, (5) Pre-Specification of Regulatory Concern Responses, (6) Cross-Reference Strategy to Other Submission Documents.<br><span class="key">[Constraints]</span> RAI: No actual product names or study results. Bias: Present balanced totality of evidence including limitations. Source Accuracy: Data integration per FDA guidance on ISE. Human Oversight: ISE strategy requires Regulatory, Medical, and Statistical review.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Content Reconciliation</span>
                        <span class="level-desc">Interactive Problem Solving</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Data Discrepancy Resolution</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Medical Writer using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to resolve a discrepancy between narrative text and tables in a clinical document before submission.<br>
<span class="key">[Tools]</span> You have access to: [DraftDocument], [StatisticalOutput], [DatabaseLock_Memo], [VersionHistory], [AuthorComments]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> During QC review of the Clinical Study Report, you discovered that the safety narrative states "15 patients (12.5%) experienced serious adverse events" but Table 14.3.1 shows 18 patients (15.0%). The document is scheduled for sign-off tomorrow. The statistical programmer who generated the tables is out of office.<br><span class="key">[Constraints]</span> RAI: Use placeholder numbers—no actual patient counts. Data Integrity: Never submit with unresolved discrepancies. Transparency: Escalate timeline concerns immediately. Human Oversight: Discrepancy resolution requires source verification before document release.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to change the narrative to match the table. ReAct forces you to first verify which data is correct by checking source documents and version history, understand if definitions might differ (e.g., ITT vs. Safety population), and determine when the discrepancy was introduced. This prevents propagating errors into the final document by correcting to match potentially wrong data.
                    </div>
                </div>

                <div id="drug-safety" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/shield.svg" class="local-icon icon-red" alt="Safety"> Drug Safety Scientist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Aggregate Report Writing</span><span class="level-desc">Focus: Compliance (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>DSUR Section Drafting</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I am drafting the "Actions Taken in the Reporting Period" section for the annual Development Safety Update Report (DSUR) for Product-J. During the reporting period, we updated the Investigator's Brochure to add a new potential risk based on non-clinical findings, and we amended 2 ongoing protocols to add additional safety monitoring.<br><span class="key">[Role]</span> Drug Safety Scientist responsible for DSUR authoring.<br><span class="key">[Instruction]</span> Draft the Actions Taken section describing these safety-related changes.<br><span class="key">[Style]</span> ICH E2F compliant regulatory writing—factual, chronological, and complete.<br><span class="key">[Parameters]</span> For each action, include: what was done, when, why (safety rationale), and outcome/status. Reference relevant documents (IB version, protocol amendment numbers). Keep concise but complete.<br><span class="key">[Constraints]</span> RAI: No actual product names or study identifiers. Data Accuracy: Actions must accurately reflect what occurred in reporting period. Source Accuracy: Follow ICH E2F format requirements. Human Oversight: DSUR content requires Pharmacovigilance Director sign-off.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Safety Analysis</span><span class="level-desc">Focus: Interpretation (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Cumulative Safety Review</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> For the NDA submission for Product-K, I am preparing the cumulative review of cardiac adverse events across the clinical program. The safety database includes 3,500 patients with exposure to the study drug. There were 45 reported cardiac events across various terms (palpitations, tachycardia, arrhythmia, etc.). The comparator arm had 32 cardiac events. No deaths were attributed to cardiac events.<br><span class="key">[Role]</span> Drug Safety Scientist responsible for integrated safety analysis.<br><span class="key">[Instruction]</span> Create an outline for the cardiac safety review section.<br><span class="key">[Style]</span> ICH E1/M4E compliant safety analysis format.<br><span class="key">[Parameters]</span> Include sections for: event incidence (by preferred term and grouped), exposure-adjusted analysis, temporal relationship to dosing, risk factors, comparator analysis, and overall assessment. Identify key tables and figures needed. Reference relevant guidance on cardiac safety.<br><span class="key">[Example]</span> 2.3.1 Cardiac Events Overview<br>2.3.1.1 Incidence by Preferred Term (Table X)<br>2.3.1.2 Incidence by Grouped Term (Table X)<br>2.3.2 Exposure-Response Analysis<br>2.3.3 Temporal Patterns (Figure X)<br><span class="key">[Constraints]</span> RAI: No actual patient data or product identifiers. Data Accuracy: Safety incidence must match validated safety database. Source Accuracy: Follow ICH E1/M4E and FDA cardiac safety guidance. Human Oversight: Cardiac safety conclusions require Medical Officer review.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Benefit-Risk Assessment</span><span class="level-desc">Focus: Strategic Analysis (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Benefit-Risk Framework</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Product-L has completed Phase 3 development for a chronic condition with significant unmet medical need. Efficacy was demonstrated, but the safety profile includes a rare but serious adverse event (hepatotoxicity) occurring in 0.5% of patients, with 1 fatal case. Existing therapies have lower efficacy but better safety profiles. The regulatory submission is being prepared.<br><span class="key">[Objective]</span> Develop a benefit-risk assessment framework that presents a balanced view while supporting approval.<br><span class="key">[Style]</span> FDA Benefit-Risk Assessment Framework format.<br><span class="key">[Tone]</span> Balanced and scientific. Acknowledge risks honestly while presenting the overall value proposition.<br><span class="key">[Audience]</span> FDA review team and Advisory Committee.<br><span class="key">[Response]</span> A benefit-risk framework including: (1) Analysis of Condition (severity, unmet need), (2) Current Treatment Options, (3) Benefit Assessment (efficacy data, clinical meaningfulness), (4) Risk Assessment (incidence, severity, reversibility, risk factors), (5) Risk Management Plan, (6) Benefit-Risk Conclusion with Uncertainty Analysis.<br><span class="key">[Constraints]</span> RAI: No actual product or competitor names. Bias: Present balanced benefit and risk assessment. Patient Safety: Fatal events require prominent discussion. Human Oversight: Benefit-risk conclusions require Medical, Regulatory, and Safety leadership review.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Emerging Safety Signal</span>
                        <span class="level-desc">Interactive Assessment</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>New Signal Evaluation</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Drug Safety Scientist using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to assess an emerging safety signal from ongoing clinical trials and determine appropriate action.<br>
<span class="key">[Tools]</span> You have access to: [SafetyDatabase], [LiteratureSearch], [MechanismOfAction], [ComparatorData], [RegulatoryGuidance]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> The medical monitor for Study-017 reported 3 cases of suspected drug-induced liver injury (DILI) in the past month. The study has 400 patients enrolled. Prior to this month, there had been only 1 suspected DILI case over 18 months. The compound is a kinase inhibitor. Two of the three new cases occurred at the same clinical site. The current Investigator's Brochure lists hepatic events as a potential risk but not DILI specifically.<br><span class="key">[Constraints]</span> RAI: No actual case numbers or site identifiers. Patient Safety: Treat potential signals seriously—err on side of caution. Data Accuracy: Case adjudication must be complete before conclusions. Human Oversight: Signal determination requires Safety Committee review.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately alert regulatory authorities and update the IB. ReAct forces you to first assess whether this cluster is a true signal (are the cases adjudicated as DILI?), investigate the site cluster (same lab, same population, same concomitant medications?), review mechanism plausibility, and compare to background rates before determining the appropriate response level. This ensures a proportionate response that neither under-reacts to a real signal nor over-reacts to a statistical cluster.
                    </div>
                </div>

                <div id="med-info" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/search.svg" class="local-icon icon-red" alt="Info"> Medical Information Specialist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Inquiry Response</span><span class="level-desc">Focus: Accuracy (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Standard Medical Inquiry Response</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A pharmacist called asking about drug interactions between Product-M and a common antihypertensive medication. This is a frequently asked question. The information is available in the approved prescribing information and we have a standard response document. The pharmacist mentioned a specific patient scenario.<br><span class="key">[Role]</span> Medical Information Specialist responsible for HCP inquiries.<br><span class="key">[Instruction]</span> Draft a response letter to the pharmacist addressing their interaction question.<br><span class="key">[Style]</span> Medical information response format—scientific, accurate, and appropriately referenced.<br><span class="key">[Parameters]</span> Use only approved sources (prescribing information, published literature). Include appropriate disclaimers. Do not provide specific patient management advice—that's the HCP's clinical judgment. Reference the specific PI section. Include standard MI contact information.<br><span class="key">[Constraints]</span> RAI: No actual HCP names, patient scenarios, or product names. Source Accuracy: Reference only approved PI and peer-reviewed literature. Regulatory: Strictly on-label information; no treatment recommendations. Human Oversight: Responses require Medical Information review before sending.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Response Document Development</span><span class="level-desc">Focus: Scientific Rigor (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Standard Response Document Creation</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are receiving frequent inquiries about using Product-N in elderly patients (≥75 years). The pivotal trials had limited enrollment of this age group. We have post-marketing data and a recent pharmacokinetic study in elderly volunteers. A standard response document is needed for consistent responses.<br><span class="key">[Role]</span> Senior Medical Information Specialist responsible for response document development.<br><span class="key">[Instruction]</span> Create a standard response document outline for elderly use inquiries.<br><span class="key">[Style]</span> Medical information standard response format with appropriate scientific balance.<br><span class="key">[Parameters]</span> Include: key message summary, labeled information, clinical trial data (limitations noted), post-marketing data, pharmacokinetic considerations, and recommendations. Include strength of evidence ratings where applicable. Reference all sources.<br><span class="key">[Example]</span> Section 1: Summary of Labeled Information<br>Product-N is approved for [indication] in adults. The prescribing information does not specify age restrictions. [PI Section X.X] notes that...<br>Section 2: Clinical Trial Evidence<br>In the pivotal Phase 3 trials, X% of enrolled patients were ≥75 years (n=XX)...<br><span class="key">[Constraints]</span> RAI: Use placeholder product names and data. Source Accuracy: All statements must cite approved sources. Bias: Present evidence limitations transparently. Human Oversight: Standard response documents require Medical Director approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Off-Label Inquiry Management</span><span class="level-desc">Focus: Compliance (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Complex Off-Label Request Response</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A hospital pharmacy director has requested comprehensive information about using Product-O for an off-label indication. They are considering adding it to the hospital formulary for this use. The request includes efficacy data, safety data, dosing recommendations, and comparison to current standard of care. This is a legitimate unsolicited request, but the scope approaches promotional communication.<br><span class="key">[Objective]</span> Develop a compliant response strategy that provides scientific information while maintaining appropriate boundaries.<br><span class="key">[Style]</span> Medical information compliance analysis and response plan.<br><span class="key">[Tone]</span> Scientifically supportive while compliance-conscious.<br><span class="key">[Audience]</span> Medical Information Manager and Compliance Officer (internal), Hospital Pharmacy Director (external).<br><span class="key">[Response]</span> A response strategy including: (1) Request Assessment (legitimate unsolicited vs. potentially solicited), (2) Information Scope Analysis (what can be provided compliantly), (3) Source Selection (peer-reviewed literature, approved labeling, ClinicalTrials.gov), (4) Response Document Outline, (5) Appropriate Disclaimers, (6) Documentation Requirements, (7) Follow-up Limitations.<br><span class="key">[Constraints]</span> RAI: No actual institution or requestor names. Regulatory: No promotional content for off-label use. Source Accuracy: Only peer-reviewed and registered trial data. Human Oversight: Complex off-label requests require Compliance and Legal review.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Complex Inquiry Triage</span>
                        <span class="level-desc">Interactive Assessment</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Escalation Decision</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Medical Information Specialist using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to triage a complex medical inquiry and determine the appropriate response pathway.<br>
<span class="key">[Tools]</span> You have access to: [ResponseLibrary], [EscalationCriteria], [MSL_Directory], [AdverseEventCriteria], [ComplianceGuidelines]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> A physician called requesting detailed information about Product-P for a pediatric patient. The product is only approved for adults. During the call, the physician mentioned that they had already tried it "off-label" in two previous pediatric patients with "mixed results" including one with "an unusual rash." They want guidance on dosing adjustments for children.<br><span class="key">[Constraints]</span> RAI: No actual physician names or patient details. Patient Safety: Recognize and report potential adverse events embedded in inquiries. Regulatory: No dosing recommendations for unapproved populations. Human Oversight: AE detection requires immediate Pharmacovigilance escalation.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to provide the requested pediatric information since it's an unsolicited request. ReAct forces you to first recognize the potential adverse event report embedded in the inquiry (unusual rash may be reportable), determine if this crosses into medical advice territory (dosing recommendations), assess compliance boundaries, and identify the appropriate escalation paths (AE reporting, MSL engagement) before providing any response. This ensures both compliance and patient safety obligations are met.
                    </div>
                </div>

                <div id="cra" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/search.svg" class="local-icon icon-red" alt="CRA"> Clinical Research Associate (CRA)
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Monitoring Visit Preparation</span><span class="level-desc">Focus: Organization (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Pre-Visit Agenda</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I am preparing for a routine monitoring visit to Site-025 for Study-018. The site has enrolled 8 patients and the last visit was 6 weeks ago. The previous visit noted 2 minor findings related to source document completion. There are 3 open queries in the EDC system. I need to plan the visit agenda to maximize efficiency during my 2-day on-site time.<br><span class="key">[Role]</span> Clinical Research Associate responsible for site monitoring.<br><span class="key">[Instruction]</span> Create a monitoring visit agenda with time allocations.<br><span class="key">[Style]</span> Structured visit plan optimized for efficiency.<br><span class="key">[Parameters]</span> Include: regulatory document review, source document verification (SDV), query resolution, protocol compliance check, drug accountability, and site staff meetings. Prioritize critical activities. Include contingency time for unexpected findings.<br><span class="key">[Constraints]</span> RAI: No actual site names, staff names, or study identifiers. Data Accuracy: Pre-visit status must reflect current site metrics. Source Accuracy: Reference ICH GCP monitoring requirements. Human Oversight: Major findings require CTM notification within 24 hours.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Finding Documentation</span><span class="level-desc">Focus: Clarity (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Monitoring Report Finding</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> During SDV at Site-025, I discovered that Patient 019's informed consent was dated June 15, but their screening labs in the source documents were dated June 12. The consent form version and protocol version are correct. The site coordinator explained that the patient had labs drawn at their primary care physician before deciding to participate in the study.<br><span class="key">[Role]</span> CRA responsible for monitoring report documentation.<br><span class="key">[Instruction]</span> Document this finding in the monitoring visit report.<br><span class="key">[Style]</span> GCP-compliant finding documentation—objective, specific, and actionable.<br><span class="key">[Parameters]</span> Include: what was found, regulatory reference (ICH GCP, protocol), classification (deviation/observation), root cause explanation from site, immediate actions taken during visit, and required corrective action. Do not editorialize on site quality.<br><span class="key">[Example]</span> Finding: Screening procedures performed prior to informed consent<br>Reference: ICH E6(R2) Section 4.8.8; Protocol Section 7.1<br>Details: Patient 019 screening laboratory assessments (CBC, CMP) dated 12-JUN-2024 precede informed consent date of 15-JUN-2024...<br><span class="key">[Constraints]</span> RAI: Use placeholder patient IDs and generic dates. Data Accuracy: Finding must accurately describe observed discrepancy. Source Accuracy: Cite specific ICH GCP and protocol sections. Human Oversight: Major protocol deviations require Medical Monitor notification.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Risk-Based Monitoring</span><span class="level-desc">Focus: Analytics (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Site Risk Assessment</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Under our risk-based monitoring strategy, Site-030 has been flagged as high-risk based on key risk indicators: high protocol deviation rate (8% vs. study average 3%), slow query response (14 days vs. study average 5 days), and recent PI change. The site has enrolled 25 patients, representing 15% of total study enrollment. I need to develop a remediation approach.<br><span class="key">[Objective]</span> Develop a site-specific monitoring intensification plan based on risk assessment.<br><span class="key">[Style]</span> Risk-based monitoring action plan.<br><span class="key">[Tone]</span> Data-driven and collaborative—focus on support, not punishment.<br><span class="key">[Audience]</span> Clinical Operations Lead and Site Management.<br><span class="key">[Response]</span> A monitoring intensification plan including: (1) Risk Indicator Analysis, (2) Root Cause Hypothesis, (3) Enhanced Monitoring Activities (increased visit frequency, targeted SDV), (4) Site Support Actions, (5) Success Metrics and Timeline, (6) De-escalation Criteria.<br><span class="key">[Constraints]</span> RAI: No actual site names, PI names, or enrollment data. Data Accuracy: Risk indicators must reflect verified metrics. Bias: Focus on improvement support, not punitive measures. Human Oversight: Site escalation decisions require Clinical Operations leadership approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Site Finding Escalation</span>
                        <span class="level-desc">Interactive Decision Making</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Serious Finding Discovery</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Clinical Research Associate using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to assess a potentially serious finding discovered during monitoring and determine appropriate escalation.<br>
<span class="key">[Tools]</span> You have access to: [SourceDocuments], [EDC_Data], [ProtocolDocument], [EscalationMatrix], [CRA_Manager_Contact]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> During SDV at Site-035, you discovered that Patient 042's SAE hospitalization dates in the EDC do not match the source documents. The EDC shows a 3-day hospitalization, but the discharge summary shows 8 days. Additionally, the discharge summary mentions the patient was transferred to ICU, which was not documented in the SAE report. The SAE was reported to regulatory authorities 45 days ago using the EDC data.<br><span class="key">[Constraints]</span> RAI: Use placeholder IDs—no actual patient or site data. Patient Safety: SAE discrepancies require immediate attention. Data Integrity: Regulatory reports may need amendment. Human Oversight: SAE data correction requires Pharmacovigilance and Regulatory Affairs notification.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately correct the EDC data and notify the site coordinator. ReAct forces you to first assess the full impact (were regulatory reports filed with incorrect information?), determine if other patients might have similar issues, understand the root cause (training? workload? systematic error?), and identify all stakeholders who need to be informed before taking corrective action. This ensures complete remediation rather than fixing one patient while missing a systemic issue.
                    </div>
                </div>

                <div id="recruitment" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/user-tie.svg" class="local-icon icon-red" alt="Recruit"> Patient Recruitment Specialist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Recruitment Materials</span><span class="level-desc">Focus: Compliance (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>IRB Recruitment Flyer</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Site-040 needs a patient recruitment flyer for Study-020, a diabetes clinical trial. The flyer will be posted in the clinic waiting room. It must be IRB-approved before use. Key eligibility criteria include: adults 18-75, Type 2 diabetes diagnosis, HbA1c 7.5-10.5%, not currently on insulin. The study offers free study medication and compensation for visits.<br><span class="key">[Role]</span> Patient Recruitment Specialist responsible for recruitment material development.<br><span class="key">[Instruction]</span> Draft content for a patient recruitment flyer that is IRB-compliant.<br><span class="key">[Style]</span> Patient-friendly language at 6th-grade reading level; IRB-compliant formatting.<br><span class="key">[Parameters]</span> Include: study purpose (briefly), key eligibility in plain language, what participation involves, compensation mention (without overemphasizing), and contact information. Avoid coercive language. Do not promise cure or guaranteed benefit. Do not include medical claims.<br><span class="key">[Constraints]</span> RAI: No actual study numbers, site names, or investigator names. Regulatory: Content must be IRB-approved before use. Bias: No coercive language or exaggerated benefit claims. Human Oversight: All recruitment materials require IRB submission and approval.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Recruitment Analytics</span><span class="level-desc">Focus: Performance Tracking (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Recruitment Funnel Analysis</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Study-021 has screened 200 patients but only randomized 60 (30% screen-to-randomization rate). The target was 50%. We need to understand where in the recruitment funnel patients are dropping out. Available data shows: 200 screened, 180 met initial criteria, 120 completed screening, 80 were eligible, 60 randomized.<br><span class="key">[Role]</span> Patient Recruitment Specialist responsible for enrollment analytics.<br><span class="key">[Instruction]</span> Create a recruitment funnel analysis with conversion rate calculations at each stage.<br><span class="key">[Style]</span> Data-driven recruitment analysis with visual representation.<br><span class="key">[Parameters]</span> Calculate conversion rates between each stage. Identify the highest-dropout stage. Compare to industry benchmarks where available. Suggest hypotheses for dropout causes at the problem stage. Format as a funnel diagram with percentages.<br><span class="key">[Example]</span> Screening Funnel Analysis:<br>Pre-Screen → Screen: 200 patients (baseline)<br>Screen → Meet Initial Criteria: 180 (90% conversion)<br>Initial Criteria → Complete Screening: 120 (67% conversion) ← Problem Stage<br>Complete Screening → Eligible: 80 (67% conversion)<br><span class="key">[Constraints]</span> RAI: Use placeholder numbers—no actual enrollment data. Data Accuracy: Funnel metrics must match CTMS/EDC data. Transparency: Identify problem areas honestly. Human Oversight: Enrollment projections require Clinical Operations review.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Recruitment Strategy</span><span class="level-desc">Focus: Campaign Planning (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Multi-Channel Recruitment Campaign</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Study-022 is a rare disease trial requiring 150 patients globally. After 6 months, enrollment is at 40 patients (27% of target) with only 8 months remaining. Traditional site-based recruitment has plateaued. Budget exists for expanded recruitment but must be justified. The disease primarily affects adults 40-60 with specific genetic markers; patient advocacy groups exist but are fragmented.<br><span class="key">[Objective]</span> Develop a multi-channel recruitment campaign to accelerate enrollment.<br><span class="key">[Style]</span> Strategic recruitment plan with budget allocation.<br><span class="key">[Tone]</span> Ambitious but realistic—acknowledge challenges while proposing solutions.<br><span class="key">[Audience]</span> Clinical Operations Leadership and Finance.<br><span class="key">[Response]</span> A recruitment campaign including: (1) Current State Analysis, (2) Patient Journey Mapping, (3) Channel Strategy (digital, advocacy, physician referral), (4) Messaging Framework (patient-centric), (5) Site Activation for New Referral Sites, (6) Budget Allocation by Channel, (7) Timeline and Milestones, (8) Success Metrics and Monitoring.<br><span class="key">[Constraints]</span> RAI: No actual disease names, study numbers, or budget figures. Regulatory: All patient-facing materials require IRB approval. Bias: Patient-centric messaging without exaggeration. Human Oversight: Campaign budget requires Finance and Clinical Operations approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Enrollment Crisis Response</span>
                        <span class="level-desc">Interactive Problem Solving</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Enrollment Target Miss</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Patient Recruitment Specialist using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to diagnose the root cause of enrollment shortfall and develop corrective actions.<br>
<span class="key">[Tools]</span> You have access to: [EnrollmentDashboard], [SitePerformance], [ScreenFailureReasons], [CompetitorTrials], [PatientFeedback]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> Study-023 has been enrolling for 12 months but is only at 45% of target with 6 months remaining. The enrollment curve flattened 4 months ago. Top-enrolling sites have reached capacity. Screen failure rate suddenly increased to 60% last quarter (was 35% previously). A competitor trial for the same indication opened at several of our sites 5 months ago.<br><span class="key">[Constraints]</span> RAI: No actual study numbers, site names, or competitor identifiers. Data Accuracy: Enrollment metrics must reflect verified CTMS data. Transparency: Honestly assess root causes without blame. Human Oversight: Strategic enrollment changes require Clinical Operations leadership approval.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to add more sites or increase advertising spend. ReAct forces you to first diagnose the real problem (is it awareness, site capacity, competition, or eligibility criteria?), analyze the screen failure spike timing and reasons, assess the competitor trial impact quantitatively, and gather patient feedback before investing in solutions that may not address the root cause. This prevents wasting budget on ineffective interventions.
                    </div>
                </div>

                <div id="pv" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/eye-off.svg" class="local-icon icon-red" alt="PV"> Pharmacovigilance Analyst
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Case Processing</span><span class="level-desc">Focus: Follow-up (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Adverse Event Follow-up Request</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We received an initial adverse event report for a serious case involving Product-G. The reporter (a nurse at an outpatient clinic) provided limited information: patient age, the adverse event term, and that the patient was hospitalized. We need additional information to complete our regulatory assessment, including patient medical history, concomitant medications, event onset date, and current patient status.<br><span class="key">[Role]</span> Pharmacovigilance Case Processor responsible for case follow-up.<br><span class="key">[Instruction]</span> Draft a professional follow-up request to the reporter to obtain missing information.<br><span class="key">[Style]</span> Formal medical correspondence—clear, specific about what is needed, and respectful of the reporter's time.<br><span class="key">[Parameters]</span> Include a numbered list of specific data elements needed. Acknowledge the initial report. Provide contact information for response. Keep under 200 words.<br><span class="key">[Constraints]</span> RAI: No actual patient identifiers, reporter names, or product names. Patient Safety: Prioritize information that affects patient care decisions. Data Accuracy: Clearly specify required vs. optional data elements. Human Oversight: Serious cases require expedited medical review.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Case Narrative</span><span class="level-desc">Focus: Medical Writing (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>ICSR Narrative Writing</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I need to write a case narrative for an Individual Case Safety Report (ICSR) involving a 67-year-old male patient who experienced a serious adverse event (acute kidney injury) while taking Product-H for an approved indication. The patient has a complex medical history including Type 2 diabetes and hypertension. He was also taking 3 concomitant medications. The event occurred 6 weeks after starting Product-H and resolved after discontinuation and supportive care.<br><span class="key">[Role]</span> Pharmacovigilance Scientist responsible for case narrative authoring.<br><span class="key">[Instruction]</span> Write a case narrative following CIOMS format conventions.<br><span class="key">[Style]</span> Medical/scientific writing—objective, chronological, and focused on the facts without causality conclusions.<br><span class="key">[Parameters]</span> Structure chronologically: patient demographics, medical history, suspect product details, adverse event description, treatment, and outcome. Do not include causality assessment in the narrative body. Use past tense throughout.<br><span class="key">[Example]</span> This case, reported by a healthcare professional, concerns a 67-year-old male patient who experienced acute kidney injury while receiving Product-H.<br><span class="key">[Constraints]</span> RAI: No actual patient identifiers or specific product names in examples. Data Accuracy: Narrative must accurately reflect case data. Source Accuracy: Follow CIOMS format conventions. Human Oversight: Serious case narratives require medical review before submission.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Signal Assessment</span><span class="level-desc">Focus: Risk Evaluation (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Safety Signal Evaluation</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Routine signal detection activities have identified a potential safety signal for Product-J: a disproportionate reporting of hepatic events compared to other products in the same class. The signal is based on 23 cases reported over 18 months, including 2 cases of acute liver failure. The product has been on the market for 4 years with an estimated exposure of 500,000 patient-years. Hepatotoxicity is not currently listed as a known risk in the product labeling.<br><span class="key">[Objective]</span> Prepare a signal evaluation report for the Safety Management Team that assesses the validity of the signal and recommends next steps.<br><span class="key">[Style]</span> Pharmacovigilance signal assessment report.<br><span class="key">[Tone]</span> Scientific, balanced, and appropriately cautious. Neither dismiss nor overstate the signal.<br><span class="key">[Audience]</span> Safety Management Team (VP Pharmacovigilance, Chief Medical Officer, Head of Regulatory).<br><span class="key">[Response]</span> A structured assessment including: (1) Signal Description and Detection Method, (2) Case Series Summary, (3) Literature and Mechanism Review, (4) Comparator Analysis, (5) Confounding Factors, (6) Preliminary Causality Assessment, (7) Recommended Actions (e.g., enhanced monitoring, label update, health authority notification).<br><span class="key">[Constraints]</span> RAI: No actual product names, case numbers, or exposure data. Bias: Present balanced signal assessment—neither dismiss nor overstate. Source Accuracy: Reference published literature and regulatory guidance. Human Oversight: Signal conclusions require Safety Management Team approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Expedited Report Triage</span>
                        <span class="level-desc">Interactive Assessment</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Serious AE Intake Assessment</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Pharmacovigilance Scientist using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to assess an incoming serious adverse event report to determine reportability timelines, identify missing critical information, and route appropriately.<br>
<span class="key">[Tools]</span> You have access to: [ProductLabel], [ReportingRequirements], [CaseDatabase], [MedicalDictionary], [RegulatoryCalendar]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> It is Friday at 4:45 PM. You receive an initial report from a clinical trial site: a 52-year-old female patient in Study-005 experienced a cardiac arrhythmia requiring hospitalization. The patient was randomized 3 weeks ago but the site has not yet confirmed whether she is in the active treatment arm or placebo arm. The study is blinded. The site PI believes the event may be related to study treatment. The regulatory reporting clock starts from your company's awareness date.<br><span class="key">[Constraints]</span> RAI: No actual patient identifiers or study numbers. Patient Safety: Prioritize patient welfare over administrative convenience. Regulatory: Know exact reporting timelines for each jurisdiction. Human Oversight: Unblinding decisions require Medical Monitor approval per protocol.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately start the 15-day expedited reporting clock and scramble to fill in gaps. ReAct forces you to first verify the seriousness criteria, check if unblinding is required per protocol, review whether cardiac events are expected based on the mechanism of action, and calculate exact regulatory deadlines before acting. This prevents unnecessary unblinding while ensuring compliant, timely reporting.
                    </div>
                </div>

                <div id="qc-analyst" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/search.svg" class="local-icon icon-red" alt="QC"> Quality Control Analyst
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Test Documentation</span><span class="level-desc">Focus: Accuracy (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>OOS Investigation Initiation</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> During routine potency testing of Batch 2024-0892, the result came back at 94.2%, which is below our specification of 95.0-105.0%. This is the first OOS result for this product in 6 months. The analyst who performed the test is experienced and followed the method correctly according to their notebook entries. The sample was from a retained stability sample at the 6-month timepoint.<br><span class="key">[Role]</span> QC Analyst responsible for OOS investigation initiation.<br><span class="key">[Instruction]</span> Document the initial laboratory investigation findings for the OOS investigation report.<br><span class="key">[Style]</span> GMP investigation documentation—factual, thorough, and objective.<br><span class="key">[Parameters]</span> Include: test method verification, equipment calibration status, reagent/standard verification, calculation check, and analyst interview summary. Do not draw conclusions about root cause at this stage.<br><span class="key">[Constraints]</span> RAI: No actual batch numbers, analyst names, or product identifiers. Data Accuracy: Laboratory findings must be documented exactly as observed. Bias: Do not prejudge root cause during initial investigation. Human Oversight: OOS investigations require QA oversight and approval.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Method Transfer</span><span class="level-desc">Focus: Protocol Design (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Analytical Method Transfer Protocol</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are transferring an HPLC assay method for Product-A from our R&D laboratory (sending unit) to the QC laboratory (receiving unit) for routine release testing. The method has been validated at the R&D lab. The receiving unit needs to demonstrate they can execute the method with equivalent results.<br><span class="key">[Role]</span> QC Scientist responsible for method transfer activities.<br><span class="key">[Instruction]</span> Create a method transfer protocol outline with acceptance criteria.<br><span class="key">[Style]</span> GMP protocol format with clear acceptance criteria.<br><span class="key">[Parameters]</span> Include: system suitability requirements, precision study design (minimum 6 preparations), accuracy study design, acceptance criteria based on original validation, and deviation handling. Format as protocol sections with numbered requirements.<br><span class="key">[Example]</span> 5.2 Precision Study<br>5.2.1 The receiving unit shall prepare and analyze 6 independent sample preparations of the reference standard.<br>5.2.2 Acceptance Criteria: %RSD ≤ 2.0% (consistent with original validation)<br><span class="key">[Constraints]</span> RAI: No actual product names or laboratory identifiers. Data Accuracy: Acceptance criteria must align with original validation. Source Accuracy: Reference ICH Q2 and USP requirements. Human Oversight: Method transfer acceptance requires QA approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Trend Analysis</span><span class="level-desc">Focus: Data Interpretation (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Stability Trend Evaluation</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Annual Product Review data shows that Product-B potency results have been trending downward over the past 18 months, from an average of 101.5% at release to 98.2% at the 18-month stability timepoint. All results are within specification (95.0-105.0%), but the trend is statistically significant. The product has a 24-month shelf life and we are concerned about potential OOS results at the 24-month timepoint.<br><span class="key">[Objective]</span> Evaluate the stability trend and recommend appropriate actions.<br><span class="key">[Style]</span> Technical assessment report for Quality Review Board.<br><span class="key">[Tone]</span> Data-driven and proactive. Raise the concern appropriately without being alarmist.<br><span class="key">[Audience]</span> Quality Review Board (Head of QC, Head of QA, Regulatory Affairs).<br><span class="key">[Response]</span> A trend assessment including: (1) Statistical Analysis of Trend, (2) Projected Results at Expiry, (3) Historical Comparison (other batches, other products), (4) Potential Root Causes, (5) Risk Assessment, (6) Recommended Actions (investigation, specification review, shelf life adjustment).<br><span class="key">[Constraints]</span> RAI: No actual product names or batch numbers. Data Accuracy: Statistical projections must use valid methodology. Patient Safety: Proactively address trends before OOS occurs. Human Oversight: Shelf life changes require Regulatory Affairs notification.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Instrument Failure Investigation</span>
                        <span class="level-desc">Interactive Troubleshooting</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>HPLC System Suitability Failure</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a QC Analyst using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to troubleshoot an HPLC system suitability failure and determine whether to proceed with sample analysis or escalate for instrument service.<br>
<span class="key">[Tools]</span> You have access to: [InstrumentLogs], [MaintenanceRecords], [ColumnHistory], [MobilePhasePrep], [MethodSOP]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> During system suitability for a release batch, the resolution between two critical peaks is 1.3, failing the specification of ≥1.5. This is the third system suitability run today—the first two passed. The column is 2 months old (typical life is 6 months). Fresh mobile phase was prepared this morning. A batch is waiting for release and the customer is expecting shipment tomorrow.<br><span class="key">[Constraints]</span> RAI: No actual batch numbers or customer identifiers. Data Integrity: Never proceed with failing system suitability. Transparency: Document all troubleshooting attempts. Human Oversight: Release decisions with shipping pressure require QA Manager approval.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately replace the column since it's an easy fix. ReAct forces you to first systematically check what changed between the passing and failing runs (mobile phase degradation? temperature drift? sample carryover?), review the column history for gradual degradation patterns, and verify instrument logs for any anomalies. This prevents unnecessary column changes and identifies the true root cause for proper documentation.
                    </div>
                </div>

                <div id="validation" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/clipboard.svg" class="local-icon icon-red" alt="Validation"> Validation Specialist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Protocol Execution</span><span class="level-desc">Focus: Documentation (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>IQ Execution Summary</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I completed the Installation Qualification (IQ) for a new analytical balance in the QC laboratory. All tests passed except for one: the environmental monitoring sensor was not detecting the balance location. This was resolved by IT updating the sensor configuration. All other IQ tests (physical installation, utility connections, documentation verification) passed on first attempt.<br><span class="key">[Role]</span> Validation Specialist responsible for IQ documentation.<br><span class="key">[Instruction]</span> Write the IQ execution summary for the validation report.<br><span class="key">[Style]</span> GMP validation documentation—clear, factual, and compliant.<br><span class="key">[Parameters]</span> Include: overall result (pass/fail), summary of tests performed, any deviations encountered and their resolution, and a statement that the equipment is ready for OQ. Use formal validation language.<br><span class="key">[Constraints]</span> RAI: No actual equipment serial numbers or vendor names. Data Accuracy: Results must accurately reflect executed tests. Source Accuracy: Follow applicable GAMP 5 and GMP requirements. Human Oversight: IQ completion requires QA review and approval before OQ.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Risk Assessment</span><span class="level-desc">Focus: FMEA Methodology (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Process FMEA Documentation</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are conducting a Failure Mode and Effects Analysis (FMEA) for a new tablet coating process as part of process validation. The coating process has 5 critical parameters: pan speed, inlet air temperature, spray rate, atomization pressure, and coating duration. We need to identify potential failure modes and their impact on product quality.<br><span class="key">[Role]</span> Validation Engineer responsible for risk assessment documentation.<br><span class="key">[Instruction]</span> Create an FMEA table for the tablet coating process focusing on the critical parameters.<br><span class="key">[Style]</span> ICH Q9 compliant risk assessment format.<br><span class="key">[Parameters]</span> Format as FMEA table with columns: Process Step, Potential Failure Mode, Potential Effect, Severity (1-10), Potential Cause, Occurrence (1-10), Current Controls, Detection (1-10), RPN, Recommended Action. Include at least 2 failure modes per critical parameter.<br><span class="key">[Example]</span> | Coating | Spray rate too high | Tablet picking, uneven coating | 7 | Pump calibration drift | 4 | Inline flow meter alarm | 3 | 84 | Add redundant flow verification |<br><span class="key">[Constraints]</span> RAI: No actual product names or equipment identifiers. Data Accuracy: Risk scores must follow consistent methodology. Source Accuracy: Follow ICH Q9 risk management principles. Human Oversight: High-RPN items require management review and risk acceptance.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Validation Strategy</span><span class="level-desc">Focus: Planning (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Computer System Validation Plan</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are implementing a new Laboratory Information Management System (LIMS) that will manage sample tracking, test results, and electronic batch records for the QC laboratory. The system is a commercial off-the-shelf (COTS) product with configuration capabilities. It will integrate with instruments, the ERP system, and the document management system. The system is subject to 21 CFR Part 11 requirements.<br><span class="key">[Objective]</span> Develop a validation master plan that ensures GxP compliance while optimizing validation effort.<br><span class="key">[Style]</span> Computer System Validation master plan per GAMP 5.<br><span class="key">[Tone]</span> Thorough and risk-based. Apply appropriate rigor without over-validating.<br><span class="key">[Audience]</span> Quality Assurance, IT, and Regulatory Affairs stakeholders.<br><span class="key">[Response]</span> A validation plan including: (1) System Description and GAMP Category, (2) Regulatory Requirements Mapping, (3) Risk Assessment Approach, (4) Validation Deliverables Matrix (by GAMP category), (5) Testing Strategy (leveraging vendor documentation), (6) 21 CFR Part 11 Compliance Approach, (7) Roles and Responsibilities, (8) Change Control and Periodic Review Requirements.<br><span class="key">[Constraints]</span> RAI: No actual vendor names or system identifiers. Source Accuracy: Follow GAMP 5 and 21 CFR Part 11 requirements. Data Integrity: Electronic records must be compliant with regulatory expectations. Human Oversight: Validation plan requires QA and IT stakeholder approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Validation Deviation Assessment</span>
                        <span class="level-desc">Interactive Investigation</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>PQ Test Failure Analysis</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Validation Specialist using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to assess a Performance Qualification test failure and determine the appropriate path forward (retest, investigate, or modify acceptance criteria).<br>
<span class="key">[Tools]</span> You have access to: [ValidationProtocol], [TestData], [EquipmentSpecs], [HistoricalPQ], [ProcessCapability]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> During PQ of a new lyophilizer, one of three test runs failed the cake appearance acceptance criterion. The specification requires "uniform white cake with no meltback." Run 2 showed slight browning at the vial shoulders in 3 of 100 vials. Runs 1 and 3 met all acceptance criteria. The lyophilizer manufacturer states this is within normal variability. Production wants to proceed with qualification approval.<br><span class="key">[Constraints]</span> RAI: No actual equipment serial numbers or vendor names. Data Integrity: Failed tests cannot be dismissed without scientific justification. Bias: Evaluate vendor claims objectively. Human Oversight: Acceptance of failures requires QA and Validation management approval.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to either accept the vendor's assessment and proceed or require complete repeat testing. ReAct forces you to first compare the failure to the original risk assessment, review historical PQ data for similar equipment, assess the statistical significance of the failure rate, and determine if the acceptance criteria are appropriately stringent. This ensures a scientifically justified decision rather than arbitrary acceptance or rejection.
                    </div>
                </div>

                <div id="doc-control" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/layers.svg" class="local-icon icon-red" alt="Doc"> Document Control Specialist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Document Processing</span><span class="level-desc">Focus: Compliance (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>SOP Review Notification</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> SOP-QC-042 "HPLC System Operation and Maintenance" is due for its 2-year periodic review in 30 days. The document owner is the QC Manager. The SOP has had 3 minor revisions since the last periodic review, all related to clarifying procedural steps. No significant changes in practice or regulatory requirements have occurred.<br><span class="key">[Role]</span> Document Control Specialist responsible for periodic review coordination.<br><span class="key">[Instruction]</span> Draft the periodic review notification email to the document owner.<br><span class="key">[Style]</span> Professional and actionable—clear on requirements and deadlines.<br><span class="key">[Parameters]</span> Include: document title and number, current version, review due date, review options (approve as-is, revise, obsolete), required actions, and deadline for response. Keep concise and focused.<br><span class="key">[Constraints]</span> RAI: No actual document numbers or owner names. Data Accuracy: Review dates and version history must be accurate. Transparency: Clearly communicate review requirements. Human Oversight: Document revisions require appropriate subject matter expert review.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Change Control</span><span class="level-desc">Focus: Impact Assessment (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Document Change Impact Analysis</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A significant revision to SOP-MFG-015 "Tablet Compression Operation" has been submitted. The changes include new in-process control limits, addition of a second compression station, and revised cleaning procedures. This SOP is referenced by 12 other documents including batch records, training materials, and equipment SOPs. We need to assess the impact of these changes on related documents.<br><span class="key">[Role]</span> Senior Document Control Specialist responsible for change impact assessment.<br><span class="key">[Instruction]</span> Create a document impact assessment matrix for this SOP revision.<br><span class="key">[Style]</span> Change control documentation format with clear traceability.<br><span class="key">[Parameters]</span> Format as a matrix with columns: Related Document, Document Type, Relationship to Changed SOP, Impact Assessment (None/Minor/Major), Required Action, Responsible Party, Target Date. Categorize impacts by type (procedural, training, batch record).<br><span class="key">[Example]</span> | BR-TAB-001 | Batch Record | References IPC limits | Major | Update IPC section | Production | Prior to SOP effective |<br><span class="key">[Constraints]</span> RAI: Use placeholder document numbers. Data Accuracy: Impact assessments must reflect actual document relationships. Transparency: Identify all affected documents before change implementation. Human Oversight: Major impacts require cross-functional review.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">System Implementation</span><span class="level-desc">Focus: Process Design (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>eDMS Migration Strategy</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company is migrating from a paper-based document management system to an electronic Document Management System (eDMS). We have approximately 3,000 controlled documents across 4 sites. The new system must maintain compliance with 21 CFR Part 11 and EU Annex 11. Historical documents must be accessible for regulatory inspections. The migration timeline is 18 months with a hard deadline due to lease termination of the current records storage facility.<br><span class="key">[Objective]</span> Develop a migration strategy that ensures document integrity and regulatory compliance throughout the transition.<br><span class="key">[Style]</span> Strategic implementation plan.<br><span class="key">[Tone]</span> Methodical and risk-aware. Acknowledge the complexity while providing a clear path forward.<br><span class="key">[Audience]</span> Quality Leadership, IT, and Site Directors.<br><span class="key">[Response]</span> A migration strategy including: (1) Document Inventory and Categorization, (2) Migration Prioritization Criteria, (3) Document Conversion Requirements, (4) Hybrid Operating Procedures (during transition), (5) Validation Approach for eDMS, (6) Training Requirements, (7) Historical Document Handling, (8) Risk Register and Contingency Plans.<br><span class="key">[Constraints]</span> RAI: No actual document counts or vendor names. Data Integrity: Document integrity must be maintained throughout migration. Source Accuracy: Follow 21 CFR Part 11 and EU Annex 11 requirements. Human Oversight: Migration plan requires QA and IT leadership approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Document Discrepancy Resolution</span>
                        <span class="level-desc">Interactive Investigation</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Version Control Issue</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Document Control Specialist using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to investigate a document version control discrepancy discovered during an audit and determine the scope of impact.<br>
<span class="key">[Tools]</span> You have access to: [DocumentHistory], [TrainingRecords], [BatchRecords], [AuditTrail], [DistributionLog]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> During a regulatory inspection preparation audit, an auditor discovered that two different versions of SOP-QC-018 (Version 3 and Version 4) are both marked as "Current" in different locations. Version 4 was issued 6 months ago, but some training records reference Version 3, and some printed copies of Version 3 were found in the laboratory. Production batches have been released during this 6-month period.<br><span class="key">[Constraints]</span> RAI: Use placeholder document numbers. Data Integrity: Version discrepancies require immediate resolution. Transparency: Assess full scope of impact before determining CAPA. Human Oversight: Potential batch impact requires QA and Regulatory notification.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately correct the version status and retrain everyone. ReAct forces you to first determine the actual scope of the issue (how many people were trained on the wrong version? were any batches affected?), understand what changed between versions (is it a significant procedural change?), and assess the regulatory risk before determining the appropriate CAPA. This prevents both under-reaction and unnecessary batch recalls.
                    </div>
                </div>

                <div id="cmc" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/cube.svg" class="local-icon icon-red" alt="CMC"> CMC Regulatory Scientist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">CTD Preparation</span><span class="level-desc">Focus: Organization (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Module 3 Section Summary</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I am preparing Module 3.2.S.4 "Control of Drug Substance" for an IND submission. The analytical methods have been validated and we have batch data from 3 GMP batches. The specification includes 8 tests covering identity, assay, impurities, and physical properties. I need to write the introductory summary for this section that orients the reviewer to the control strategy.<br><span class="key">[Role]</span> CMC Scientist responsible for regulatory submission authoring.<br><span class="key">[Instruction]</span> Write the introductory paragraph for CTD Section 3.2.S.4.<br><span class="key">[Style]</span> ICH M4Q compliant regulatory writing—technical, precise, and well-organized.<br><span class="key">[Parameters]</span> Keep to 1-2 paragraphs. Reference the specification table that follows. Briefly describe the control strategy rationale. Do not include detailed test descriptions (those go in subsections).<br><span class="key">[Constraints]</span> RAI: No actual product names or batch data. Source Accuracy: Follow ICH M4Q CTD format requirements. Data Accuracy: Control strategy must align with validated methods. Human Oversight: Module 3 content requires CMC lead review.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Specification Justification</span><span class="level-desc">Focus: Scientific Rationale (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Impurity Specification Justification</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We need to justify the specification limit for a known process-related impurity in Product-A drug substance. The proposed limit is 0.15%. Batch data from 5 GMP batches shows results ranging from 0.05% to 0.11%. The impurity has been qualified in toxicology studies at levels supporting a daily intake of 1.5 mg. The maximum daily dose of the drug product is 100 mg.<br><span class="key">[Role]</span> CMC Regulatory Scientist responsible for specification justification.<br><span class="key">[Instruction]</span> Write the specification justification for this impurity limit for inclusion in Module 3.2.S.4.5.<br><span class="key">[Style]</span> ICH Q6A/Q3A compliant scientific justification.<br><span class="key">[Parameters]</span> Include: manufacturing capability (batch data summary), toxicological qualification calculation, and any additional supporting rationale. Show the math for tox qualification. Reference ICH guidelines where applicable.<br><span class="key">[Example]</span> Toxicological Qualification:<br>Qualified daily intake: 1.5 mg<br>Maximum daily dose: 100 mg<br>Qualified limit: (1.5 mg / 100 mg) × 100% = 1.5%<br>Proposed limit (0.15%) is well below the qualified limit.<br><span class="key">[Constraints]</span> RAI: Use placeholder values—no actual product data. Data Accuracy: Calculations must be mathematically correct. Source Accuracy: Follow ICH Q3A/Q3B and Q6A guidance. Human Oversight: Specification justifications require Toxicology and Regulatory review.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Regulatory Strategy</span><span class="level-desc">Focus: Agency Communication (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>CMC Pre-Submission Meeting Request</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are developing a novel drug delivery system for an existing approved drug (505(b)(2) pathway). The formulation uses a new excipient that has not been previously used in an approved US product. We are seeking a Pre-IND meeting with FDA to align on the CMC development strategy, particularly regarding excipient safety requirements and comparability study design. We have preliminary stability data but have not started pivotal bioequivalence studies.<br><span class="key">[Objective]</span> Prepare a compelling Pre-IND meeting request that obtains FDA feedback on our critical CMC questions.<br><span class="key">[Style]</span> FDA meeting request format per guidance.<br><span class="key">[Tone]</span> Professional, scientifically rigorous, and focused on obtaining actionable feedback.<br><span class="key">[Audience]</span> FDA CDER review division.<br><span class="key">[Response]</span> A meeting request package including: (1) Meeting Request Cover Letter, (2) Proposed Agenda, (3) List of Questions (3-5 focused questions), (4) Background Package Outline with key CMC data summaries, (5) Proposed Regulatory Strategy for CMC Development.<br><span class="key">[Constraints]</span> RAI: No actual product names or proprietary formulation details. Source Accuracy: Follow FDA meeting request guidance format. Data Accuracy: Questions must be specific and actionable. Human Oversight: Meeting requests require Regulatory Affairs leadership approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Post-Approval Change Assessment</span>
                        <span class="level-desc">Interactive Analysis</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Manufacturing Change Evaluation</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a CMC Regulatory Scientist using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to assess a proposed manufacturing change and determine the appropriate regulatory filing strategy (annual report, CBE-30, PAS).<br>
<span class="key">[Tools]</span> You have access to: [FDAGuidance_SUPAC], [ApprovedNDA], [ChangeDescription], [ComparabilityData], [GlobalFilingMatrix]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> Manufacturing Operations wants to increase batch size for Product-C from 100 kg to 300 kg to meet demand. The product is a tablet formulation. The change requires a larger granulator and tablet press. Process parameters will be scaled using established principles. The product is approved in the US, EU, and Japan. Operations wants to implement the change in 3 months.<br><span class="key">[Constraints]</span> RAI: No actual product names or batch sizes. Source Accuracy: Follow SUPAC and regional guidance requirements. Transparency: Assess all aspects of change—not just batch size. Human Oversight: Global regulatory strategy requires Regional RA team alignment.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to check the SUPAC guidance and file accordingly. ReAct forces you to first assess all aspects of the change (equipment change, process parameter changes, batch size increase), check the approved application for any relevant commitments or post-approval requirements, and consider global regulatory implications before recommending a strategy. This prevents filing deficiencies and ensures the change can be implemented on the desired timeline in all markets.
                    </div>
                </div>

                <div id="labeling" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/clipboard.svg" class="local-icon icon-red" alt="Label"> Labeling Specialist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Label Review</span><span class="level-desc">Focus: Accuracy (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Label Proof Review Checklist</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The printer has submitted final proofs for Product-D primary container labels. This is a commercial label for US market distribution. The label includes drug name, strength, lot number placeholder, expiration date placeholder, NDC, barcode, and storage conditions. I need to complete the final proof review before approval for printing.<br><span class="key">[Role]</span> Labeling Specialist responsible for label proof verification.<br><span class="key">[Instruction]</span> Create a comprehensive label proof review checklist.<br><span class="key">[Style]</span> Quality control checklist format—systematic and auditable.<br><span class="key">[Parameters]</span> Cover: text accuracy (vs. approved master), regulatory compliance (FDA labeling requirements), technical specifications (dimensions, barcodes, variable data fields), and artwork quality. Format as a numbered checklist with pass/fail/NA options.<br><span class="key">[Constraints]</span> RAI: No actual product names, NDCs, or lot numbers. Data Accuracy: All label content must match approved master exactly. Patient Safety: Labeling errors can cause medication errors. Human Oversight: Final proof approval requires QA sign-off.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Labeling Change Management</span><span class="level-desc">Focus: Compliance (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Safety Labeling Update Assessment</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Following a signal evaluation, the Pharmacovigilance team has recommended adding a new warning to the Product-E prescribing information regarding hepatic events. The Medical Affairs team has drafted the proposed warning language. We need to assess the labeling implementation requirements including timing, global harmonization considerations, and regulatory pathways.<br><span class="key">[Role]</span> Senior Labeling Specialist responsible for safety labeling updates.<br><span class="key">[Instruction]</span> Create a labeling change implementation assessment.<br><span class="key">[Style]</span> Regulatory labeling project plan format.<br><span class="key">[Parameters]</span> Include: affected label sections (USPI, patient labeling, carton), regulatory pathway for each region (US CBE-0, EU variation type), timeline requirements, affected markets matrix, and coordination requirements with supply chain. Format as an implementation checklist with dependencies.<br><span class="key">[Example]</span> US Implementation:<br>• Regulatory pathway: CBE-0 (safety labeling change)<br>• Submit within 30 days of safety determination<br>• No approval required before implementation<br>• Supply chain lead time: 8 weeks for new labels<br><span class="key">[Constraints]</span> RAI: No actual product names or regulatory submission numbers. Patient Safety: Safety labeling updates are time-critical—do not delay. Source Accuracy: Follow regional labeling guidance requirements. Human Oversight: Safety labeling requires Medical, Regulatory, and Legal approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Global Labeling Strategy</span><span class="level-desc">Focus: Harmonization (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Global Labeling Harmonization Plan</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Product-F is approved in 45 countries with significant labeling differences that have accumulated over 15 years of marketing. The core data sheet (CDS) was last updated 5 years ago. Recent Phase 4 studies have generated new efficacy data that could support label expansion in some markets. Leadership wants to harmonize global labeling while incorporating the new data.<br><span class="key">[Objective]</span> Develop a global labeling harmonization strategy that maximizes consistency while respecting regional requirements.<br><span class="key">[Style]</span> Strategic labeling plan for global alignment.<br><span class="key">[Tone]</span> Pragmatic and prioritized. Acknowledge that full harmonization may not be achievable and focus on high-impact changes.<br><span class="key">[Audience]</span> Global Regulatory Affairs Leadership and Regional Regulatory teams.<br><span class="key">[Response]</span> A harmonization strategy including: (1) Current State Gap Analysis, (2) Updated CDS with New Data, (3) Prioritization Criteria (market size, gap severity, regulatory complexity), (4) Regional Implementation Plans, (5) Timeline and Resource Requirements, (6) Risk Assessment (rejection scenarios), (7) Success Metrics.<br><span class="key">[Constraints]</span> RAI: No actual product names or market-specific data. Bias: Present realistic assessment of harmonization challenges. Source Accuracy: Respect regional regulatory requirements. Human Oversight: Global harmonization requires Regional RA teams and Medical Affairs alignment.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Urgent Label Recall Assessment</span>
                        <span class="level-desc">Interactive Decision Making</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Label Error Discovery</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Labeling Specialist using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to assess a discovered labeling error and determine the appropriate response (field alert, recall, or correction in next print run).<br>
<span class="key">[Tools]</span> You have access to: [ApprovedLabel], [PrintedLabel], [DistributionRecords], [FDAGuidance], [RiskAssessment]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> QA discovered that 10,000 units of Product-G were shipped with labels showing "Store at 2-8°C" when the approved storage condition is "Store at 20-25°C." The product is actually stable at room temperature. The error occurred due to a template mix-up with a different product. Approximately 2,000 units have already been dispensed to patients through retail pharmacies.<br><span class="key">[Constraints]</span> RAI: No actual product names, lot numbers, or distribution data. Patient Safety: Primary consideration is patient welfare, not business impact. Data Accuracy: Distribution scope must be verified before recall decisions. Human Oversight: Recall decisions require QA, Regulatory, and Executive approval.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately issue a recall given the labeling error. ReAct forces you to first assess the actual patient safety risk (will incorrect storage harm the product?), determine the scope of distribution, check FDA guidance on labeling errors vs. safety issues, and evaluate the risk of patient harm from unnecessary medication changes vs. the labeling error. This ensures a proportionate response that prioritizes patient safety.
                    </div>
                </div>

                <div id="audit" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/search.svg" class="local-icon icon-red" alt="Audit"> Audit & Inspection Specialist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Audit Preparation</span><span class="level-desc">Focus: Organization (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Internal Audit Notification</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Per the annual audit schedule, an internal audit of the Packaging department is scheduled to begin in 3 weeks. The audit scope includes batch record review, line clearance procedures, and label reconciliation practices. The last audit of this area was 18 months ago and resulted in 2 minor observations that have been closed.<br><span class="key">[Role]</span> Internal Auditor responsible for audit coordination.<br><span class="key">[Instruction]</span> Draft the formal audit notification letter to the Packaging Manager.<br><span class="key">[Style]</span> Professional audit communication—formal but collaborative.<br><span class="key">[Parameters]</span> Include: audit dates, scope, auditor names, requested documentation for advance review, and contact for scheduling interviews. Set appropriate expectations without creating unnecessary anxiety.<br><span class="key">[Constraints]</span> RAI: No actual auditor names or department identifiers. Data Accuracy: Audit scope must accurately reflect the audit plan. Transparency: Provide clear expectations for documentation. Human Oversight: Audit notifications follow approved QA procedures.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Finding Documentation</span><span class="level-desc">Focus: Objectivity (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Audit Observation Writing</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> During an internal audit, I observed that the equipment calibration stickers on 3 of 10 sampled balances showed calibration due dates that had passed. The balances were still in use for GMP testing. When questioned, the QC supervisor stated that calibrations had been performed but the stickers hadn't been updated due to workload. Calibration records confirmed the calibrations were current.<br><span class="key">[Role]</span> Internal Auditor responsible for finding documentation.<br><span class="key">[Instruction]</span> Write the audit observation for the final audit report.<br><span class="key">[Style]</span> Objective audit finding format—factual, specific, and citing relevant requirements.<br><span class="key">[Parameters]</span> Structure as: Observation Statement, Supporting Evidence, Reference to Requirement (SOP or regulation), Risk/Impact Assessment, Suggested Classification (Critical/Major/Minor). Do not include root cause or corrective action—that's for the auditee to provide.<br><span class="key">[Example]</span> Observation: Equipment calibration status indicators did not accurately reflect current calibration status.<br>Evidence: Balances QC-BAL-003, QC-BAL-007, and QC-BAL-012 displayed calibration due dates of [past date] at the time of audit on [audit date].<br><span class="key">[Constraints]</span> RAI: Use placeholder equipment IDs and dates. Data Accuracy: Findings must accurately reflect evidence. Bias: Document observations objectively without prejudgment. Human Oversight: Audit findings require QA review before issuance.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Inspection Management</span><span class="level-desc">Focus: Strategy (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Regulatory Inspection Response Strategy</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> FDA has issued a Form 483 following a routine GMP inspection of our manufacturing facility. The form contains 5 observations: 2 related to data integrity in the QC laboratory, 2 related to equipment cleaning validation, and 1 related to complaint handling timelines. The observations reference specific batch records, SOPs, and employee interviews. We have 15 business days to respond.<br><span class="key">[Objective]</span> Develop a comprehensive response strategy that demonstrates commitment to compliance while appropriately addressing each observation.<br><span class="key">[Style]</span> FDA 483 response strategy document.<br><span class="key">[Tone]</span> Respectful and responsive. Accept responsibility where appropriate but clarify misunderstandings professionally.<br><span class="key">[Audience]</span> Site Leadership, Corporate Quality, and Legal (internal), FDA (external response).<br><span class="key">[Response]</span> A response strategy including: (1) Observation-by-Observation Response Approach, (2) Root Cause Analysis Methodology, (3) CAPA Development Framework, (4) Response Writing Guidelines, (5) Review and Approval Workflow, (6) Supporting Documentation Matrix, (7) Timeline for Implementation Commitments, (8) Risk Assessment if Escalation to Warning Letter.<br><span class="key">[Constraints]</span> RAI: No actual batch numbers, employee names, or system details. Data Accuracy: Commitments must be achievable within stated timelines. Transparency: Accept responsibility where appropriate. Human Oversight: 483 responses require Executive, Legal, and QA approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Live Inspection Support</span>
                        <span class="level-desc">Interactive Response</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Inspector Request Handling</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are an Inspection Coordinator using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to respond appropriately to an inspector's document request during a live regulatory inspection.<br>
<span class="key">[Tools]</span> You have access to: [DocumentManagement], [TrainingRecords], [DeviationLog], [SME_Directory], [InspectionLog]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> During a live FDA inspection, the investigator has requested "all deviation reports related to sterility test failures in the past 3 years." You know there have been approximately 15 such deviations, including 2 that resulted in batch rejections. The investigator is currently reviewing batch records and seems to be focusing on aseptic processing. The QA Director is in another meeting.<br><span class="key">[Constraints]</span> RAI: No actual deviation numbers or batch identifiers. Transparency: Provide requested documents—do not hide information. Data Accuracy: Clarify scope before retrieving documents. Human Oversight: Significant document requests require QA Director notification.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately retrieve and provide all requested documents to demonstrate cooperation. ReAct forces you to first clarify the exact scope of the request (all sterility failures or just media fills?), verify you understand what documents exist and their sensitivity, assess whether any documents require SME context before presentation, and determine if leadership should be informed before providing potentially significant findings. This ensures cooperative but strategic document production.
                    </div>
                </div>

                <div id="capa" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/bullseye.svg" class="local-icon icon-red" alt="CAPA"> CAPA Specialist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">CAPA Initiation</span><span class="level-desc">Focus: Documentation (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>CAPA Problem Statement</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A deviation investigation identified that a batch of Product-H was released with incomplete environmental monitoring documentation. The monitoring was performed but the results were not transcribed to the batch record before release. This is the second instance of this type of documentation gap in the past 6 months. QA has determined a CAPA is required.<br><span class="key">[Role]</span> CAPA Coordinator responsible for CAPA initiation.<br><span class="key">[Instruction]</span> Write the problem statement section of the CAPA record.<br><span class="key">[Style]</span> GMP CAPA documentation—factual, specific, and scope-appropriate.<br><span class="key">[Parameters]</span> Include: what happened, when it was discovered, what product/process was affected, and reference to source deviation. Do not include root cause or corrective actions at this stage. Keep factual and non-judgmental.<br><span class="key">[Constraints]</span> RAI: No actual batch numbers, product names, or employee identifiers. Data Accuracy: Problem statement must accurately reflect deviation findings. Bias: Document facts objectively without prejudgment. Human Oversight: CAPA initiation requires QA approval.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Root Cause Analysis</span><span class="level-desc">Focus: Methodology (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Ishikawa Diagram Analysis</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are conducting root cause analysis for a CAPA related to recurring label mix-up errors on the packaging line. Over the past year, there have been 4 near-miss events where wrong labels were loaded into the labeling machine. All were caught during in-process verification. The events occurred across different shifts and different operators.<br><span class="key">[Role]</span> CAPA Specialist responsible for root cause analysis.<br><span class="key">[Instruction]</span> Conduct an Ishikawa (fishbone) analysis to identify potential root causes.<br><span class="key">[Style]</span> Structured root cause analysis per quality management methodology.<br><span class="key">[Parameters]</span> Use the 6M categories (Man, Machine, Method, Material, Measurement, Mother Nature/Environment). Identify at least 2 potential causes per category where applicable. For each potential cause, note the evidence for or against.<br><span class="key">[Example]</span> Man (People):<br>• Training gaps on new labeling equipment - Evidence: 2 of 4 events involved recently trained operators<br>• Fatigue due to overtime - Evidence: 3 of 4 events occurred during extended shifts<br><span class="key">[Constraints]</span> RAI: No actual employee names or identifying details. Data Accuracy: Evidence must support each potential cause. Bias: Consider all 6M categories without prejudgment. Human Oversight: Root cause conclusions require cross-functional review.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Effectiveness Verification</span><span class="level-desc">Focus: Metrics (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>CAPA Effectiveness Criteria Design</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A CAPA was implemented 6 months ago to address recurring equipment calibration delays. The corrective actions included a new calibration scheduling system, additional calibration technician training, and revised SOP for calibration prioritization. The preventive action was implementing predictive maintenance alerts. We need to design the effectiveness verification to demonstrate the CAPA achieved its objectives.<br><span class="key">[Objective]</span> Design a comprehensive effectiveness verification plan that provides objective evidence of CAPA success.<br><span class="key">[Style]</span> CAPA effectiveness verification protocol.<br><span class="key">[Tone]</span> Rigorous and objective. The verification must withstand regulatory scrutiny.<br><span class="key">[Audience]</span> Quality Assurance Management and Regulatory Inspectors.<br><span class="key">[Response]</span> An effectiveness verification plan including: (1) Success Criteria Definition (specific, measurable), (2) Verification Methods (data analysis, audits, interviews), (3) Sampling Plan (what data, what time period), (4) Statistical Approach (if applicable), (5) Verification Timeline, (6) Acceptance Criteria for Closure, (7) Contingency if Effectiveness Not Demonstrated.<br><span class="key">[Constraints]</span> RAI: No actual metric data or system names. Data Accuracy: Criteria must be measurable and objective. Transparency: If effectiveness not demonstrated, reopen CAPA. Human Oversight: CAPA closure requires QA verification and approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Systemic Issue Identification</span>
                        <span class="level-desc">Interactive Investigation</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>CAPA Trend Analysis</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a CAPA Specialist using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to analyze CAPA trends to identify potential systemic issues that individual CAPAs may not have addressed.<br>
<span class="key">[Tools]</span> You have access to: [CAPA_Database], [DeviationTrends], [TrainingRecords], [ProcessChanges], [OrganizationalChanges]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> The annual CAPA metrics show that 35% of CAPAs in the manufacturing area have required extension of their implementation timelines, and 15% of closed CAPAs have had recurrence of similar issues within 12 months. Leadership is concerned about CAPA effectiveness but individual CAPA files show adequate root cause analysis and appropriate corrective actions. The issue appears to be systemic rather than case-specific.<br><span class="key">[Constraints]</span> RAI: Use example metrics—no actual CAPA data. Data Accuracy: Trend analysis must use verified metrics. Bias: Look for systemic issues, not blame individuals. Human Oversight: Systemic findings require Quality Management Review.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to audit individual CAPAs more rigorously or add more approval layers. ReAct forces you to first look for patterns across CAPAs (are certain departments, root cause categories, or corrective action types overrepresented in failures?), check if organizational changes correlate with the trend, and assess whether the CAPA process itself has systemic weaknesses. This identifies true systemic issues rather than adding bureaucracy that doesn't address root causes.
                    </div>
                </div>

                <div id="compliance" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/lock.svg" class="local-icon icon-red" alt="Compliance"> Compliance & Legal Affairs
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Policy Interpretation</span><span class="level-desc">Focus: Clarity (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Policy Clarification Response</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> An employee from the Commercial team submitted a question to the Compliance inbox asking whether they can accept a dinner invitation from a healthcare professional who is also a paid consultant for our company. Our policy on interactions with HCPs has specific provisions about meals, but the consultant relationship adds complexity.<br><span class="key">[Role]</span> Compliance Specialist responsible for policy guidance.<br><span class="key">[Instruction]</span> Draft a response that interprets the applicable policies and provides clear guidance.<br><span class="key">[Style]</span> Formal compliance advisory—clear, factual, and appropriately cautious.<br><span class="key">[Parameters]</span> Reference the specific policy sections that apply. Provide a clear yes/no/conditional answer. Include any documentation or approval requirements. Keep under 200 words.<br><span class="key">[Constraints]</span> RAI: No actual employee names, HCP names, or company identifiers. Source Accuracy: Reference specific policy sections. Data Accuracy: Guidance must accurately reflect policy requirements. Human Oversight: Complex interpretations require Compliance leadership review.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Investigation Documentation</span><span class="level-desc">Focus: Objectivity (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Investigation Summary Report</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The Compliance team completed an investigation into an anonymous hotline report alleging that a sales representative provided unapproved promotional materials to a healthcare provider. The investigation included interviews with the representative, their manager, and the HCP. Document review included email records and the materials in question. The investigation found that the representative shared an internal training deck that contained off-label information, which was a policy violation but appeared unintentional.<br><span class="key">[Role]</span> Compliance Investigator responsible for case documentation.<br><span class="key">[Instruction]</span> Write the investigation summary section for the case file.<br><span class="key">[Style]</span> Legal/compliance investigation format—objective, chronological, and evidence-based.<br><span class="key">[Parameters]</span> Structure as: (1) Allegation Summary, (2) Investigation Methodology, (3) Findings of Fact, (4) Policy Analysis, (5) Conclusion. Do not include recommendations in this section. Use neutral language—"the investigation found" rather than accusatory statements.<br><span class="key">[Example]</span> Allegation Summary: On [date], the Compliance Hotline received an anonymous report alleging that...<br><span class="key">[Constraints]</span> RAI: No actual employee names, dates, or identifying details. Data Accuracy: Findings must be based on documented evidence. Bias: Use neutral language—findings, not accusations. Human Oversight: Investigation conclusions require Legal and Compliance leadership review.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Risk Assessment</span><span class="level-desc">Focus: Strategic Analysis (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Compliance Risk Assessment</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company is expanding commercial operations into a new region with a different regulatory environment and higher corruption risk according to international indices. The local business development team is eager to move quickly and has proposed using a third-party distributor with strong government relationships. Compliance has been asked to assess the risks and provide recommendations for proceeding safely.<br><span class="key">[Objective]</span> Provide a comprehensive risk assessment that enables informed decision-making while protecting the company from FCPA/anti-bribery exposure.<br><span class="key">[Style]</span> Executive risk assessment memo.<br><span class="key">[Tone]</span> Analytical, balanced, and constructive. Identify risks without being obstructionist—focus on mitigation rather than simple rejection.<br><span class="key">[Audience]</span> General Counsel, Chief Compliance Officer, and VP of Business Development.<br><span class="key">[Response]</span> A risk assessment including: (1) Regional Risk Profile, (2) Third-Party Due Diligence Requirements, (3) Specific Red Flags to Investigate, (4) Recommended Contractual Protections, (5) Ongoing Monitoring Framework, (6) Go/No-Go Criteria.<br><span class="key">[Constraints]</span> RAI: No actual company names, regions, or distributor details. Source Accuracy: Reference FCPA, UK Bribery Act, and applicable local laws. Bias: Focus on risk mitigation, not obstruction. Human Oversight: High-risk market entry requires Legal and Executive approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Conflict of Interest Review</span>
                        <span class="level-desc">Interactive Assessment</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>COI Disclosure Analysis</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Compliance Officer using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to assess a conflict of interest disclosure and determine appropriate mitigation measures by systematically gathering information.<br>
<span class="key">[Tools]</span> You have access to: [COI_Policy], [EmployeeRecord], [VendorDatabase], [OrganizationalChart], [ApprovalWorkflow]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> A senior director in the Procurement department disclosed that their spouse recently accepted a position at a company that is one of our major contract manufacturing organizations (CMO). The director currently has signature authority for contracts with this CMO and participated in the last contract renewal negotiation. The next contract review is scheduled in 4 months.<br><span class="key">[Constraints]</span> RAI: No actual employee names, titles, or vendor names. Data Accuracy: Assess actual decision-making influence. Bias: Design proportionate mitigation, not overreaction. Human Oversight: COI mitigation plans require Legal and HR approval.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately recuse the employee from all interactions with the CMO. ReAct forces you to first assess the actual scope of the conflict (what decisions does this person influence?), review the CMO relationship terms, check if there are alternative approvers, and design a mitigation plan that protects the company while being proportionate to the actual risk. This prevents both under-protection and unnecessarily disrupting business operations.
                    </div>
                </div>

                <div id="supply" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/layers.svg" class="local-icon icon-red" alt="Supply"> Supply Chain & Procurement
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Vendor Communication</span><span class="level-desc">Focus: Professionalism (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Supplier Performance Notice</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> One of our key raw material suppliers has had 3 late deliveries in the past quarter, causing production scheduling disruptions. Per our supplier quality agreement, we are required to issue a formal notice after repeated performance issues. We want to maintain the relationship but need to communicate the seriousness of the situation.<br><span class="key">[Role]</span> Procurement Manager responsible for supplier relationship management.<br><span class="key">[Instruction]</span> Draft a formal performance notice letter to the supplier.<br><span class="key">[Style]</span> Professional business correspondence—firm but constructive.<br><span class="key">[Parameters]</span> Reference the specific contract clause regarding delivery performance. List the 3 incidents with dates. Request a corrective action plan within 15 business days. Do not threaten contract termination in this first notice. Keep under 200 words.<br><span class="key">[Constraints]</span> RAI: No actual supplier names, contract numbers, or delivery dates. Data Accuracy: Performance data must reflect verified records. Bias: Focus on improvement, maintain professional relationship. Human Oversight: Supplier escalations follow approved procurement procedures.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Contract Summary</span><span class="level-desc">Focus: Key Terms (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Vendor Agreement Summary</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are preparing for a contract review meeting with internal stakeholders (Quality, Finance, Operations) regarding our agreement with a critical packaging supplier. The full contract is 45 pages with multiple amendments. Stakeholders need a concise summary of the key commercial and operational terms before the meeting.<br><span class="key">[Role]</span> Senior Procurement Specialist responsible for contract administration.<br><span class="key">[Instruction]</span> Create an executive summary of the key contract terms for stakeholder review.<br><span class="key">[Style]</span> Business summary format—clear, organized, and focused on actionable terms.<br><span class="key">[Parameters]</span> Format as sections covering: (1) Pricing & Payment Terms, (2) Volume Commitments, (3) Quality Requirements, (4) Delivery Terms, (5) Term & Termination, (6) Key Risks/Concerns. Flag any terms that expire or require action in the next 6 months.<br><span class="key">[Example]</span> Pricing & Payment Terms:<br>• Base price: $X per unit with annual escalator tied to PPI<br>• Payment: Net 45 from invoice date<br>• Volume discount: 5% rebate if annual volume exceeds X units<br><span class="key">[Constraints]</span> RAI: No actual contract values, supplier names, or pricing. Data Accuracy: Summary must accurately reflect contract terms. Source Accuracy: Reference specific contract sections and amendments. Human Oversight: Contract summaries require Legal review for accuracy.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Supply Risk Mitigation</span><span class="level-desc">Focus: Strategic Planning (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Supply Continuity Plan</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A critical active pharmaceutical ingredient (API) for one of our top-selling products is single-sourced from a manufacturer in a region experiencing geopolitical instability. Recent events have disrupted shipping routes and increased lead times from 8 weeks to 14 weeks. We have 6 months of safety stock, but leadership is concerned about long-term supply continuity. Qualifying an alternative supplier would take 18-24 months due to regulatory requirements.<br><span class="key">[Objective]</span> Develop a supply continuity plan that addresses both immediate risk mitigation and long-term resilience.<br><span class="key">[Style]</span> Strategic supply chain planning document.<br><span class="key">[Tone]</span> Analytical, action-oriented, and realistic about constraints (regulatory timelines, cost implications).<br><span class="key">[Audience]</span> VP Supply Chain, VP Quality, CFO, and SVP Operations.<br><span class="key">[Response]</span> A continuity plan including: (1) Current State Assessment, (2) Immediate Actions (0-6 months), (3) Medium-Term Actions (6-18 months), (4) Long-Term Resilience Strategy, (5) Investment Requirements, (6) Risk Scenarios with Response Protocols.<br><span class="key">[Constraints]</span> RAI: No actual product names, supplier names, or inventory levels. Data Accuracy: Safety stock and lead time data must be current. Transparency: Honestly assess regulatory constraints on qualification timeline. Human Oversight: Supply continuity decisions require Executive and Quality approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Supplier Qualification Decision</span>
                        <span class="level-desc">Interactive Evaluation</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>New Vendor Assessment</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Procurement Manager using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to evaluate a potential new supplier and make a qualification recommendation by systematically gathering information from multiple sources.<br>
<span class="key">[Tools]</span> You have access to: [SupplierQuestionnaire], [FinancialDatabase], [QualityAuditReports], [ReferenceCheck], [ComplianceScreening]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> Operations has requested qualification of a new secondary supplier for a critical excipient. The proposed supplier is 20% less expensive than our current primary supplier and claims to have capacity for our volume requirements. However, they are a relatively new company (established 5 years ago) and have never supplied to a pharmaceutical company before. The qualification audit is scheduled for next month.<br><span class="key">[Constraints]</span> RAI: No actual supplier names, pricing, or material identifiers. Data Accuracy: Verify all supplier claims independently. Bias: Don't let cost savings override quality concerns. Human Oversight: Supplier qualification requires Quality and Procurement leadership approval.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to focus primarily on the cost savings and capacity claims. ReAct forces you to first verify financial stability (can they survive if we become a major customer?), check regulatory compliance history, assess their quality systems maturity for pharma requirements, and gather references from their current customers. This prevents qualifying a supplier who may fail or require extensive remediation.
                    </div>
                </div>

                <div id="hr" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/user-tie.svg" class="local-icon icon-red" alt="HR"> Human Resources
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Employee Communication</span><span class="level-desc">Focus: Clarity (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Benefits Change Announcement</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Starting next quarter, the company is changing health insurance providers. The new plan has comparable coverage but different network providers and a new enrollment portal. Employees need to re-enroll during open enrollment next month, or they will be defaulted to the base plan. This affects all 500+ employees and their dependents.<br><span class="key">[Role]</span> HR Benefits Specialist responsible for employee communications.<br><span class="key">[Instruction]</span> Draft an initial announcement email about the health insurance transition.<br><span class="key">[Style]</span> Clear, reassuring, and action-oriented—employees are often anxious about benefits changes.<br><span class="key">[Parameters]</span> Include: what is changing, what is staying the same, key action required (re-enrollment), deadline, and where to get help. Keep under 200 words. Do not include detailed plan comparisons—reference the attached summary instead.<br><span class="key">[Constraints]</span> RAI: No actual insurance provider names or employee identifiers. Data Accuracy: Enrollment deadlines must be accurate. Transparency: Clearly communicate required actions and consequences of inaction. Human Oversight: Benefits communications require HR and Legal review.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Performance Documentation</span><span class="level-desc">Focus: Objectivity (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Performance Improvement Plan</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A manager has requested HR support in documenting a Performance Improvement Plan (PIP) for an employee who has consistently missed project deadlines and received multiple verbal warnings over the past 6 months. The employee is otherwise technically skilled and has been with the company for 3 years. The manager wants to give the employee a genuine opportunity to improve while documenting appropriately.<br><span class="key">[Role]</span> HR Business Partner responsible for performance management documentation.<br><span class="key">[Instruction]</span> Draft the Performance Improvement Plan document.<br><span class="key">[Style]</span> Formal HR documentation—objective, specific, and legally defensible.<br><span class="key">[Parameters]</span> Structure as: (1) Performance Concern Summary (specific examples, not generalizations), (2) Expected Performance Standards, (3) Improvement Actions with Measurable Goals, (4) Support/Resources Provided, (5) Timeline (typically 30-60 days), (6) Consequences of Not Meeting Expectations. Use neutral language focused on behaviors, not personality.<br><span class="key">[Example]</span> Performance Concern: On [date], the Q3 financial report was submitted 5 business days after the established deadline of [date]. This was the third deadline miss in the current quarter...<br><span class="key">[Constraints]</span> RAI: No actual employee names, performance data, or identifying details. Data Accuracy: Performance examples must be documented and specific. Bias: Focus on behaviors, not personality. Human Oversight: PIPs require HR and Legal review before issuance.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Organizational Change</span><span class="level-desc">Focus: Change Management (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Restructuring Communication Plan</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company is consolidating two departments (Field Operations and Technical Support) into a single Customer Success organization. This will result in a new reporting structure, some role changes, and unfortunately, elimination of 8 positions due to redundancy. The affected employees have been identified but not yet notified. The merger is intended to improve customer experience and operational efficiency.<br><span class="key">[Objective]</span> Develop a comprehensive communication plan that manages the organizational change while treating affected employees with dignity.<br><span class="key">[Style]</span> Change management communication strategy.<br><span class="key">[Tone]</span> Empathetic but honest. Acknowledge the difficulty while explaining the business rationale.<br><span class="key">[Audience]</span> HR Leadership, Legal, and the executives who will deliver the communications.<br><span class="key">[Response]</span> A communication plan including: (1) Stakeholder Matrix (who needs to know what, when), (2) Day-of Communication Sequence, (3) Scripts for Individual Notifications (affected vs. retained employees), (4) FAQ Document for Managers, (5) Follow-up Communications Timeline, (6) Key Messages and Off-Limits Topics.<br><span class="key">[Constraints]</span> RAI: No actual employee names, department names, or position titles. Transparency: Honest communication while maintaining dignity. Bias: Treat all affected employees with respect and fairness. Human Oversight: Restructuring communications require Legal, HR, and Executive approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Workplace Investigation</span>
                        <span class="level-desc">Interactive Assessment</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Employee Relations Case</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are an HR Business Partner using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to assess an employee relations complaint and determine appropriate next steps by systematically gathering information.<br>
<span class="key">[Tools]</span> You have access to: [EmployeeFile], [PolicyManual], [PriorComplaints], [OrganizationalChart], [WitnessInterviewGuide]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> An employee has submitted a formal complaint alleging that their manager creates a hostile work environment through frequent public criticism and unreasonable workload expectations. The employee states this has been ongoing for 4 months and is affecting their mental health. The manager is a high performer who was recently promoted. Two other team members have informally mentioned similar concerns to their peers.<br><span class="key">[Constraints]</span> RAI: No actual employee names, departments, or identifying details. Bias: Investigate objectively—don't prejudge based on performance ratings. Employee Welfare: Take mental health concerns seriously. Human Oversight: Investigation findings require HR and Legal review.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately interview the manager and make a quick assessment. ReAct forces you to first review the manager's prior complaints history, check if the employee has documented specific incidents, understand the team dynamics and workload metrics, and plan a proper investigation sequence. This ensures a thorough, fair process that protects both the complainant and the company.
                    </div>
                </div>

                <div id="finance" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/chart-bar.svg" class="local-icon icon-red" alt="Finance"> Finance & Planning
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Variance Analysis</span><span class="level-desc">Focus: Explanation (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Budget Variance Commentary</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The monthly close shows that the R&D department is 15% over budget for the quarter, primarily driven by higher-than-planned external consulting costs. The department head has explained that this was due to accelerating a critical Phase 2 study timeline. Finance needs to provide variance commentary for the executive report.<br><span class="key">[Role]</span> Financial Analyst responsible for R&D cost center reporting.<br><span class="key">[Instruction]</span> Write the variance commentary for the R&D budget section of the monthly finance report.<br><span class="key">[Style]</span> Finance reporting format—factual, quantified, and forward-looking.<br><span class="key">[Parameters]</span> Include: (1) Variance amount in dollars and percentage, (2) Root cause explanation, (3) Whether this is a timing variance or a true over-run, (4) Outlook for remainder of year. Keep under 100 words.<br><span class="key">[Constraints]</span> RAI: No actual budget amounts, department names, or project identifiers. Data Accuracy: Variance amounts must match financial records. Transparency: Clearly distinguish timing vs. permanent variances. Human Oversight: Significant variances require Finance leadership review.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Financial Modeling</span><span class="level-desc">Focus: Assumptions Documentation (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Forecast Assumptions Summary</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are preparing the annual operating plan for next fiscal year. The CFO has requested that all forecast assumptions be clearly documented and defensible. Our Commercial team has submitted revenue projections for Product-A that show 25% growth, which is higher than historical trends. We need to document the assumptions supporting this projection.<br><span class="key">[Role]</span> Senior Financial Analyst responsible for planning and forecasting.<br><span class="key">[Instruction]</span> Create an assumptions documentation summary for the Product-A revenue forecast.<br><span class="key">[Style]</span> Financial planning documentation—structured, auditable, and conservative where appropriate.<br><span class="key">[Parameters]</span> Format as a table with columns: Assumption, Value, Source/Rationale, Risk Level (Low/Medium/High), Sensitivity. Include both upside and downside scenarios.<br><span class="key">[Example]</span> | Assumption | Value | Source/Rationale | Risk | Sensitivity |<br>|------------|-------|------------------|------|-------------|<br>| Market growth rate | 8% | Industry analyst report | Low | +/- 2% = $X revenue impact |<br><span class="key">[Constraints]</span> RAI: No actual product names, revenue figures, or growth rates. Data Accuracy: Assumptions must be documented and defensible. Source Accuracy: Reference specific data sources for each assumption. Human Oversight: Forecast assumptions require Finance leadership approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Investment Analysis</span><span class="level-desc">Focus: Decision Support (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Capital Investment Business Case</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Operations has requested $5M in capital expenditure for a new packaging line that would increase capacity by 40% and reduce per-unit costs by 12%. The current line is at 85% capacity and demand forecasts suggest we will exceed capacity in 18 months. However, the company is also evaluating a potential acquisition that may provide alternative capacity. The investment committee meets in 2 weeks.<br><span class="key">[Objective]</span> Prepare a comprehensive business case that enables the investment committee to make an informed capital allocation decision.<br><span class="key">[Style]</span> Investment committee presentation format.<br><span class="key">[Tone]</span> Analytical, balanced, and transparent about uncertainties.<br><span class="key">[Audience]</span> CFO, CEO, and Board Investment Committee.<br><span class="key">[Response]</span> A business case including: (1) Investment Summary, (2) Strategic Rationale, (3) Financial Analysis (NPV, IRR, Payback), (4) Key Assumptions and Sensitivities, (5) Risk Factors (including acquisition scenario), (6) Alternatives Considered, (7) Recommendation with Conditions.<br><span class="key">[Constraints]</span> RAI: No actual investment amounts, project names, or acquisition targets. Data Accuracy: Financial projections must use validated assumptions. Bias: Present balanced analysis including risks and alternatives. Human Oversight: Capital investment decisions require Executive and Board approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Financial Close Investigation</span>
                        <span class="level-desc">Interactive Analysis</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Unexpected Variance Investigation</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Finance Manager using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to investigate an unexpected variance identified during month-end close and determine the appropriate accounting treatment.<br>
<span class="key">[Tools]</span> You have access to: [GeneralLedger], [SubledgerDetail], [JournalEntryLog], [PriorPeriodClose], [AccountingPolicy]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> During the month-end close process, you identified a $450,000 favorable variance in the Cost of Goods Sold account that cannot be explained by volume or price changes. The variance appeared in the third week of the month. The Operations team says nothing unusual happened, and the purchasing team reports no significant price changes. The external auditors have flagged this for investigation.<br><span class="key">[Constraints]</span> RAI: No actual account balances, department names, or dates. Data Integrity: Unexplained variances must be investigated before close. Transparency: Document investigation steps and findings. Human Oversight: Auditor-flagged items require Controller and CFO notification.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to accept a favorable variance at face value or make a quick adjustment. ReAct forces you to first trace the variance to specific transactions, compare to prior period patterns, verify that inventory and accruals are properly stated, and determine if this is a true economic gain or an accounting error. This prevents misstatements that could require later restatement.
                    </div>
                </div>

                <div id="training" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/bullseye.svg" class="local-icon icon-red" alt="Training"> Training & Development
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Training Communication</span><span class="level-desc">Focus: Engagement (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Mandatory Training Reminder</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Annual compliance training is due in 2 weeks, and 40% of employees have not yet completed it. This is a regulatory requirement and late completion can result in audit findings. Previous reminder emails have been ignored by many employees. We need a more effective communication approach.<br><span class="key">[Role]</span> Training Coordinator responsible for compliance training administration.<br><span class="key">[Instruction]</span> Draft a reminder email that motivates completion without being threatening.<br><span class="key">[Style]</span> Firm but friendly—acknowledge that employees are busy while emphasizing the importance and deadline.<br><span class="key">[Parameters]</span> Include: specific deadline, how long the training takes, link to access, and consequences of non-completion (stated factually, not threateningly). Keep under 150 words. Avoid compliance jargon that causes email fatigue.<br><span class="key">[Constraints]</span> RAI: No actual employee names or completion statistics by name. Data Accuracy: Deadlines and requirements must be accurate. Transparency: Clearly state consequences without exaggeration. Human Oversight: Training non-compliance escalations follow HR procedures.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Competency Assessment</span><span class="level-desc">Focus: Measurement (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Training Effectiveness Evaluation</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We recently completed a new product training program for the sales team (50 participants over 3 sessions). The training included classroom instruction, role-playing exercises, and a written assessment. We need to evaluate whether the training was effective and identify any gaps that require reinforcement.<br><span class="key">[Role]</span> Learning & Development Specialist responsible for training evaluation.<br><span class="key">[Instruction]</span> Create a training effectiveness summary report based on the Kirkpatrick model.<br><span class="key">[Style]</span> L&D reporting format—data-driven, actionable, and focused on continuous improvement.<br><span class="key">[Parameters]</span> Structure using Kirkpatrick's 4 levels: (1) Reaction (participant satisfaction), (2) Learning (assessment scores), (3) Behavior (observed application), (4) Results (business impact). Include specific metrics and recommendations for each level.<br><span class="key">[Example]</span> Level 1 - Reaction:<br>• Average satisfaction score: 4.2/5.0<br>• 85% rated the training as "relevant to my job"<br>• Improvement opportunity: Participants requested more hands-on practice time<br><span class="key">[Constraints]</span> RAI: No actual participant names or individual scores. Data Accuracy: Metrics must accurately reflect training outcomes. Bias: Honest assessment of effectiveness including gaps. Human Oversight: Training effectiveness results inform curriculum decisions.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Curriculum Design</span><span class="level-desc">Focus: Strategic Planning (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Training Curriculum Proposal</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company is implementing a new enterprise system that will change how 80% of employees do their daily work. The system go-live is in 6 months. Leadership has asked Training & Development to propose a comprehensive training curriculum that ensures all users are proficient by go-live. Budget is limited, so we need to prioritize high-impact training while leveraging self-service options where possible.<br><span class="key">[Objective]</span> Propose a training curriculum strategy that maximizes user adoption within budget and timeline constraints.<br><span class="key">[Style]</span> Strategic curriculum design proposal.<br><span class="key">[Tone]</span> Practical, resource-conscious, and focused on outcomes rather than training hours.<br><span class="key">[Audience]</span> Project Steering Committee (IT, Operations, HR, and Finance leadership).<br><span class="key">[Response]</span> A curriculum proposal including: (1) Training Needs Analysis by Role, (2) Delivery Strategy (instructor-led vs. self-paced vs. on-the-job), (3) Timeline with Milestones, (4) Resource Requirements (trainers, materials, systems), (5) Budget Breakdown, (6) Success Metrics, (7) Risk Mitigation (what if go-live is accelerated?).<br><span class="key">[Constraints]</span> RAI: No actual system names, budget figures, or employee counts. Data Accuracy: Resource estimates must be realistic and defensible. Transparency: Acknowledge timeline risks honestly. Human Oversight: Curriculum proposals require HR and project leadership approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Training Gap Analysis</span>
                        <span class="level-desc">Interactive Assessment</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Competency Gap Investigation</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Training Manager using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to identify the root cause of a performance gap and determine whether training is the appropriate solution.<br>
<span class="key">[Tools]</span> You have access to: [TrainingRecords], [PerformanceMetrics], [JobDescriptions], [ProcessDocumentation], [ManagerFeedback]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> The Quality department has reported that error rates in batch documentation have increased 40% over the past quarter. They have requested "refresher training" for production operators as an immediate corrective action. The operators completed their initial GMP training 6 months ago, and all passed the assessment. Three new SOPs were introduced last month.<br><span class="key">[Constraints]</span> RAI: No actual department names, error counts, or employee identifiers. Data Accuracy: Verify performance data before proposing solutions. Bias: Determine if training is the actual solution—don't assume. Human Oversight: Performance gap analysis requires cross-functional input.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately schedule the requested training. ReAct forces you to first verify whether this is actually a training problem (did operators ever know this?) or a systems/process problem (did something change that training didn't cover?). By checking the timeline of the new SOPs and correlating with the error spike, you might discover the solution is updating job aids, not retraining. This prevents wasting training resources on non-training problems.
                    </div>
                </div>

                <div id="comms" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/email.svg" class="local-icon icon-red" alt="Comms"> Communications & Public Relations
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Internal Communications</span><span class="level-desc">Focus: Clarity (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Company Announcement</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company has been named to a "Best Places to Work in Pharma" list by a respected industry publication. This is the first time the company has received this recognition. Leadership wants to share this news with all employees to boost morale, but without being self-congratulatory.<br><span class="key">[Role]</span> Internal Communications Specialist responsible for employee announcements.<br><span class="key">[Instruction]</span> Draft an all-employee announcement about the award recognition.<br><span class="key">[Style]</span> Celebratory but humble—thank employees rather than just announcing an achievement.<br><span class="key">[Parameters]</span> Keep under 150 words. Credit employees as the reason for the recognition. Include what the award measured (culture, benefits, etc.). Do not overstate the significance. Include any relevant metrics from the survey.<br><span class="key">[Constraints]</span> RAI: No actual survey scores or identifying metrics. Data Accuracy: Award details must accurately reflect the recognition. Bias: Celebrate without being self-congratulatory. Human Oversight: External communications require HR and Legal review.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">External Communications</span><span class="level-desc">Focus: Media Relations (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Press Release Draft</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company has received FDA approval for Product-Q, a new treatment for a chronic condition affecting 5 million patients in the US. This is the company's third approved product. The approval was based on positive Phase 3 results announced last quarter. Commercial launch is planned for next month.<br><span class="key">[Role]</span> Public Relations Manager responsible for regulatory milestone communications.<br><span class="key">[Instruction]</span> Draft a press release announcing the FDA approval.<br><span class="key">[Style]</span> AP Style press release format suitable for wire distribution.<br><span class="key">[Parameters]</span> Follow inverted pyramid structure. Include quotes from CEO and Chief Medical Officer (placeholder). Include standard boilerplate. Reference the disease burden and unmet need. Include forward-looking statement disclaimer. Do not include specific pricing.<br><span class="key">[Example]</span> [Company Name] Receives FDA Approval for [Product Name] for Treatment of [Indication]<br>– First [category] therapy approved since [year] –<br>– Commercial availability expected in [timeframe] –<br>[City, Date] – [Company Name] (Ticker: XYZ) today announced...<br><span class="key">[Constraints]</span> RAI: No actual product names, trial data, or patient counts. Data Accuracy: All clinical claims must match approved labeling. Regulatory: Include required disclaimers for forward-looking statements. Human Oversight: Press releases require Legal, Medical, and Regulatory approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Crisis Communications</span><span class="level-desc">Focus: Reputation Management (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Crisis Response Strategy</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A product quality issue has been identified that may require a voluntary recall of Product-R from the market. No patient harm has been reported, but the issue affects product efficacy and regulatory notification is required. News of the issue has begun circulating on social media through a patient advocacy group post. Traditional media inquiries are expected within 24 hours.<br><span class="key">[Objective]</span> Develop a comprehensive crisis communication strategy that protects patient safety, maintains stakeholder trust, and manages reputational risk.<br><span class="key">[Style]</span> Crisis communication playbook.<br><span class="key">[Tone]</span> Transparent, responsible, and patient-centric. Take accountability without admitting liability.<br><span class="key">[Audience]</span> Multiple: patients, HCPs, employees, investors, regulators, media.<br><span class="key">[Response]</span> A crisis strategy including: (1) Stakeholder Prioritization Matrix, (2) Key Messages by Audience, (3) Spokesperson Designation, (4) Communication Timeline, (5) Channel Strategy (proactive vs. reactive), (6) Q&A Document, (7) Social Media Response Protocol, (8) Internal Communication Plan.<br><span class="key">[Constraints]</span> RAI: No actual product names, batch numbers, or patient impact data. Patient Safety: Patient welfare is the primary consideration in all messaging. Transparency: Take accountability without admitting liability prematurely. Human Oversight: Crisis communications require Legal, Medical, and Executive approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Media Inquiry Response</span>
                        <span class="level-desc">Interactive Assessment</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Sensitive Media Request</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a PR Manager using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to assess a media inquiry and develop an appropriate response strategy.<br>
<span class="key">[Tools]</span> You have access to: [MediaContactDatabase], [ApprovedMessages], [LegalReview], [ExecutiveCalendar], [CompetitorNews]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> A journalist from a major business publication has requested an interview with the CEO regarding "recent layoffs and their impact on R&D pipeline." The company did reduce headcount by 8% last quarter, but it was described internally as "restructuring," not layoffs. The R&D pipeline has not been affected. The journalist's previous articles have been critical of pharma industry cost-cutting. The request deadline is tomorrow morning.<br><span class="key">[Constraints]</span> RAI: No actual headcount numbers, journalist names, or publication names. Data Accuracy: Verify facts before spokesperson preparation. Transparency: Prepare honest responses while protecting sensitive information. Human Oversight: Media responses require Legal and Executive approval.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to either decline the interview or immediately prepare talking points. ReAct forces you to first understand the journalist's angle (review their previous articles), assess what information is already public, check for any upcoming announcements that could change the narrative, and coordinate with legal and executive teams before deciding whether to engage and how. This prevents being blindsided by difficult questions and ensures coordinated messaging.
                    </div>
                </div>

                <div id="facilities" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/cube.svg" class="local-icon icon-red" alt="Facilities"> Facilities Management
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Work Orders</span><span class="level-desc">Focus: Communication (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Service Request Response</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A department head submitted an urgent facilities request: the HVAC system in the QC laboratory is not maintaining the required temperature range (20-25°C). Current readings show 28°C. This is a GMP-controlled area where out-of-spec temperatures can affect equipment calibration and sample integrity. The technician is scheduled to arrive in 2 hours.<br><span class="key">[Role]</span> Facilities Coordinator responsible for service request management.<br><span class="key">[Instruction]</span> Draft an acknowledgment email to the requestor with interim guidance.<br><span class="key">[Style]</span> Prompt, professional, and solution-oriented.<br><span class="key">[Parameters]</span> Acknowledge urgency. Provide technician ETA. Suggest interim measures if safe (e.g., portable cooling, equipment relocation). Ask about critical operations in progress that may need to be paused. Keep under 100 words.<br><span class="key">[Constraints]</span> RAI: No actual temperature readings, department names, or equipment IDs. Data Accuracy: Response times must be achievable. Patient Safety: GMP-critical areas take priority. Human Oversight: Critical environmental excursions require QA notification.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Vendor Management</span><span class="level-desc">Focus: Contracts (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Service Level Agreement Review</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The janitorial services contract is up for renewal. Over the past year, we've received 15 complaints about cleaning quality, particularly in laboratory areas requiring GMP-compliant cleaning. The current vendor has been with the company for 5 years. We need to evaluate whether to renew with enhanced SLAs or go to bid.<br><span class="key">[Role]</span> Facilities Manager responsible for service contracts.<br><span class="key">[Instruction]</span> Create a vendor performance scorecard and draft enhanced SLA requirements.<br><span class="key">[Style]</span> Contract management documentation with measurable KPIs.<br><span class="key">[Parameters]</span> Include performance categories: response time, cleaning quality (inspection scores), compliance (GMP areas), staffing consistency, and complaint resolution. Define specific metrics with targets. Include consequences for non-performance.<br><span class="key">[Example]</span> GMP Area Cleaning Compliance:<br>• Metric: % of GMP areas passing weekly inspection<br>• Current Performance: 82%<br>• Required Target: 98%<br>• Measurement: Weekly QA inspection checklist<br>• Consequence: <95% for 2 consecutive months = corrective action plan required<br><span class="key">[Constraints]</span> RAI: No actual vendor names, contract values, or complaint details. Data Accuracy: Performance metrics must reflect verified inspection data. Transparency: Document performance gaps objectively. Human Oversight: Contract modifications require Procurement and Legal approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Space Planning</span><span class="level-desc">Focus: Strategy (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Campus Master Plan</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company is planning significant growth over the next 5 years, with headcount expected to increase 40% and new GMP manufacturing capacity needed. Current campus is at 85% utilization. Options include: expanding on-site, leasing nearby space, or consolidating to a new purpose-built facility. Budget constraints require phased investment.<br><span class="key">[Objective]</span> Develop a campus master plan that accommodates growth while managing capital investment.<br><span class="key">[Style]</span> Strategic facilities planning document.<br><span class="key">[Tone]</span> Forward-thinking but financially grounded.<br><span class="key">[Audience]</span> Executive Leadership Team and Board Facilities Committee.<br><span class="key">[Response]</span> A master plan including: (1) Current State Assessment, (2) Growth Projections and Space Needs, (3) Option Analysis (expand/lease/build), (4) Phased Investment Approach, (5) Capital and Operating Cost Comparison, (6) Risk Assessment, (7) Recommended Path with Decision Points.<br><span class="key">[Constraints]</span> RAI: No actual headcount projections, cost figures, or site identifiers. Data Accuracy: Space utilization data must be verified. Bias: Present balanced analysis of all options. Human Oversight: Capital planning requires Executive and Board approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Emergency Response</span>
                        <span class="level-desc">Interactive Problem Solving</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Building System Failure</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Facilities Manager using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to respond to a critical building system failure and minimize business impact.<br>
<span class="key">[Tools]</span> You have access to: [BuildingManagementSystem], [EmergencyContacts], [BackupSystems], [OccupancyList], [VendorContracts]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> At 6:30 AM on Monday, the building management system alerted that the main chiller serving the manufacturing building has failed. Outside temperature is forecast to reach 35°C today. The manufacturing floor requires 18-22°C for GMP operations. Production is scheduled to start at 7:00 AM with a batch of temperature-sensitive product in progress. The backup chiller was taken offline for maintenance last week.<br><span class="key">[Constraints]</span> RAI: No actual building names, product names, or batch identifiers. Data Accuracy: Temperature requirements must reflect actual GMP specifications. Patient Safety: Product integrity takes priority over production schedules. Human Oversight: Production decisions during environmental excursions require QA and Operations approval.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to call the HVAC vendor and tell production to halt. ReAct forces you to first assess the full situation (can the backup chiller come online quickly? what's the current temperature trend?), understand the product impact (how temperature-sensitive is the batch in progress?), and explore interim solutions (portable cooling, load reduction) before making decisions that halt production or risk product quality. This ensures a measured response that balances multiple constraints.
                    </div>
                </div>

                <div id="admin" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/calendar.svg" class="local-icon icon-red" alt="Admin"> Administrative Coordinator
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Meeting Coordination</span><span class="level-desc">Focus: Organization (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Complex Meeting Setup</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I need to schedule a quarterly business review meeting with 12 participants across 4 time zones (US East, US West, UK, Japan). The meeting requires 3 hours. Preferred timing is during US business hours, but we need to accommodate the Japan team member who is a key presenter. The meeting room must have video conferencing capability for hybrid attendance.<br><span class="key">[Role]</span> Administrative Coordinator responsible for executive meeting logistics.<br><span class="key">[Instruction]</span> Create a meeting scheduling proposal with time options and logistics checklist.<br><span class="key">[Style]</span> Organized and considerate of all participants' time zones.<br><span class="key">[Parameters]</span> Propose 3 time slot options showing all time zones. Identify which participants would be significantly inconvenienced by each option. Include AV and catering requirements. Note any holidays or known conflicts.<br><span class="key">[Constraints]</span> RAI: No actual participant names, locations, or meeting content. Data Accuracy: Time zone conversions must be accurate. Transparency: Clearly identify trade-offs for each option. Human Oversight: Executive meeting logistics follow company protocols.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Process Improvement</span><span class="level-desc">Focus: Efficiency (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Administrative Process Documentation</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The department's expense report process has multiple pain points: reports are frequently rejected for missing receipts, approvals are delayed when managers travel, and reconciliation with finance takes weeks. I've been asked to document the current process and identify improvement opportunities.<br><span class="key">[Role]</span> Administrative Coordinator leading process improvement.<br><span class="key">[Instruction]</span> Create a process map of the current expense report workflow and identify bottlenecks.<br><span class="key">[Style]</span> Process documentation with improvement recommendations.<br><span class="key">[Parameters]</span> Map the current state process (steps, actors, decision points). Identify pain points at each step. Quantify impact where possible (average cycle time, rejection rate). Propose solutions categorized as quick wins vs. system changes.<br><span class="key">[Example]</span> Step 3: Manager Approval<br>Current: Email notification to manager, manual approval in system<br>Pain Point: 45% of reports delayed >5 days due to manager travel<br>Proposed Solution: Implement mobile approval app (Quick Win) or delegation workflow (System Change)<br><span class="key">[Constraints]</span> RAI: No actual employee names, amounts, or system names. Data Accuracy: Cycle time and rejection metrics must be verified. Transparency: Identify root causes objectively. Human Oversight: Process changes require Finance and IT approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Department Operations</span><span class="level-desc">Focus: Resource Planning (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Administrative Support Model</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company has grown from 200 to 500 employees over 3 years. The administrative support model hasn't changed: 3 administrative coordinators serve all departments. Workload has become unsustainable, with frequent overtime and complaints about response times. Leadership is considering options: add headcount, implement shared services, or outsource some functions.<br><span class="key">[Objective]</span> Analyze the current administrative support model and recommend a scalable approach.<br><span class="key">[Style]</span> Operational analysis with business case.<br><span class="key">[Tone]</span> Data-driven and solution-focused.<br><span class="key">[Audience]</span> HR Director and CFO.<br><span class="key">[Response]</span> An analysis including: (1) Current State Workload Assessment, (2) Industry Benchmarks (admin-to-employee ratios), (3) Service Level Analysis (what's not getting done), (4) Option Analysis (hire/shared services/outsource), (5) Cost-Benefit Comparison, (6) Recommended Model with Phasing, (7) Success Metrics.<br><span class="key">[Constraints]</span> RAI: No actual employee counts, salary data, or vendor names. Data Accuracy: Workload metrics must reflect verified data. Bias: Present balanced analysis of all options. Human Oversight: Staffing decisions require HR and Finance approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Executive Support Challenge</span>
                        <span class="level-desc">Interactive Problem Solving</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Conflicting Priorities</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are an Administrative Coordinator using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to resolve conflicting requests from multiple executives and maintain positive working relationships.<br>
<span class="key">[Tools]</span> You have access to: [ExecutiveCalendars], [PriorityGuidelines], [DelegationAuthority], [ResourceAvailability]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> Three executives have simultaneously requested urgent support: the CEO needs a presentation finalized for a board meeting tomorrow, the CFO needs expense reports processed before month-end close today, and the VP of Sales needs travel arrangements for a client meeting that was just scheduled for tomorrow morning. You are the only admin available and cannot complete all three tasks in the time remaining.<br><span class="key">[Constraints]</span> RAI: No actual executive names or meeting details. Data Accuracy: Assess true deadlines and flexibility. Transparency: Communicate limitations honestly. Human Oversight: Escalate resource conflicts to appropriate leadership.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to either work overtime to attempt all three or simply prioritize by executive rank. ReAct forces you to first assess the true deadlines and flexibility (can any be delegated or delayed?), understand the consequences of missing each (board meeting vs. month-end vs. client relationship), and explore resources (can another admin help? can technology assist?). This enables a reasoned decision and transparent communication with all parties.
                    </div>
                </div>

                <div id="travel" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/calendar.svg" class="local-icon icon-red" alt="Travel"> Travel & Events Coordinator
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Travel Booking</span><span class="level-desc">Focus: Efficiency (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Complex Itinerary Creation</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> An executive needs to visit 3 client sites in one week: Monday in Chicago, Wednesday in Dallas, and Friday in San Francisco. They prefer morning meetings and need to be back home (New York) by Friday evening for a family commitment. The executive prefers aisle seats and has airline elite status that should be leveraged for upgrades.<br><span class="key">[Role]</span> Travel Coordinator responsible for executive travel arrangements.<br><span class="key">[Instruction]</span> Create a detailed travel itinerary with booking recommendations.<br><span class="key">[Style]</span> Comprehensive itinerary format with all relevant details.<br><span class="key">[Parameters]</span> Include: flight options with timing, hotel recommendations near meeting locations, ground transportation needs, and backup options for critical legs. Note any tight connections or risks. Align with travel policy.<br><span class="key">[Constraints]</span> RAI: No actual traveler names, client names, or specific flight numbers. Data Accuracy: All options must be verified as available. Transparency: Identify risks and backup options clearly. Human Oversight: Executive travel follows company travel policy.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Event Planning</span><span class="level-desc">Focus: Coordination (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Corporate Event Checklist</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company is hosting a 2-day investigator meeting for an upcoming clinical trial. Expected attendance is 75 physicians from across the US. The event includes presentations, breakout sessions, and a dinner. The venue is a hotel conference center. Budget is $150,000 including travel reimbursement for attendees. Compliance requires fair market value documentation for all HCP payments.<br><span class="key">[Role]</span> Events Coordinator responsible for investigator meetings.<br><span class="key">[Instruction]</span> Create a comprehensive event planning checklist with timeline.<br><span class="key">[Style]</span> Project management checklist with compliance considerations.<br><span class="key">[Parameters]</span> Organize by planning phase: 12 weeks out, 8 weeks, 4 weeks, 1 week, day-of, and post-event. Include: venue, AV, catering, travel logistics, speaker preparation, materials production, compliance documentation, and attendee communication. Flag items requiring compliance review.<br><span class="key">[Example]</span> 8 Weeks Out:<br>☐ Finalize attendee list with Compliance (FMV documentation)<br>☐ Send save-the-date and registration link<br>☐ Confirm AV requirements with Medical Affairs for presentations<br>☐ Submit catering selections (no alcohol at working sessions per policy)<br><span class="key">[Constraints]</span> RAI: No actual attendee names, venue names, or budget figures. Regulatory: HCP interactions require FMV documentation. Data Accuracy: Compliance requirements must reflect current policies. Human Oversight: HCP meeting materials require Compliance and Legal review.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Travel Program Management</span><span class="level-desc">Focus: Optimization (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Travel Policy Revision</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company's travel policy hasn't been updated in 4 years. Travel spending has increased 60% while headcount grew 40%. Common pain points include: advance booking requirements that don't reflect business realities, unclear approval authorities, and inconsistent interpretation of "reasonable expenses." Sustainability goals now require consideration of travel carbon footprint.<br><span class="key">[Objective]</span> Recommend revisions to the travel policy that balance cost control, traveler experience, and sustainability.<br><span class="key">[Style]</span> Policy revision proposal with rationale.<br><span class="key">[Tone]</span> Balanced—address cost concerns while acknowledging traveler needs.<br><span class="key">[Audience]</span> CFO and HR Director (policy approval), all employees (policy users).<br><span class="key">[Response]</span> A policy revision including: (1) Current State Analysis, (2) Benchmark Comparison (industry practices), (3) Proposed Policy Changes with Rationale, (4) Sustainability Considerations, (5) Exception Process, (6) Implementation Approach, (7) Expected Impact (cost, traveler satisfaction, carbon reduction).<br><span class="key">[Constraints]</span> RAI: No actual spend data, company names, or employee feedback. Data Accuracy: Benchmark data must be current and sourced. Bias: Balance cost control with employee experience. Human Oversight: Policy changes require Finance, HR, and Legal approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Event Crisis Management</span>
                        <span class="level-desc">Interactive Problem Solving</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Last-Minute Event Change</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are an Events Coordinator using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to manage a major disruption to a planned event while minimizing impact on attendees and budget.<br>
<span class="key">[Tools]</span> You have access to: [VenueContract], [AttendeeList], [VendorContacts], [BackupVenues], [BudgetTracker]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> The hotel hosting next week's 100-person national sales meeting just called to say they had a pipe burst and the conference center is flooded. They cannot host the event. 85 attendees have already booked flights. The event includes product training that requires specific AV setup. Cancellation would disrupt the product launch timeline.<br><span class="key">[Constraints]</span> RAI: No actual venue names, attendee names, or budget figures. Data Accuracy: Verify alternative venue capabilities. Transparency: Communicate situation honestly to stakeholders. Human Oversight: Major event changes require leadership approval for budget impact.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to start calling alternative venues immediately. ReAct forces you to first assess the full scope (is hotel accommodations also affected? are there contract protections?), review backup options and their capabilities (can they support our AV needs?), consider attendee impact (can flights be changed? what's the rebooking cost?), and evaluate whether partial solutions might work (different venue same hotel, reduced attendance). This ensures a comprehensive response rather than reactive scrambling.
                    </div>
                </div>

                <div id="records" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/layers.svg" class="local-icon icon-red" alt="Records"> Records Management Specialist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Records Retrieval</span><span class="level-desc">Focus: Service (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Urgent Record Request</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The Legal department needs original signed contracts from 2018 related to a licensing agreement. They mention "possible litigation" and need the documents within 24 hours. The records are archived at our off-site storage facility. Normal retrieval takes 3-5 business days.<br><span class="key">[Role]</span> Records Management Specialist responsible for retrieval services.<br><span class="key">[Instruction]</span> Draft a response acknowledging the request and outlining the expedited retrieval process.<br><span class="key">[Style]</span> Professional and responsive—acknowledge urgency, confirm capabilities.<br><span class="key">[Parameters]</span> Confirm understanding of what's needed. Explain the expedited process and any associated costs. Identify what information you need from them (box numbers, date ranges). Set realistic expectations on timing. Request legal hold instruction if litigation is pending.<br><span class="key">[Constraints]</span> RAI: No actual contract names, parties, or storage locations. Data Accuracy: Retrieval timelines must be achievable. Transparency: Clearly communicate expedited costs. Human Oversight: Legal hold requests require immediate escalation to Legal.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Retention Schedule</span><span class="level-desc">Focus: Compliance (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Department Retention Assessment</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The Clinical Operations department has requested a review of their record retention practices. They have accumulated large volumes of paper trial master files from completed studies, along with electronic records on shared drives and in clinical systems. Retention requirements vary by record type (regulatory vs. research vs. administrative) and by country where trials were conducted.<br><span class="key">[Role]</span> Records Management Specialist responsible for retention compliance.<br><span class="key">[Instruction]</span> Create a retention assessment checklist for Clinical Operations records.<br><span class="key">[Style]</span> Regulatory compliance assessment format.<br><span class="key">[Parameters]</span> Categorize records by type. Cite applicable retention requirements (ICH, CFR, country-specific). Include both paper and electronic records. Note any records that may require extended retention due to ongoing obligations (open IND, post-marketing commitments).<br><span class="key">[Example]</span> Trial Master File Documents:<br>• Category: Regulatory/Essential Documents<br>• Retention Requirement: 2 years after drug approval or investigation discontinuation (21 CFR 312.62)<br>• Note: Extended if IND remains open or post-marketing commitments exist<br><span class="key">[Constraints]</span> RAI: No actual study numbers, document counts, or storage locations. Source Accuracy: Cite applicable regulations accurately. Data Accuracy: Retention periods must reflect current regulatory requirements. Human Oversight: Retention decisions require Regulatory and Legal approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Information Governance</span><span class="level-desc">Focus: Strategy (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Enterprise Records Strategy</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company has grown through 3 acquisitions, each bringing different records management systems and practices. There is no unified retention schedule, records are stored in multiple locations (physical and electronic), and there's concern about both compliance gaps and over-retention of data that increases litigation discovery costs. Leadership wants a unified information governance framework.<br><span class="key">[Objective]</span> Develop an enterprise information governance strategy that addresses compliance, efficiency, and risk.<br><span class="key">[Style]</span> Strategic planning document for information governance.<br><span class="key">[Tone]</span> Comprehensive but practical—acknowledge complexity while proposing achievable steps.<br><span class="key">[Audience]</span> Legal, IT, and Compliance leadership.<br><span class="key">[Response]</span> A governance strategy including: (1) Current State Assessment, (2) Regulatory Requirements Matrix, (3) Unified Retention Schedule Development, (4) Legacy Records Remediation Approach, (5) Technology Consolidation Recommendations, (6) Governance Operating Model, (7) Implementation Roadmap, (8) Risk-Based Prioritization.<br><span class="key">[Constraints]</span> RAI: No actual record counts, system names, or acquisition details. Source Accuracy: Follow applicable regulatory requirements for each jurisdiction. Data Integrity: Ensure chain of custody during any migration. Human Oversight: Governance framework requires Legal, IT, and Compliance approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Legal Hold Response</span>
                        <span class="level-desc">Interactive Compliance</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Litigation Hold Implementation</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Records Management Specialist using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to implement a legal hold across the organization to preserve potentially relevant records.<br>
<span class="key">[Tools]</span> You have access to: [LegalHoldPolicy], [CustodianList], [RecordsInventory], [IT_Systems], [DisposalSchedule]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> Legal has issued a litigation hold notice related to a patent dispute over Product-S. The hold covers all documents related to the product's development from 2018-2022. This includes R&D notebooks, email communications, meeting minutes, and regulatory submissions. A scheduled destruction of 2018-2019 archived records is planned for this week. Multiple departments globally may have relevant records.<br><span class="key">[Constraints]</span> RAI: No actual product names, date ranges, or department names. Data Integrity: Immediately halt any destruction that might affect relevant records. Transparency: Document all hold implementation steps. Human Oversight: Legal holds require immediate Legal oversight and IT coordination.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to send a company-wide hold notice and stop all destruction. ReAct forces you to first identify the scope precisely (which departments, which systems, which date ranges?), halt any immediate destruction that might affect relevant records, identify key custodians who likely have the most relevant materials, and coordinate with IT on electronic preservation before broadly notifying all employees. This ensures comprehensive preservation while targeting the most critical records first.
                    </div>
                </div>

                <div id="office-mgr" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/user-tie.svg" class="local-icon icon-red" alt="Office"> Office Manager
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Office Operations</span><span class="level-desc">Focus: Communication (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Policy Reminder Communication</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> After the recent return-to-office transition, there have been issues with conference room bookings: people booking rooms but not using them, meetings running over their scheduled times, and rooms left untidy. These issues are causing friction among teams. A gentle reminder about conference room etiquette is needed.<br><span class="key">[Role]</span> Office Manager responsible for workplace operations.<br><span class="key">[Instruction]</span> Draft an all-staff email about conference room etiquette.<br><span class="key">[Style]</span> Friendly but clear—avoid lecturing while setting expectations.<br><span class="key">[Parameters]</span> Keep under 150 words. Focus on positive behaviors rather than complaints. Include specific guidelines for booking, use, and cleanup. Mention the impact on colleagues. Avoid naming individuals or departments.<br><span class="key">[Constraints]</span> RAI: No actual employee names, room names, or specific incidents. Data Accuracy: Guidelines must reflect current booking system. Transparency: Set clear expectations without lecturing. Human Oversight: Office policies follow company HR guidelines.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Vendor Coordination</span><span class="level-desc">Focus: Problem Solving (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Service Complaint Resolution</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Employees have been complaining about the coffee service: machines frequently run out of supplies, the quality is inconsistent, and the vendor's response time for restocking has been poor. The current contract includes service level commitments that are not being met. We need to address this with the vendor professionally while considering whether to escalate or seek alternatives.<br><span class="key">[Role]</span> Office Manager responsible for vendor management.<br><span class="key">[Instruction]</span> Draft a formal communication to the coffee service vendor documenting performance issues and requesting improvement.<br><span class="key">[Style]</span> Professional vendor communication—firm but preserving the relationship.<br><span class="key">[Parameters]</span> Include: specific incidents with dates, reference to contract SLA requirements, impact on our employees, requested corrective actions, and timeline for improvement. Request a meeting to discuss. Do not threaten termination in the first communication.<br><span class="key">[Example]</span> Service Level Concern #1: Restocking Response Time<br>• Contract Requirement: Restocking within 4 hours of notification<br>• Actual Performance: 3 incidents in past month where restocking took 8+ hours<br>• Dates: [Date 1], [Date 2], [Date 3]<br>• Impact: Employees unable to access coffee service during business hours<br><span class="key">[Constraints]</span> RAI: No actual vendor names, contract values, or specific dates. Data Accuracy: Performance data must be documented and verified. Transparency: Focus on improvement, not termination threats. Human Oversight: Vendor escalations follow procurement procedures.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Workplace Strategy</span><span class="level-desc">Focus: Planning (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Hybrid Work Space Design</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company has adopted a permanent hybrid work model (3 days in office, 2 days remote). Current office design assumes 100% daily occupancy with assigned desks. With hybrid work, average daily attendance is 60%, but it varies significantly by day (Monday: 40%, Tuesday-Thursday: 75%, Friday: 35%). Leadership wants to optimize office space and potentially sublease unused space, but employees resist giving up "their" desks.<br><span class="key">[Objective]</span> Develop a workplace redesign proposal that optimizes space utilization while maintaining employee satisfaction.<br><span class="key">[Style]</span> Workplace strategy proposal with change management considerations.<br><span class="key">[Tone]</span> Forward-thinking but sensitive to employee concerns.<br><span class="key">[Audience]</span> HR Director, CFO, and employee representatives.<br><span class="key">[Response]</span> A workplace proposal including: (1) Current Utilization Analysis, (2) Space Optimization Options (hot-desking, neighborhoods, activity-based), (3) Employee Experience Considerations, (4) Technology Requirements, (5) Change Management Approach, (6) Financial Impact (savings vs. investment), (7) Pilot Program Recommendation, (8) Success Metrics.<br><span class="key">[Constraints]</span> RAI: No actual headcount, utilization figures, or cost data. Data Accuracy: Utilization metrics must be verified. Bias: Balance cost savings with employee experience. Human Oversight: Workplace changes require HR, Facilities, and Executive approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Office Emergency Response</span>
                        <span class="level-desc">Interactive Problem Solving</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Unexpected Office Closure</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are an Office Manager using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to manage an unexpected office closure while ensuring business continuity and employee safety.<br>
<span class="key">[Tools]</span> You have access to: [EmergencyContacts], [EmployeeDirectory], [FacilitiesHotline], [ITHelpdesk], [ExecutiveCalendars]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> At 6:15 AM, building security called to report a water main break affecting the building's water supply. The building cannot be occupied without water service per health codes. The water utility estimates repairs will take 12-24 hours. The office normally opens at 7:30 AM with 150 employees. There are critical meetings scheduled including a client presentation at 10 AM and an FDA pre-submission meeting at 2 PM.<br><span class="key">[Constraints]</span> RAI: No actual building names, employee counts, or meeting details. Data Accuracy: Verify utility estimates before communicating. Transparency: Communicate closure and alternatives clearly. Human Oversight: Business continuity decisions require Executive and IT coordination.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately send an all-staff closure notice. ReAct forces you to first assess which activities are truly impacted (can most people work from home?), identify critical on-site activities that need alternative arrangements (client meeting, regulatory meeting), coordinate with IT on remote access capacity, and develop a prioritized communication plan (executives with critical meetings first, then all staff). This ensures critical business needs are addressed while managing the closure efficiently.
                    </div>
                </div>

                <div id="ehs" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/shield.svg" class="local-icon icon-red" alt="EHS"> Environmental Health & Safety
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Incident Reporting</span><span class="level-desc">Focus: Accuracy (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Near-Miss Report</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> An operator in the packaging area reported a near-miss incident: a pallet of finished goods began to tip while being moved by forklift, but the operator was able to stabilize it before it fell. No one was injured and no product was damaged, but if the pallet had fallen, it could have struck a nearby worker. The incident occurred during shift change when the area was particularly crowded.<br><span class="key">[Role]</span> EHS Coordinator responsible for incident documentation.<br><span class="key">[Instruction]</span> Document the near-miss incident for the EHS reporting system.<br><span class="key">[Style]</span> Safety incident report format—factual, specific, and focused on prevention.<br><span class="key">[Parameters]</span> Include: date/time/location, description of what happened, potential consequences if the incident had not been controlled, immediate actions taken, and preliminary contributing factors. Do not assign blame. Keep factual.<br><span class="key">[Constraints]</span> RAI: No actual employee names, equipment IDs, or specific locations. Data Accuracy: Incident details must accurately reflect what occurred. Bias: Document objectively without assigning blame. Human Oversight: Near-miss reports contribute to safety trending.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Safety Procedure</span><span class="level-desc">Focus: Compliance (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Job Hazard Analysis</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The maintenance team is planning to perform preventive maintenance on a high-voltage electrical panel next week. This task requires lockout/tagout procedures and involves working in a confined space adjacent to the panel. A Job Hazard Analysis (JHA) is required before the work can proceed.<br><span class="key">[Role]</span> EHS Specialist responsible for job hazard assessments.<br><span class="key">[Instruction]</span> Create a Job Hazard Analysis document for this maintenance task.<br><span class="key">[Style]</span> OSHA-compliant JHA format—systematic, comprehensive, and focused on hazard controls.<br><span class="key">[Parameters]</span> Format as a table with columns: Task Step, Potential Hazard, Risk Level (H/M/L), Control Measures, Responsible Party. Include all applicable hazard categories: electrical, confined space, ergonomic, chemical, and fall hazards.<br><span class="key">[Example]</span> | Task Step | Hazard | Risk | Control | Responsible |<br>|-----------|--------|------|---------|-------------|<br>| De-energize panel | Electrical shock | H | LOTO procedure, voltage verification | Electrician |<br><span class="key">[Constraints]</span> RAI: No actual equipment IDs, employee names, or location details. Source Accuracy: Follow OSHA standards and company EHS procedures. Data Accuracy: Risk levels must reflect actual hazard severity. Human Oversight: JHAs require EHS approval before work begins.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Safety Program Strategy</span><span class="level-desc">Focus: Culture Change (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Safety Improvement Initiative</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The site's recordable incident rate has increased 20% year-over-year, driven primarily by ergonomic injuries in the manufacturing area. Analysis shows that most injuries occur during manual material handling tasks. Previous "stretch break" programs had poor participation. Leadership is committed to improving safety but skeptical of programs that impact productivity.<br><span class="key">[Objective]</span> Develop a comprehensive safety improvement proposal that addresses the root causes of ergonomic injuries while maintaining operational efficiency.<br><span class="key">[Style]</span> Safety program proposal with business case elements.<br><span class="key">[Tone]</span> Data-driven, practical, and sensitive to operational concerns.<br><span class="key">[Audience]</span> Site Leadership Team (Plant Manager, VP Operations, VP HR, EHS Director).<br><span class="key">[Response]</span> A proposal including: (1) Current State Analysis with incident data, (2) Root Cause Assessment, (3) Proposed Interventions (engineering controls, administrative controls, PPE), (4) Implementation Timeline, (5) Resource Requirements, (6) Expected Outcomes (injury reduction targets), (7) ROI Analysis (workers' comp savings, productivity gains).<br><span class="key">[Constraints]</span> RAI: No actual employee names, injury details, or workers' comp costs. Data Accuracy: Incident rates must reflect verified OSHA recordables. Bias: Focus on systemic controls, not blame. Human Oversight: Safety programs require EHS, HR, and Operations leadership approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Incident Investigation</span>
                        <span class="level-desc">Interactive Root Cause</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Safety Incident Root Cause</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are an EHS Manager using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to investigate a workplace injury to identify root causes and recommend corrective actions that prevent recurrence.<br>
<span class="key">[Tools]</span> You have access to: [IncidentReport], [WitnessStatements], [EquipmentLogs], [TrainingRecords], [SafetyProcedures], [PriorIncidentHistory]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> A lab technician sustained a chemical splash to the forearm yesterday while transferring a corrosive solution between containers. The technician was wearing a lab coat but not the required chemical-resistant gloves. Initial reports suggest the technician was rushing to complete the task before a meeting. The injured area was a walkway where another employee bumped into the technician during the transfer.<br><span class="key">[Constraints]</span> RAI: No actual employee names, chemical names, or injury details. Employee Welfare: Support injured employee while investigating. Bias: Investigate systemic factors, not just individual behavior. Human Oversight: Serious injuries require OSHA reporting and leadership notification.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to focus on the immediate cause (no gloves) and require refresher training. ReAct forces you to investigate the systemic factors: Why was the technician rushing? Why was the transfer happening in a walkway? Why were gloves not being enforced? You might discover that the real root cause is inadequate workspace design or schedule pressure, not a training gap. This leads to controls that actually prevent recurrence.
                    </div>
                </div>

                <div id="manufacturing" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/cube.svg" class="local-icon icon-red" alt="Mfg"> Manufacturing Operations Specialist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Batch Documentation</span><span class="level-desc">Focus: Accuracy (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Batch Record Entry</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I am completing a batch record entry for a granulation step. The actual weight of excipient added was 24.85 kg, but my handwriting could be misread as 24.35 kg. The specification allows 24.5-25.5 kg. I need to ensure the entry is clear and compliant with ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate).<br><span class="key">[Role]</span> Manufacturing Operator responsible for batch record documentation.<br><span class="key">[Instruction]</span> Describe the correct procedure for making this batch record entry and handling potential legibility issues.<br><span class="key">[Style]</span> GMP documentation guidance—clear and compliant.<br><span class="key">[Parameters]</span> Include: proper entry technique, how to correct errors if needed, and what constitutes ALCOA+ compliant documentation. Reference applicable SOP requirements.<br><span class="key">[Constraints]</span> RAI: No actual batch numbers, product names, or operator identifiers. Data Integrity: All entries must follow ALCOA+ principles. Source Accuracy: Reference current GMP documentation SOPs. Human Oversight: Corrections require supervisor verification per SOP.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Process Monitoring</span><span class="level-desc">Focus: Problem Detection (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>In-Process Control Assessment</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> During tablet compression, the in-process weight check shows 3 consecutive tablets at the lower end of the specification range (198, 199, 198 mg against a spec of 195-205 mg, target 200 mg). While all tablets are within specification, this trend suggests the compression force may need adjustment. The batch is 40% complete.<br><span class="key">[Role]</span> Manufacturing Technician responsible for in-process monitoring.<br><span class="key">[Instruction]</span> Document the in-process observation and recommended action.<br><span class="key">[Style]</span> GMP process monitoring documentation.<br><span class="key">[Parameters]</span> Include: observation details (time, data points, trend), assessment of significance, recommended action (adjust, continue monitoring, escalate), and rationale. Reference process knowledge and control limits.<br><span class="key">[Example]</span> Observation: 10:45 - IPC weight check tablets trending low (198-199 mg)<br>Assessment: Values within spec but 3 consecutive below target suggests negative drift<br>Recommended Action: Increase compression force by 0.5 kN per SOP, resample in 15 minutes<br><span class="key">[Constraints]</span> RAI: Use placeholder batch numbers and weights. Data Accuracy: IPC data must reflect actual measurements. Process Knowledge: Adjustments must be within validated ranges. Human Oversight: Significant process adjustments require supervisor notification.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Process Transfer</span><span class="level-desc">Focus: Scale-up (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Technology Transfer Documentation</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are transferring the manufacturing process for Product-T from our development facility to the commercial manufacturing site. The process uses a specialized granulation technique that is sensitive to scale. Equipment at the receiving site is larger (300L vs. 50L granulator). Process parameters need to be scaled while maintaining product quality.<br><span class="key">[Objective]</span> Document the technology transfer protocol with critical process parameters and acceptance criteria.<br><span class="key">[Style]</span> Technology transfer protocol format per ICH Q10.<br><span class="key">[Tone]</span> Scientifically rigorous with appropriate risk consideration.<br><span class="key">[Audience]</span> QA, Regulatory, and Manufacturing at both sending and receiving sites.<br><span class="key">[Response]</span> A transfer protocol including: (1) Process Description and Critical Quality Attributes, (2) Equipment Comparison and Gap Assessment, (3) Parameter Scaling Rationale, (4) Protocol for Demonstration Batches, (5) Acceptance Criteria, (6) Knowledge Transfer Requirements, (7) Change Control Considerations.<br><span class="key">[Constraints]</span> RAI: No actual product names, equipment identifiers, or site locations. Source Accuracy: Follow ICH Q10 technology transfer guidance. Data Accuracy: Scaling rationale must be scientifically justified. Human Oversight: Transfer protocols require QA, Regulatory, and site leadership approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Batch Deviation Assessment</span>
                        <span class="level-desc">Interactive Problem Solving</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Process Excursion Response</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Manufacturing Specialist using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to assess a process deviation during batch manufacturing and determine the appropriate response.<br>
<span class="key">[Tools]</span> You have access to: [BatchRecord], [ProcessValidation], [HistoricalData], [ProductSpecifications], [QA_Contact]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> During the drying step of Batch 2024-1234, the product temperature exceeded the maximum validated limit of 55°C and reached 58°C for approximately 12 minutes before the operator noticed and adjusted the inlet air temperature. The product is known to be sensitive to heat, with degradation studies showing increased impurity formation above 60°C. The batch is 80% through the manufacturing process.<br><span class="key">[Constraints]</span> RAI: No actual batch numbers, product names, or temperature data. Data Accuracy: Reference actual validation parameters and stability data. Patient Safety: Product quality is primary consideration. Human Oversight: Process excursions require QA assessment before batch disposition.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to either stop the batch immediately or continue and hope it's okay. ReAct forces you to first quantify the actual exposure (temperature × time vs. degradation kinetics), review historical data for similar excursions, assess whether the excursion is within the proven acceptable range, and consult QA before deciding to continue or reject. This ensures a scientifically-justified decision rather than a reactive one.
                    </div>
                </div>

                <div id="packaging" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/layers.svg" class="local-icon icon-red" alt="Pack"> Packaging Operations Specialist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Line Clearance</span><span class="level-desc">Focus: Compliance (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Line Clearance Documentation</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I am completing line clearance documentation before starting a new packaging batch. The previous product was Product-U (blue tablets). The new product is Product-V (white tablets). Line clearance requires verification that all materials, components, and products from the previous batch have been removed.<br><span class="key">[Role]</span> Packaging Operator responsible for line clearance verification.<br><span class="key">[Instruction]</span> Create a comprehensive line clearance checklist for this changeover.<br><span class="key">[Style]</span> GMP documentation format with verification points.<br><span class="key">[Parameters]</span> Include all areas requiring verification: equipment surfaces, hoppers, conveyor belts, coding stations, rejection bins, staging areas, and documentation. Include visual verification and physical verification steps. Note high-risk areas for cross-contamination.<br><span class="key">[Constraints]</span> RAI: No actual product names, batch numbers, or equipment identifiers. Patient Safety: Cross-contamination can cause serious harm. Data Accuracy: Checklist must cover all critical areas per SOP. Human Oversight: Line clearance requires independent verification per GMP.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Serialization</span><span class="level-desc">Focus: Track & Trace (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Serialization Exception Report</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> During packaging of Batch 2024-5678, the serialization system rejected 47 units due to "unreadable code" errors. The batch size is 50,000 units, so this is a 0.09% rejection rate. Normal rejection rate is under 0.05%. The rejected units need to be investigated to determine if this is a camera calibration issue, print quality issue, or label defect.<br><span class="key">[Role]</span> Packaging Technician responsible for serialization compliance.<br><span class="key">[Instruction]</span> Document the serialization exception investigation and recommended corrective action.<br><span class="key">[Style]</span> DSCSA compliance documentation format.<br><span class="key">[Parameters]</span> Include: exception summary with statistics, investigation methodology (camera check, print sample analysis, label inspection), root cause determination, corrective action, and impact on batch disposition. Reference serialization SOP requirements.<br><span class="key">[Example]</span> Investigation Summary:<br>• Total Rejections: 47 units (0.09%)<br>• Visual Inspection: 32 units had partial print voids, 15 units had label wrinkle affecting code area<br>• Root Cause: Printhead nozzle clog (32 units), Label applicator tension out of spec (15 units)<br><span class="key">[Constraints]</span> RAI: No actual batch numbers, serial numbers, or rejection counts. Regulatory: DSCSA compliance requires full traceability. Data Accuracy: Exception data must match serialization system logs. Human Oversight: Elevated rejection rates require QA notification.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Line Optimization</span><span class="level-desc">Focus: OEE Improvement (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Packaging Line Performance Analysis</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Packaging Line 3 has been underperforming against OEE targets (actual 62%, target 80%). Major loss categories are: changeover time (35% of losses), minor stops (30%), and speed losses (25%). The line packages 5 different products with frequent changeovers. Management wants a performance improvement plan without significant capital investment.<br><span class="key">[Objective]</span> Develop a packaging line performance improvement plan based on OEE analysis.<br><span class="key">[Style]</span> Lean manufacturing improvement proposal.<br><span class="key">[Tone]</span> Data-driven and action-oriented.<br><span class="key">[Audience]</span> Packaging Manager and Continuous Improvement Lead.<br><span class="key">[Response]</span> An improvement plan including: (1) Current State OEE Breakdown, (2) Loss Category Pareto Analysis, (3) Quick Win Opportunities, (4) SMED Analysis for Changeover Reduction, (5) Minor Stop Root Cause Analysis, (6) Implementation Roadmap, (7) Target OEE with Milestones.<br><span class="key">[Constraints]</span> RAI: No actual OEE figures, line identifiers, or product names. Data Accuracy: OEE calculations must use verified data. Bias: Focus on process improvement, not blame. Human Oversight: Process changes require validation assessment.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Label Mix-Up Prevention</span>
                        <span class="level-desc">Interactive Troubleshooting</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Label Verification Failure</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Packaging Supervisor using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to investigate a label verification system failure and determine if any mislabeled product may have been released.<br>
<span class="key">[Tools]</span> You have access to: [VisionSystemLogs], [PackagingBatchRecords], [LabelInventory], [RejectionBinContents], [QA_Hold]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> During a routine audit, QA discovered that the label verification camera on Line 2 was not aligned correctly and may have been passing labels without proper verification for the past 2 batches. Both batches have been shipped to the distribution center. The batches contained Product-W 10mg and Product-W 25mg tablets packaged on the same line consecutively.<br><span class="key">[Constraints]</span> RAI: No actual batch numbers, product names, or line identifiers. Patient Safety: Label mix-ups can cause serious patient harm. Data Accuracy: Verify actual scope of verification gap before conclusions. Human Oversight: Potential mislabeling requires immediate QA and Regulatory notification.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately recall both batches. ReAct forces you to first determine the actual scope of the verification gap (when did misalignment occur?), review the rejection bin for any evidence of wrong labels being caught, check secondary verification points (operator checks, label reconciliation), and assess the actual risk of mislabeled product before determining the appropriate response level. This prevents unnecessary recalls while ensuring patient safety.
                    </div>
                </div>

                <div id="warehouse" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/cube.svg" class="local-icon icon-red" alt="Warehouse"> Warehouse & Distribution
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Receiving</span><span class="level-desc">Focus: Verification (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Receipt Discrepancy Documentation</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A shipment of raw materials arrived from a qualified supplier. The packing slip indicates 20 drums of Excipient-A (500 kg total). Physical count shows 19 drums with intact seals plus 1 drum with a damaged seal showing signs of leakage. The material is a controlled substance precursor requiring strict accountability.<br><span class="key">[Role]</span> Warehouse Receiving Specialist responsible for incoming inspection.<br><span class="key">[Instruction]</span> Document the receiving discrepancy and initiate the appropriate procedures.<br><span class="key">[Style]</span> GMP receiving documentation format.<br><span class="key">[Parameters]</span> Include: shipment details, discrepancy description with photos, immediate containment actions, notifications required (QA, Supplier, Procurement), and recommended disposition. Note regulatory implications for controlled substance.<br><span class="key">[Constraints]</span> RAI: No actual supplier names, material names, or shipment numbers. Regulatory: Controlled substance discrepancies have DEA reporting requirements. Data Accuracy: Document discrepancy exactly as observed. Human Oversight: Material discrepancies require QA assessment before acceptance.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Cold Chain</span><span class="level-desc">Focus: Temperature Management (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Temperature Excursion Assessment</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A shipment of temperature-sensitive finished product (2-8°C storage requirement) arrived with the data logger showing a temperature spike to 14°C for 45 minutes during transit. The shipment left the distribution center 18 hours ago. The product is urgently needed for a patient who has been waiting 2 weeks for this medication.<br><span class="key">[Role]</span> Distribution Specialist responsible for cold chain compliance.<br><span class="key">[Instruction]</span> Document the temperature excursion and perform initial impact assessment.<br><span class="key">[Style]</span> GDP compliance documentation.<br><span class="key">[Parameters]</span> Include: excursion details (duration, peak temperature, time since shipped), reference stability data if available, initial assessment of impact, QA notification, and recommended disposition (hold for assessment, release, reject). Note patient urgency in context.<br><span class="key">[Example]</span> Excursion Details:<br>• Product: [Name], 2-8°C storage<br>• Peak Temperature: 14°C for 45 minutes<br>• Total time out of refrigeration: Unknown (excursion during transit)<br>• Stability Reference: Product stable at 15°C for up to 72 hours per stability data<br>• Initial Assessment: Excursion within documented stability margins<br><span class="key">[Constraints]</span> RAI: No actual product names, temperatures, or shipment details. Patient Safety: Product integrity is primary consideration—when in doubt, don't release. Source Accuracy: Reference documented stability data. Human Oversight: Temperature excursion disposition requires QA approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Distribution Network</span><span class="level-desc">Focus: Optimization (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Distribution Network Analysis</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The company's distribution network has grown organically with acquisitions. We now have 4 distribution centers serving overlapping territories. Transportation costs have increased 25% year-over-year, and delivery times are inconsistent. Some customers are served from multiple DCs depending on inventory availability. Cold chain products require specialized handling available at only 2 DCs.<br><span class="key">[Objective]</span> Analyze the distribution network and recommend optimization opportunities.<br><span class="key">[Style]</span> Supply chain optimization analysis.<br><span class="key">[Tone]</span> Data-driven and strategic.<br><span class="key">[Audience]</span> VP Supply Chain and Finance leadership.<br><span class="key">[Response]</span> A network analysis including: (1) Current State Mapping (DCs, territories, volume), (2) Service Level Analysis by Region, (3) Cost Analysis (transportation, warehousing, inventory holding), (4) Optimization Scenarios (consolidation, territory realignment), (5) Cold Chain Considerations, (6) Implementation Risks and Mitigations, (7) Financial Impact of Recommended Changes.<br><span class="key">[Constraints]</span> RAI: No actual DC locations, volumes, or cost figures. Data Accuracy: Network data must be verified before modeling. Bias: Balance cost optimization with service level requirements. Human Oversight: Network changes require Supply Chain and Finance leadership approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Inventory Discrepancy</span>
                        <span class="level-desc">Interactive Investigation</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Controlled Substance Count Error</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Warehouse Manager using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to investigate and resolve a controlled substance inventory discrepancy before regulatory reporting deadlines.<br>
<span class="key">[Tools]</span> You have access to: [InventorySystem], [TransactionHistory], [AccessLogs], [CycleCountRecords], [DEA_Reporting]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> During the monthly controlled substance reconciliation, the physical count for Product-X (Schedule II) shows 485 units, but the inventory system shows 500 units. The last reconciliation 30 days ago was in balance. During the month, there were 3 receipts and 47 shipments. The discrepancy of 15 units must be explained or reported to DEA within 72 hours.<br><span class="key">[Constraints]</span> RAI: No actual product names, quantities, or transaction details. Regulatory: DEA reporting requirements are mandatory—do not miss deadlines. Data Integrity: Investigate thoroughly before concluding loss. Human Oversight: Controlled substance discrepancies require immediate Security, QA, and Legal notification.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately report the discrepancy to DEA to meet the deadline. ReAct forces you to first systematically reconcile all transactions (receipts, shipments, returns, destructions), check for data entry errors, review access logs for unauthorized activity, and re-count to confirm the physical inventory before concluding there's an actual loss. This may identify an explanation that avoids unnecessary regulatory reporting while ensuring compliance if there's a true discrepancy.
                    </div>
                </div>

                <div id="qc-lab" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/search.svg" class="local-icon icon-red" alt="Lab"> QC Laboratory Technician
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Sample Management</span><span class="level-desc">Focus: Chain of Custody (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Sample Receipt Documentation</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Manufacturing submitted 5 in-process samples for moisture testing from Batch 2024-9012. The samples are in sealed containers with the batch number, sample ID, time of collection, and collector's initials on each label. Sample 3 has a partially illegible time stamp. The moisture test must be completed within 4 hours of collection.<br><span class="key">[Role]</span> QC Laboratory Technician responsible for sample receipt.<br><span class="key">[Instruction]</span> Document the sample receipt and describe how to handle the illegible label issue.<br><span class="key">[Style]</span> GLP/GMP sample management documentation.<br><span class="key">[Parameters]</span> Include: verification of sample integrity, documentation of the legibility issue, communication required with manufacturing, and impact assessment on testing timeline. Reference chain of custody requirements.<br><span class="key">[Constraints]</span> RAI: No actual batch numbers, sample IDs, or analyst names. Data Integrity: Chain of custody must be maintained. Transparency: Document all discrepancies at receipt. Human Oversight: Sample integrity issues require QA assessment.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Equipment Qualification</span><span class="level-desc">Focus: Compliance (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Equipment Performance Verification</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The daily performance verification of HPLC System 4 showed a system suitability failure: the resolution between peaks 1 and 2 was 1.3 (requirement ≥1.5). The previous day's verification passed. The column is 4 months into its 6-month expected life. Three batches are waiting for release testing on this system.<br><span class="key">[Role]</span> QC Laboratory Technician responsible for equipment verification.<br><span class="key">[Instruction]</span> Document the performance verification failure and troubleshooting steps.<br><span class="key">[Style]</span> Equipment logbook documentation format.<br><span class="key">[Parameters]</span> Include: verification result, immediate actions (equipment quarantine), troubleshooting sequence, escalation if troubleshooting fails, and impact on pending work. Reference equipment SOP requirements.<br><span class="key">[Example]</span> Performance Verification Log - HPLC-04<br>Date: [Date] Technician: [Initials]<br>Result: FAIL - Resolution (Peaks 1-2): 1.3 (Spec: ≥1.5)<br>Immediate Action: System placed out of service<br>Troubleshooting Step 1: Check mobile phase preparation...<br><span class="key">[Constraints]</span> RAI: No actual equipment IDs, dates, or analyst names. Data Integrity: Failed verifications must be documented and investigated. Source Accuracy: Reference equipment SOP requirements. Human Oversight: Failed equipment must not be used until issue resolved.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Method Troubleshooting</span><span class="level-desc">Focus: Scientific Investigation (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Analytical Method Investigation</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> An HPLC impurity method that has been used for 3 years is suddenly showing an unidentified peak in 4 of the last 10 batches tested. The peak elutes at a retention time not corresponding to any known impurities. The batches are from the same API lot. The method validation included forced degradation studies. QA is holding batch release pending investigation.<br><span class="key">[Objective]</span> Design an analytical investigation to identify the source of the unknown peak.<br><span class="key">[Style]</span> Laboratory investigation protocol.<br><span class="key">[Tone]</span> Scientifically rigorous and systematic.<br><span class="key">[Audience]</span> QC Manager and QA investigation lead.<br><span class="key">[Response]</span> An investigation plan including: (1) Peak Characterization Strategy, (2) System Suitability Verification, (3) Blank and Standard Analysis, (4) Sample Preparation Review, (5) API Lot Analysis, (6) Chromatographic Conditions Evaluation, (7) Peak Identification Approaches (MS, reference standards), (8) Decision Criteria for Batch Disposition.<br><span class="key">[Constraints]</span> RAI: No actual batch numbers, method names, or peak data. Data Integrity: Investigate systematically before retest. Source Accuracy: Reference validated method parameters. Human Oversight: Unknown impurities require Regulatory notification if above thresholds.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Test Result Anomaly</span>
                        <span class="level-desc">Interactive Investigation</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Unexpected Test Result</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a QC Laboratory Technician using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to investigate an unexpected test result and determine if it represents a true result or a laboratory error.<br>
<span class="key">[Tools]</span> You have access to: [LIMS_Data], [EquipmentLogs], [ReagentLogs], [StandardPreparation], [MethodSOP]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> The assay result for Batch 2024-1111 came back at 97.2%, while historical batches of the same product have always been 99.0-101.0%. The specification is 95.0-105.0%, so the result passes, but it's a significant outlier. The batch is from the same API lot as 3 previous batches that tested at 99.5-100.2%. Manufacturing is asking for the batch to be released today.<br><span class="key">[Constraints]</span> RAI: No actual batch numbers, assay results, or product names. Data Integrity: Outliers require investigation before release—don't succumb to pressure. Transparency: Document investigation regardless of outcome. Human Oversight: Unusual results require QC Manager and QA review.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to either release the batch (it passes specification) or immediately retest. ReAct forces you to first investigate potential laboratory causes (was the standard prepared correctly? was the equipment performing properly? was sample preparation done correctly?) before concluding the low result is real or requesting a retest. This ensures data integrity and prevents reporting potentially erroneous results.
                    </div>
                </div>

                <div id="production" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/calendar.svg" class="local-icon icon-red" alt="Plan"> Production Planner
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Schedule Management</span><span class="level-desc">Focus: Communication (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Schedule Change Communication</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A raw material delivery delay will push the scheduled production of Product-Y from next Monday to Wednesday. This affects downstream packaging (scheduled for Friday) and QC testing (weekend shift). The product is needed to fulfill a customer order due in 2 weeks. All stakeholders need to be notified of the revised schedule.<br><span class="key">[Role]</span> Production Planner responsible for schedule coordination.<br><span class="key">[Instruction]</span> Draft a schedule change notification to all affected departments.<br><span class="key">[Style]</span> Clear and action-oriented—minimize confusion, maximize visibility.<br><span class="key">[Parameters]</span> Include: original vs. revised schedule, reason for change, impact on downstream activities, actions required from each department, and confirmation of customer delivery commitment. Use a table format for clarity.<br><span class="key">[Constraints]</span> RAI: No actual product names, customer names, or schedule dates. Data Accuracy: Schedule changes must reflect verified information. Transparency: Communicate impacts honestly to all stakeholders. Human Oversight: Schedule changes follow change management procedures.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Capacity Planning</span><span class="level-desc">Focus: Optimization (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Capacity Utilization Analysis</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Q4 demand forecast shows a 30% increase over Q3 for 3 products that share Manufacturing Line A. Current utilization is 85%. Overtime has been approved but is limited to 20% above standard hours. We need to determine if demand can be met with current capacity or if alternatives (outsourcing, prioritization, inventory build) are needed.<br><span class="key">[Role]</span> Production Planner responsible for capacity analysis.<br><span class="key">[Instruction]</span> Create a capacity analysis for Q4 demand on Line A.<br><span class="key">[Style]</span> Capacity planning analysis with recommendations.<br><span class="key">[Parameters]</span> Include: demand by product, available capacity (standard + overtime), capacity gap calculation, scenario analysis (with/without overtime, product prioritization), and recommendations. Format with clear calculations showing logic.<br><span class="key">[Example]</span> Available Capacity (Q4):<br>• Standard hours: 2,080 (13 weeks × 40 hrs × 4 crew)<br>• Overtime allowance: 416 hrs (20%)<br>• Total available: 2,496 hrs<br>Required Capacity:<br>• Product-Y: 800 hrs (projected volume × cycle time)<br>• Product-Z: 1,200 hrs<br>• Product-AA: 700 hrs<br>• Total required: 2,700 hrs<br>Gap: 204 hrs (8% over capacity)<br><span class="key">[Constraints]</span> RAI: No actual capacity figures, product names, or demand data. Data Accuracy: Capacity calculations must use verified cycle times. Transparency: Clearly show gaps and assumptions. Human Oversight: Capacity decisions require Operations leadership approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">S&OP Integration</span><span class="level-desc">Focus: Strategic Planning (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>S&OP Demand-Supply Balancing</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The monthly S&OP process has identified a significant demand-supply imbalance for next quarter. Commercial is forecasting aggressive growth for a newly launched product, but Manufacturing has capacity constraints and QC is at maximum testing capacity. Finance is concerned about inventory carrying costs if we build ahead. A balanced plan is needed that considers all constraints.<br><span class="key">[Objective]</span> Prepare the demand-supply balancing analysis for the S&OP executive meeting.<br><span class="key">[Style]</span> Executive S&OP presentation format.<br><span class="key">[Tone]</span> Balanced across functions—present trade-offs objectively.<br><span class="key">[Audience]</span> S&OP Executive Team (VP Commercial, VP Operations, VP Finance, VP Quality).<br><span class="key">[Response]</span> An S&OP analysis including: (1) Demand Forecast with Assumptions, (2) Supply Capability Assessment, (3) Gap Analysis, (4) Scenario Modeling (conservative, base, aggressive), (5) Options with Trade-offs (inventory build, capacity add, demand shaping), (6) Financial Impact per Scenario, (7) Recommended Plan with Risks.<br><span class="key">[Constraints]</span> RAI: No actual forecast numbers, financial projections, or product names. Bias: Present balanced options with trade-offs honestly. Data Accuracy: Forecasts must include uncertainty ranges. Human Oversight: S&OP decisions require cross-functional executive approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Supply Chain Disruption</span>
                        <span class="level-desc">Interactive Problem Solving</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Critical Material Shortage</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Production Planner using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to respond to a critical material shortage and minimize impact on customer deliveries.<br>
<span class="key">[Tools]</span> You have access to: [InventoryStatus], [ProductionSchedule], [AlternateSuppliers], [CustomerOrders], [FinishedGoodsStock]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> The primary supplier for a critical API has declared force majeure due to a facility fire. They estimate 8-12 weeks to resume supply. Current API inventory supports 4 weeks of production. The alternate supplier is qualified but has only 50% of required capacity. Two major customer orders are due in 6 weeks representing 40% of quarterly revenue.<br><span class="key">[Constraints]</span> RAI: No actual supplier names, product names, or revenue figures. Data Accuracy: Verify inventory coverage and alternate supplier capacity. Transparency: Communicate supply risks honestly to customers. Human Oversight: Supply disruption response requires Executive and Commercial leadership alignment.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to immediately contact the alternate supplier and scale up their orders. ReAct forces you to first assess actual demand priority (which orders are most critical?), calculate exact inventory coverage, determine alternate supplier true capacity and lead time, and evaluate whether finished goods allocation changes could extend coverage before making commitments that may not be achievable. This ensures a realistic response plan.
                    </div>
                </div>

                <div id="continuous" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/bullseye.svg" class="local-icon icon-red" alt="CI"> Continuous Improvement Specialist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Data Collection</span><span class="level-desc">Focus: Accuracy (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Process Observation Checklist</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> As part of a Lean improvement project, I need to conduct time-motion studies on the tablet compression changeover process. The current changeover takes approximately 4 hours. I need to observe and document each step to identify waste and improvement opportunities.<br><span class="key">[Role]</span> Continuous Improvement Analyst conducting time-motion study.<br><span class="key">[Instruction]</span> Create a structured observation checklist for the changeover process.<br><span class="key">[Style]</span> Lean/SMED observation format.<br><span class="key">[Parameters]</span> Include: activity breakdown, time recording, internal vs. external activity classification, waste identification (waiting, motion, transportation), and observer notes section. Format for easy real-time data capture.<br><span class="key">[Constraints]</span> RAI: No actual product names, employee names, or batch numbers. Data Accuracy: Time observations must be recorded objectively without pre-judgment. Human Oversight: Process changes require Operations and Quality approval before implementation.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Root Cause Analysis</span><span class="level-desc">Focus: Problem Solving (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>A3 Problem Solving Report</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Packaging Line 2 yield has dropped from 98% to 94% over the past 3 months. Reject categories include: labeling errors (40%), carton damage (35%), and weight check failures (25%). The line runs 3 products with similar packaging configurations. No equipment changes or personnel changes have occurred.<br><span class="key">[Role]</span> Continuous Improvement Specialist leading root cause analysis.<br><span class="key">[Instruction]</span> Structure an A3 problem-solving report for this yield issue.<br><span class="key">[Style]</span> Toyota A3 format with clear problem statement and analysis.<br><span class="key">[Parameters]</span> Include all A3 sections: Background, Current Condition, Goal, Root Cause Analysis (5 Whys or Ishikawa), Countermeasures, Implementation Plan, and Follow-up. Keep to one page (A3 size concept).<br><span class="key">[Example]</span> Problem Statement: Packaging Line 2 yield decreased from 98% to 94% between Jan-Mar<br>Goal: Return yield to ≥98% by end of Q2<br>Root Cause Analysis (Labeling Errors):<br>Why 1: Labels misaligned on 40% of rejects<br>Why 2: Label applicator tension inconsistent<br>Why 3: Tension adjustment procedure not followed consistently<br>Why 4: Procedure requires interpretation, no visual standards<br>Why 5: Standards never developed after equipment installation<br><span class="key">[Constraints]</span> RAI: No actual product names or batch identifiers. Data Accuracy: Yield data must be verified from production records. Bias Awareness: Root cause analysis must be objective, avoiding blame. Human Oversight: Countermeasures affecting GMP processes require Quality approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Transformation Program</span><span class="level-desc">Focus: Change Leadership (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Operational Excellence Roadmap</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Leadership has committed to an operational excellence transformation with goals of 20% productivity improvement and 50% quality defect reduction over 3 years. The organization has limited Lean/Six Sigma experience. Past improvement initiatives have started strong but faded after 6 months. Budget has been allocated for training and dedicated CI resources.<br><span class="key">[Objective]</span> Develop a phased operational excellence roadmap that builds sustainable capability.<br><span class="key">[Style]</span> Strategic transformation roadmap.<br><span class="key">[Tone]</span> Ambitious but realistic about change management challenges.<br><span class="key">[Audience]</span> Executive Leadership Team and Site Directors.<br><span class="key">[Response]</span> A transformation roadmap including: (1) Current State Assessment, (2) Vision and Objectives, (3) Phased Approach (Foundation, Build, Sustain), (4) Capability Development Plan (training, certification), (5) Project Selection and Prioritization, (6) Governance Structure, (7) Change Management Strategy, (8) Success Metrics and Milestones, (9) Risk Factors and Mitigations.<br><span class="key">[Constraints]</span> RAI: No actual company metrics or employee performance data. Source Accuracy: Benchmark productivity improvements against industry data. Bias Awareness: Acknowledge that past initiative failures may have valid reasons. Human Oversight: Transformation program requires Executive Leadership approval and change management oversight.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Improvement Resistance</span>
                        <span class="level-desc">Interactive Problem Solving</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Change Resistance Analysis</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Continuous Improvement Specialist using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to diagnose why a well-designed improvement solution is not being adopted and develop an effective change strategy.<br>
<span class="key">[Tools]</span> You have access to: [ImprovementMetrics], [StaffFeedback], [TrainingRecords], [LeadershipSurvey], [BenchmarkData]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> Six months ago, a Kaizen event redesigned the batch record review process, reducing theoretical review time from 4 hours to 1.5 hours. The new process was validated and trained. However, actual review time has only improved to 3.5 hours. Supervisors report that reviewers are "not following the new process." The reviewers say the new process "doesn't work in practice." Leadership is frustrated and considering mandating compliance.<br><span class="key">[Constraints]</span> RAI: No actual employee names or performance criticisms. Bias Awareness: Seek to understand all perspectives before attributing resistance to attitude. Human Oversight: Process changes affecting batch record review require Quality validation before mandating.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to mandate compliance or provide more training. ReAct forces you to first understand why the gap exists (is the new process missing something the old process handled?), gather specific feedback on what "doesn't work," check if the improvement was sustained in the pilot area, and assess whether the design assumptions were valid. This often reveals that the "resistance" is actually feedback about design flaws that need to be addressed.
                    </div>
                </div>

                <div id="vendor-quality" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/shield.svg" class="local-icon icon-red" alt="VQ"> Vendor Quality Specialist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Supplier Qualification</span><span class="level-desc">Focus: Documentation (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Supplier Questionnaire Review</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A potential new excipient supplier has submitted their completed Supplier Quality Questionnaire. The questionnaire covers GMP compliance, quality systems, regulatory status, and manufacturing capabilities. I need to review the responses and identify any gaps or concerns that need follow-up before proceeding to an on-site audit.<br><span class="key">[Role]</span> Vendor Quality Specialist responsible for supplier assessment.<br><span class="key">[Instruction]</span> Create a questionnaire review summary with gaps identified.<br><span class="key">[Style]</span> Supplier qualification assessment format.<br><span class="key">[Parameters]</span> Organize by questionnaire section. Flag responses that are incomplete, concerning, or require clarification. Identify showstoppers vs. items that can be addressed during audit. Provide initial risk assessment.<br><span class="key">[Constraints]</span> RAI: No actual supplier names, locations, or proprietary processes. Data Accuracy: Assessment must be based on documented questionnaire responses. Source Accuracy: Reference applicable GMP requirements (FDA, EU, ICH Q10). Human Oversight: Supplier qualification decisions require Quality Management approval.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Supplier Auditing</span><span class="level-desc">Focus: Risk Assessment (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Audit Observation Report</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> During a supplier audit of an API manufacturer, I observed that their change control system does not formally evaluate the impact of changes on customers. Changes are implemented after internal approval only. The supplier has made 3 process changes in the past year that we were not notified about until after implementation.<br><span class="key">[Role]</span> Vendor Quality Specialist conducting supplier audit.<br><span class="key">[Instruction]</span> Document this audit observation and assess the risk.<br><span class="key">[Style]</span> GMP supplier audit finding format.<br><span class="key">[Parameters]</span> Include: observation statement, regulatory reference, evidence collected, risk assessment (to our products), and required corrective action. Classify severity (Critical/Major/Minor).<br><span class="key">[Example]</span> Observation: Change control procedure does not include customer impact assessment or notification<br>Reference: ICH Q10, Section 3.2.1; Quality Agreement Section 4.3<br>Evidence: Change Control SOP-CC-001 reviewed; 3 change records (CC-2024-015, -018, -022) showed no customer notification<br>Risk Assessment: High - Unnotified changes could affect our validated processes<br><span class="key">[Constraints]</span> RAI: No actual supplier names or proprietary information. Source Accuracy: Cite specific regulatory references (ICH Q10, Quality Agreement clauses). Data Accuracy: Evidence must be factual and documented during audit. Human Oversight: Finding severity classifications require Lead Auditor and Quality Management concurrence.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Supplier Development</span><span class="level-desc">Focus: Partnership (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Supplier Performance Improvement</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> A strategic supplier of a critical starting material has had declining quality performance over 18 months: OOS rate increased from 0.5% to 2.5%, and on-time delivery dropped from 95% to 80%. The material is sole-sourced due to technical requirements. Qualifying an alternate supplier would take 2 years. The supplier is experiencing financial difficulties and has reduced their quality staff.<br><span class="key">[Objective]</span> Develop a supplier performance improvement plan that addresses quality risks while maintaining supply continuity.<br><span class="key">[Style]</span> Strategic supplier management plan.<br><span class="key">[Tone]</span> Partnership-oriented but firm on quality requirements.<br><span class="key">[Audience]</span> VP Quality, VP Supply Chain, and Procurement leadership.<br><span class="key">[Response]</span> An improvement plan including: (1) Current Performance Analysis, (2) Root Cause Assessment, (3) Short-term Risk Mitigation (increased testing, safety stock), (4) Supplier Improvement Actions with Milestones, (5) Our Support Commitment (technical assistance, advance payment), (6) Escalation Triggers, (7) Parallel Path (expedited alternate supplier qualification), (8) Exit Criteria.<br><span class="key">[Constraints]</span> RAI: No actual supplier names, financial details, or contract terms. Data Accuracy: Quality metrics must be verified from incoming inspection records. Transparency: Performance concerns must be communicated clearly to supplier. Human Oversight: Supplier improvement plans and alternate qualification require Quality, Supply Chain, and Executive approval.</div></div></div>

                    <div class="level-header">
                        <span class="level-badge cell-accent text-white">ReAct Application</span>
                        <span class="level-title">Supplier Quality Issue</span>
                        <span class="level-desc">Interactive Response</span>
                    </div>

                    <div class="example-block">
                        <div class="example-header">
                            <span>Incoming Material Failure</span>
                            <span class="method-badge">ReAct</span>
                            <button class="btn-copy">Copy</button>
                        </div>
                        <div class="example-content">
                            <div class="prompt-text"><span class="key">[Role]</span> You are a Vendor Quality Specialist using the ReAct framework.<br>
<span class="key">[Goal]</span> Your goal is to investigate an incoming material quality failure and determine appropriate supplier corrective action.<br>
<span class="key">[Tools]</span> You have access to: [COA_Review], [IncomingTestResults], [SupplierHistory], [BatchTraceability], [QualityAgreement]<br>
<span class="key">[Format]</span> Thought → Action → [STOP for Observation] → Repeat<br>
<span class="key">[Scenario]</span> QC testing of incoming Excipient-B Lot 2024-456 failed the particle size specification. The supplier's COA showed passing results. This is the third lot from this supplier to fail incoming testing this year (different test failures each time). The material is needed for production starting next week. The supplier has already shipped Lot 2024-457 which is in transit.<br><span class="key">[Constraints]</span> RAI: No actual supplier names, lot numbers, or product identifiers. Data Accuracy: Test comparisons must be based on validated methods. Source Accuracy: Reference Quality Agreement clauses and regulatory requirements. Human Oversight: Material disposition and supplier escalation require Quality Management approval.</div>
                        </div>
                    </div>

                    <div class="method-explanation">
                        <strong>Why this works:</strong><br>
                        The instinct is to reject the lot and demand corrective action. ReAct forces you to first verify the test method comparison (are we testing the same way?), review the pattern of failures (is there a systemic issue?), assess the in-transit lot risk (should we hold it for testing?), and determine if this triggers Quality Agreement escalation clauses before responding. This ensures a comprehensive response that addresses both immediate and systemic concerns.
                    </div>
                </div>

                <div id="brainstorming" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/boltz.svg" class="local-icon icon-red" alt="Boltz"> Brainstorming & Ideation
                    </h2>
                    <p class="lead">Compare how the three methodologies handle creative volume. Use CRISP for speed, CRISPE for organized selection, and COSTAR for strategic alignment.</p>

                    <div class="level-header"><span class="level-badge">Method 1: Speed</span><span class="level-title">Rapid Fire Ideation</span><span class="level-desc">CRISP</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Naming a Tool</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are launching a new internal AI tool that automates helpdesk ticket triage. We need a catchy name for the pilot program to generate excitement among the staff.<br><span class="key">[Role]</span> Creative Director.<br><span class="key">[Instruction]</span> Brainstorm a list of 20 potential names.<br><span class="key">[Style]</span> Modern, Tech-forward, One-word.<br><span class="key">[Parameters]</span> Do not use generic words like "Bot", "Smart", or "Helper". Focus on themes of Speed, Clarity, and Flow.<br><span class="key">[Constraints]</span> RAI: No actual project names or internal tool details. Bias Awareness: Consider diverse naming perspectives and cultural connotations. Human Oversight: Final name selection requires stakeholder consensus and trademark review.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> When you just need raw volume to get the creative juices flowing.</div>
                    </div>

                    <div class="level-header"><span class="level-badge">Method 2: Structure</span><span class="level-title">Organized Selection</span><span class="level-desc">CRISPE</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Naming with Rationale</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are launching a new internal AI tool for ticket triage. I need to present naming options to the project stakeholders tomorrow, and I need the logic behind each name clearly explained.<br><span class="key">[Role]</span> Creative Director.<br><span class="key">[Instruction]</span> Brainstorm 10 names and provide a 1-sentence rationale for why each name fits the brand.<br><span class="key">[Style]</span> Branding Agency Presentation.<br><span class="key">[Parameters]</span> Format as a Markdown Table.<br><span class="key">[Example]</span> | Name | Vibe | Rationale |<br>|------|------|-----------|<br>| Flux | Speed | Represents continuous movement and resolution. |<br><span class="key">[Constraints]</span> RAI: No actual project names or confidential tool details. Transparency: Present rationale objectively without overselling. Human Oversight: Name presentation to stakeholders requires Marketing and Legal review.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> When you need the output organized for a presentation immediately.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Method 3: Strategy</span><span class="level-title">Stakeholder Alignment</span><span class="level-desc">COSTAR</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Safe & Corporate Options</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are naming our new AI tool. The company culture is extremely conservative and traditional (Financial/Pharma). Names that sound too "sci-fi" or "risky" will be rejected immediately by the steering committee.<br><span class="key">[Objective]</span> Find a name that sounds innovative but safe enough for a corporate enterprise.<br><span class="key">[Style]</span> Corporate Branding / Enterprise Software.<br><span class="key">[Tone]</span> Trustworthy, Reliable, and Professional.<br><span class="key">[Audience]</span> The Steering Committee (Risk-averse executives).<br><span class="key">[Response]</span> 5 Candidates, each accompanied by a "Safety Score" (1-10) and a risk analysis.<br><span class="key">[Constraints]</span> RAI: No actual company names, competitive intelligence, or confidential strategic context. Bias Awareness: Balance innovation against legitimate corporate risk concerns. Human Oversight: Enterprise naming decisions require Steering Committee approval and trademark clearance.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> When the <em>audience</em> (Risk-averse committee) determines the success of the idea more than the idea itself.</div>
                    </div>
                </div>

                <div id="lateral" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/boltz.svg" class="local-icon icon-red" alt="Lateral"> "Out of the Box" Lateral Thinking
                    </h2>
                    <p class="lead">Use AI to simulate different cognitive frameworks to solve stuck problems.</p>

                    <div class="level-header"><span class="level-badge">Method 1: Speed</span><span class="level-title">Sanity Check</span><span class="level-desc">CRISP</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Low Adoption Troubleshooting</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> User adoption of the new dashboard is extremely low (15%). The technology works perfectly, but people just aren't logging in. We are stuck on "technical fixes" but I suspect the issue is human.<br><span class="key">[Role]</span> Product Strategist and Behavioral Psychologist.<br><span class="key">[Instruction]</span> List 5 unconventional, non-technical reasons why users might be avoiding the tool.<br><span class="key">[Style]</span> Psychological and Insightful.<br><span class="key">[Parameters]</span> Ignore technical bugs. Focus entirely on human behavior, fear, and habits.<br><span class="key">[Constraints]</span> RAI: No actual user names, adoption metrics, or confidential project details. Bias Awareness: Consider multiple user perspectives without assuming negligence. Human Oversight: Behavioral interventions require HR and Change Management review.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> When you're stuck solving a problem with the same approach. The dual-role prompt (Product Strategist + Behavioral Psychologist) forces the AI to escape purely technical thinking and explore human factors.</div>
                    </div>

                    <div class="level-header"><span class="level-badge">Method 2: Structure</span><span class="level-title">Framework Simulation</span><span class="level-desc">CRISPE</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Six Thinking Hats</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Dashboard adoption is low. We are trapped in "groupthink" and need to look at the problem from different angles to find a solution.<br><span class="key">[Role]</span> Corporate Facilitator.<br><span class="key">[Instruction]</span> Analyze this adoption problem using Edward de Bono's "Six Thinking Hats" method.<br><span class="key">[Style]</span> Analytical and Comprehensive.<br><span class="key">[Parameters]</span> Provide exactly 1 specific insight for each Hat (Red, Black, Yellow, Green, White, Blue).<br><span class="key">[Example]</span> Red Hat (Emotion): "Users feel fear that the dashboard makes their manual reporting skills obsolete."<br><span class="key">[Constraints]</span> RAI: No actual employee sentiments or confidential adoption data. Bias Awareness: Each "hat" perspective should be explored genuinely, not dismissed. Human Oversight: Insights affecting people or process changes require Leadership review.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> When your team is stuck in groupthink. The Example component forces the AI to follow the Six Thinking Hats structure precisely, giving you organized insights from multiple perspectives.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Method 3: Strategy</span><span class="level-title">Strategic Pivot</span><span class="level-desc">COSTAR</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: The "Pivot Pitch"</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Adoption is critically low and the project is at risk of cancellation. We have realized that the dashboard isn't useful for "Reporting" (original goal) but is actually amazing for "Forecasting" (unintended use). We need to sell this pivot.<br><span class="key">[Objective]</span> Pivot the narrative of "Failure" into a "Strategic Discovery" to save the project budget.<br><span class="key">[Style]</span> Crisis Management / Startup Pivot.<br><span class="key">[Tone]</span> Optimistic, Realistic, and Urgent.<br><span class="key">[Audience]</span> The Project Sponsor (who is angry and wants to cut losses).<br><span class="key">[Response]</span> A "Pivot Pitch" narrative explaining why the new direction is actually more valuable than the original plan.<br><span class="key">[Constraints]</span> RAI: No actual budget figures, project names, or performance metrics. Transparency: Acknowledge original shortcomings honestly while presenting pivot value. Human Oversight: Project pivot decisions require Sponsor and Steering Committee approval.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> When you need to reframe failure as opportunity. The Audience component (angry sponsor) ensures the AI crafts messaging that addresses emotional resistance, not just logical arguments.</div>
                    </div>
                </div>

                <div id="research" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/search.svg" class="local-icon icon-red" alt="Research"> Research & Validation
                    </h2>
                    <p class="lead">Use constraints to force citations and limit hallucinations.</p>

                    <div class="level-header"><span class="level-badge">Method 1: Speed</span><span class="level-title">General Overview</span><span class="level-desc">CRISP</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: EU AI Act Summary</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I am researching the new Generative AI regulations in the EU to understand how they might impact our company's marketing tools.<br><span class="key">[Role]</span> Corporate Compliance Officer.<br><span class="key">[Instruction]</span> Summarize the "EU AI Act" and its core pillars.<br><span class="key">[Style]</span> Factual and Concise.<br><span class="key">[Parameters]</span> Use bullet points only. Keep it high-level.<br><span class="key">[Constraints]</span> RAI: No actual company-specific compliance assessments. Source Accuracy: Reference official EU AI Act text, not secondary summaries. Temporal Accuracy: Note publication dates; regulatory guidance evolves. Human Oversight: Compliance determinations require Legal and Regulatory Affairs review.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> When you need a quick overview to determine if deeper research is needed. The Role (Compliance Officer) ensures the AI focuses on regulatory impact, not technical implementation.</div>
                    </div>

                    <div class="level-header"><span class="level-badge">Method 2: Structure</span><span class="level-title">Data Extraction</span><span class="level-desc">CRISPE</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Key Dates & Fines</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We need to build a compliance timeline for the EU AI Act. I need specific dates and penalty amounts, not general text.<br><span class="key">[Role]</span> Legal Analyst.<br><span class="key">[Instruction]</span> Extract the key compliance deadlines and maximum fine structures from the Act.<br><span class="key">[Style]</span> Legal Brief.<br><span class="key">[Parameters]</span> Strict Table format with columns: Provision, Compliance Deadline, Maximum Penalty.<br><span class="key">[Example]</span> | Provision | Compliance Date | Max Fine |<br>|-----------|-----------------|----------|<br><span class="key">[Constraints]</span> RAI: No internal compliance timeline or proprietary assessments. Source Accuracy: Verify dates and fines against official legislative text. Data Accuracy: Mark any uncertain or pending dates clearly. Human Oversight: Compliance timelines require Legal validation before planning.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> When you need structured data, not narrative text. The Example component shows the AI exactly how to format the table, dramatically reducing the need for follow-up corrections.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Method 3: Strategy</span><span class="level-title">Validation with Constraints</span><span class="level-desc">COSTAR</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Pharma Risk Analysis</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We are writing a whitepaper on the risks of AI in the Pharmaceutical sector. There is a lot of outdated information online. We need to identify risks that are specific to R&D and Clinical Trials.<br><span class="key">[Objective]</span> Identify the top 3 regulatory risks for Pharma R&D under the new EU rules.<br><span class="key">[Style]</span> Academic / Whitepaper.<br><span class="key">[Tone]</span> Objective, Cautionary, and Fact-Based.<br><span class="key">[Audience]</span> The Chief Legal Officer (CLO).<br><span class="key">[Response]</span> An Executive Summary with inline citations. **Constraint: You must ONLY use sources published between 2024 and 2025. If a source is older than 2024, do not use it.**<br><span class="key">[Constraints]</span> RAI: No actual company R&D programs, clinical trials, or proprietary AI applications. Source Accuracy: Verify all citations against primary regulatory sources. Temporal Accuracy: Strictly enforce 2024-2025 date constraint; flag older sources. Human Oversight: Whitepaper content for external publication requires Legal, Regulatory, and Communications approval.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> When accuracy is critical and hallucination risk is high. The explicit date constraint forces the AI to filter its training data, while the Audience (CLO) ensures the tone is legally defensible rather than speculative.</div>
                    </div>
                </div>

                <!-- Data Science Lead -->
                <div id="data-science" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/chart.svg" class="local-icon icon-red" alt="Data Science"> Data Science Lead
                    </h2>
                    <p class="lead">Strategic data analysis to drive pharmaceutical R&D decisions and business intelligence.</p>

                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Basic Data Analysis Request</span><span class="level-desc">CRISP</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Clinical Trial Enrollment Trends</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I have enrollment data for Study-XYZ across 15 sites over 18 months. Some sites are underperforming against targets.<br><span class="key">[Role]</span> Data Science Lead in Pharma R&D.<br><span class="key">[Instruction]</span> Help me structure an analysis to identify patterns in underperforming sites.<br><span class="key">[Style]</span> Analytical and methodical.<br><span class="key">[Parameters]</span> Focus on statistical approaches suitable for small sample sizes. Suggest visualization types.<br><span class="key">[Constraints]</span> RAI: No actual study identifiers, site names, or patient enrollment data. Data Accuracy: Statistical approaches must be appropriate for actual sample sizes. Source Accuracy: Reference established biostatistical methods. Human Oversight: Enrollment analysis findings require Clinical Operations and Biostatistics review before action.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> Gets you started with a structured analytical approach when you have a dataset and need to identify meaningful patterns.</div>
                    </div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Predictive Modeling Strategy</span><span class="level-desc">CRISPE</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Drug Demand Forecasting</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We need to forecast demand for Product-Alpha across 5 markets for the next 12 months. Historical data shows seasonal patterns and promotional impacts.<br><span class="key">[Role]</span> Senior Data Scientist supporting Commercial Operations.<br><span class="key">[Instruction]</span> Recommend a forecasting methodology that accounts for seasonality, promotions, and market-specific factors.<br><span class="key">[Style]</span> Technical but accessible to business stakeholders.<br><span class="key">[Parameters]</span> Compare at least 3 modeling approaches with pros/cons for our use case.<br><span class="key">[Example]</span> Include considerations for: data requirements, implementation complexity, and explainability to non-technical leaders.<br><span class="key">[Constraints]</span> RAI: No actual product names, sales data, or market share figures. Data Accuracy: Model assumptions must be validated against historical data patterns. Transparency: Clearly communicate forecast uncertainty and limitations to stakeholders. Human Oversight: Forecasting models affecting supply chain decisions require Commercial and Supply Chain leadership approval.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> When you need to select the right modeling approach and need to justify your recommendation to both technical and business audiences.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">ML Pipeline Design</span><span class="level-desc">COSTAR</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Adverse Event Signal Detection</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Pharmacovigilance team receives 10,000+ adverse event reports monthly. Current manual triage is creating bottlenecks. We want to build an ML model to prioritize reports by severity risk.<br><span class="key">[Objective]</span> Design an end-to-end ML pipeline for AE report classification that meets GxP validation requirements.<br><span class="key">[Style]</span> Technical specification document.<br><span class="key">[Tone]</span> Precise, validation-focused, risk-aware.<br><span class="key">[Audience]</span> Data Engineering team and Quality Assurance for validation planning.<br><span class="key">[Response]</span> Architecture diagram description, data flow, model selection rationale, validation strategy aligned with FDA guidance on AI/ML, and MLOps considerations for GxP environments.<br><span class="key">[Constraints]</span> RAI: No actual adverse event data, patient identifiers, or proprietary safety signals. Source Accuracy: Reference FDA AI/ML guidance and ICH E2F pharmacovigilance requirements. Data Accuracy: Model performance metrics must be validated against labeled test sets. Human Oversight: ML for safety signal detection requires Pharmacovigilance, Quality, and Regulatory validation before production deployment.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> For designing regulated ML systems where validation, explainability, and audit trails are as important as model performance.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">ReAct Application</span><span class="level-title">Data Quality Investigation</span><span class="level-desc">Interactive Troubleshooting</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Anomaly Root Cause Analysis</span><span class="method-badge">ReAct</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Role]</span> You are a Data Science Lead investigating a data quality issue.<br><span class="key">[Goal]</span> Identify the root cause of anomalous values in a clinical dataset.<br><span class="key">[Tools]</span> You have access to: [DataProfile] - Get statistical summary; [SourceTrace] - Trace data lineage; [QueryLog] - Check ETL job history; [CompareSnapshot] - Compare current vs historical data.<br><span class="key">[Format]</span> Use Thought → Action → Observation loop.<br><br><span class="key">[Scenario]</span> Lab values for Study-789 show impossible readings (negative hemoglobin). Need to find the source of corruption.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Negative hemoglobin values are impossible. This suggests either data entry error, ETL transformation issue, or source system problem. I should first understand the scope—how many records are affected?<br><span class="key">Action:</span> [DataProfile] Run distribution analysis on hemoglobin_value field for Study-789<br><br><strong>You:</strong><br><span class="key">Observation:</span> 47 records show negative values. All from Site-003. All entered between March 5-7.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Concentrated at one site during a specific window suggests a systematic issue—possibly a software update or user error at that site. Let me check if there were any ETL changes during that period.<br><span class="key">Action:</span> [QueryLog] Show ETL jobs for lab_results table between March 1-10<br><span class="key">[Constraints]</span> RAI: No actual study identifiers, patient data, or site names. Data Accuracy: Anomaly findings must be verified against source systems. Transparency: Document investigation steps for audit trail. Human Oversight: Data quality issues affecting clinical data require Clinical Data Management, Biostatistics, and Quality review.</div></div>
                    </div>
                    <div class="method-explanation"><strong>Why this works:</strong> Data quality investigations require systematic hypothesis testing. ReAct keeps the analysis structured and creates an audit trail of the investigation steps.</div>
                </div>

                <!-- AI/ML Engineer -->
                <div id="ai-engineer" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/cpu.svg" class="local-icon icon-red" alt="AI Engineer"> AI/ML Engineer
                    </h2>
                    <p class="lead">Building and deploying machine learning models for pharmaceutical applications.</p>

                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Model Selection Guidance</span><span class="level-desc">CRISP</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Document Classification Algorithm</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I need to classify regulatory documents (CMC, clinical, nonclinical) automatically. We have 5,000 labeled examples.<br><span class="key">[Role]</span> ML Engineer in Pharma IT.<br><span class="key">[Instruction]</span> Recommend appropriate ML approaches for this text classification task.<br><span class="key">[Style]</span> Technical comparison with clear recommendations.<br><span class="key">[Parameters]</span> Consider: training data size, interpretability requirements for GxP, and deployment complexity.<br><span class="key">[Constraints]</span> RAI: No actual document content, regulatory filings, or proprietary algorithms. Data Accuracy: Model performance claims must be based on validated test datasets. Source Accuracy: Reference established ML best practices and GxP guidance. Human Oversight: Model selection for GxP applications requires Quality and IT validation review.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> Quick guidance on model selection when starting a new ML project with clear constraints.</div>
                    </div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Feature Engineering Strategy</span><span class="level-desc">CRISPE</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Patient Dropout Prediction</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Building a model to predict clinical trial patient dropout risk. Raw features include demographics, visit adherence, AE history, and site characteristics.<br><span class="key">[Role]</span> ML Engineer supporting Clinical Operations.<br><span class="key">[Instruction]</span> Design a feature engineering strategy to maximize predictive power while maintaining interpretability.<br><span class="key">[Style]</span> Technical specification with rationale.<br><span class="key">[Parameters]</span> Must handle missing data, temporal features, and categorical variables. Output should be GxP-audit friendly.<br><span class="key">[Example]</span> For each feature type, specify: transformation method, handling of edge cases, and documentation requirements.<br><span class="key">[Constraints]</span> RAI: No actual patient data, site identifiers, or clinical trial numbers. Data Accuracy: Feature transformations must be reproducible and documented. Bias Awareness: Monitor for demographic bias in dropout prediction features. Human Oversight: Feature engineering for clinical models requires Biostatistics and Clinical Operations review before deployment.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> Feature engineering is often where ML projects succeed or fail. This prompt ensures systematic coverage of all data types.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">MLOps Architecture</span><span class="level-desc">COSTAR</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: GxP-Compliant ML Deployment</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We have a validated ML model for batch release prediction. Now need to deploy it in production with full GxP compliance—version control, audit trails, model monitoring, and change control procedures.<br><span class="key">[Objective]</span> Design an MLOps architecture that meets 21 CFR Part 11 and Annex 11 requirements for a production ML system.<br><span class="key">[Style]</span> Technical architecture document.<br><span class="key">[Tone]</span> Precise, compliance-focused, implementation-ready.<br><span class="key">[Audience]</span> DevOps team, Quality Assurance, and IT Security.<br><span class="key">[Response]</span> Include: CI/CD pipeline design, model registry requirements, monitoring and alerting strategy, rollback procedures, and validation documentation requirements. Reference specific regulatory guidance where applicable.<br><span class="key">[Constraints]</span> RAI: No actual system credentials, infrastructure details, or proprietary model architectures. Source Accuracy: Reference 21 CFR Part 11, Annex 11, and GAMP 5 AI/ML addendum. Data Accuracy: Model performance metrics must be traceable to validation protocols. Human Oversight: GxP ML deployment requires Quality validation approval and change control before production release.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> ML deployment in pharma requires careful balance of agility and compliance. This prompt ensures all regulatory angles are covered.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">ReAct Application</span><span class="level-title">Model Performance Debugging</span><span class="level-desc">Interactive Troubleshooting</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Production Model Drift</span><span class="method-badge">ReAct</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Role]</span> You are an ML Engineer investigating model performance degradation.<br><span class="key">[Goal]</span> Diagnose why a production model's accuracy dropped from 94% to 78% over the past month.<br><span class="key">[Tools]</span> [MetricsHistory] - View performance metrics over time; [DataDrift] - Compare input feature distributions; [PredictionLog] - Sample recent predictions with ground truth; [ModelRegistry] - Check model versions and deployment history.<br><span class="key">[Format]</span> Use Thought → Action → Observation loop.<br><br><span class="key">[Scenario]</span> Document classification model suddenly performing poorly. No code changes deployed.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Sudden performance drop without code changes suggests either data drift (input distribution changed) or label drift (what we're predicting changed). Let me first check when the degradation started.<br><span class="key">Action:</span> [MetricsHistory] Show weekly accuracy trend for doc-classifier-v2 over past 8 weeks<br><br><strong>You:</strong><br><span class="key">Observation:</span> Accuracy was stable at 94% weeks 1-5. Dropped to 88% week 6, then 78% weeks 7-8.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Gradual decline starting week 6 suggests progressive drift rather than sudden change. Let me check if the input data distribution changed around that time.<br><span class="key">Action:</span> [DataDrift] Compare feature distributions: week 5 vs week 7<br><span class="key">[Constraints]</span> RAI: No actual production data, model details, or system configurations. Data Accuracy: Performance metrics must be verified against ground truth labels. Transparency: Document all drift findings and diagnostic steps. Human Oversight: Model retraining or replacement requires validation and change control approval.</div></div>
                    </div>
                    <div class="method-explanation"><strong>Why this works:</strong> ML debugging requires systematic hypothesis testing. ReAct structures the investigation and helps identify root causes methodically.</div>
                </div>

                <!-- Innovation Project Manager -->
                <div id="innovation-pm" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/lightbulb.svg" class="local-icon icon-red" alt="Innovation"> Innovation Project Manager
                    </h2>
                    <p class="lead">Driving AI and digital innovation initiatives from concept to implementation in pharma.</p>

                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Use Case Identification</span><span class="level-desc">CRISP</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: AI Opportunity Assessment</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Our Regulatory Affairs team spends 40% of their time on document formatting and cross-referencing. Leadership wants to explore AI solutions.<br><span class="key">[Role]</span> Innovation Project Manager in Pharma.<br><span class="key">[Instruction]</span> Help me structure an AI opportunity assessment for this use case.<br><span class="key">[Style]</span> Business case framework.<br><span class="key">[Parameters]</span> Include: problem definition, potential AI approaches, feasibility factors, and success metrics.<br><span class="key">[Constraints]</span> RAI: No actual employee productivity metrics or proprietary workflows. Data Accuracy: Time savings estimates must be based on documented process studies. Bias Awareness: Consider impact on workforce and change management needs. Human Oversight: AI use case prioritization requires Leadership and Legal/Compliance review.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> Structures early-stage innovation assessment to identify viable AI opportunities.</div>
                    </div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Pilot Program Design</span><span class="level-desc">CRISPE</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: GenAI Pilot Rollout</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> We've selected 3 use cases for a GenAI pilot in Medical Affairs: literature review, medical response drafting, and training content creation. Need to design a 90-day pilot program.<br><span class="key">[Role]</span> Innovation PM leading the AI pilot.<br><span class="key">[Instruction]</span> Design a structured pilot program that balances speed with proper risk management and success measurement.<br><span class="key">[Style]</span> Program plan with clear milestones.<br><span class="key">[Parameters]</span> Include governance structure, user selection criteria, training approach, and KPIs for each use case.<br><span class="key">[Example]</span> Phase 1 (Weeks 1-2): Setup and training. Phase 2 (Weeks 3-8): Supervised usage. Phase 3 (Weeks 9-12): Independent usage and measurement.<br><span class="key">[Constraints]</span> RAI: No actual employee names, patient data, or medical content in pilots. Data Accuracy: KPIs must be measurable and baselined before pilot start. Transparency: Communicate AI capabilities and limitations clearly to pilot users. Human Oversight: GenAI outputs in Medical Affairs require medical review before external use.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> Pilots fail when poorly designed. This ensures proper structure for meaningful results.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Enterprise AI Strategy</span><span class="level-desc">COSTAR</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: AI Roadmap Development</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Following successful pilots, leadership wants a 3-year AI roadmap. Current state: 5 pilot projects, no enterprise AI platform, fragmented governance. Target: scaled AI adoption across R&D and Commercial.<br><span class="key">[Objective]</span> Develop a phased AI transformation roadmap that addresses technology, people, process, and governance dimensions.<br><span class="key">[Style]</span> Executive strategy document.<br><span class="key">[Tone]</span> Strategic, realistic about challenges, focused on value delivery.<br><span class="key">[Audience]</span> C-suite and Board of Directors.<br><span class="key">[Response]</span> Include: maturity assessment framework, investment priorities by phase, capability building plan, risk mitigation strategies, and governance evolution. Show quick wins alongside long-term transformation.<br><span class="key">[Constraints]</span> RAI: No actual investment figures, competitive strategies, or proprietary roadmaps. Source Accuracy: Benchmark against industry frameworks (Gartner AI Maturity, etc.). Bias Awareness: Present balanced view of AI benefits and risks. Human Oversight: Enterprise AI strategy requires Board approval and ongoing governance committee oversight.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> AI transformation is multi-dimensional. This prompt ensures comprehensive strategic thinking.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">ReAct Application</span><span class="level-title">Stakeholder Alignment</span><span class="level-desc">Interactive Troubleshooting</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Innovation Resistance Analysis</span><span class="method-badge">ReAct</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Role]</span> You are an Innovation PM navigating organizational resistance to an AI initiative.<br><span class="key">[Goal]</span> Identify and address root causes of stakeholder resistance to move project forward.<br><span class="key">[Tools]</span> [StakeholderMap] - View stakeholder positions and influence; [ConcernLog] - List objections raised; [ChangeHistory] - Past change initiatives and outcomes; [BenchmarkData] - Industry adoption examples.<br><span class="key">[Format]</span> Use Thought → Action → Observation loop.<br><br><span class="key">[Scenario]</span> AI-powered document review project stalled. Key stakeholders expressing vague concerns.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Vague concerns often mask specific fears—job security, quality risks, or past failed projects. I need to identify who is blocking and why. Let me map the stakeholder landscape.<br><span class="key">Action:</span> [StakeholderMap] Show stakeholder positions for DocReview-AI project—categorize as Champion, Neutral, or Resistant<br><br><strong>You:</strong><br><span class="key">Observation:</span> Champions: IT Director, Regulatory VP. Neutral: Legal. Resistant: Quality Director, Senior Regulatory Writers (3).<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Quality Director and end-users resistant. Quality concerns are often about validation and risk. Writers may fear job displacement. Let me check what specific objections have been documented.<br><span class="key">Action:</span> [ConcernLog] List objections raised by Quality Director and Regulatory Writers<br><span class="key">[Constraints]</span> RAI: No actual employee names, performance critiques, or confidential objections. Bias Awareness: Approach resistance with empathy; concerns may be valid. Transparency: Address stakeholder concerns honestly, not dismissively. Human Oversight: Change management approaches affecting job roles require HR and Leadership alignment.</div></div>
                    </div>
                    <div class="method-explanation"><strong>Why this works:</strong> Innovation adoption is a people challenge. ReAct helps systematically uncover and address resistance root causes.</div>
                </div>

                <!-- Digital Transformation Specialist -->
                <div id="digital-transform" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/refresh.svg" class="local-icon icon-red" alt="Digital"> Digital Transformation Specialist
                    </h2>
                    <p class="lead">Modernizing pharmaceutical operations through digital technologies and process redesign.</p>

                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Process Digitization Assessment</span><span class="level-desc">CRISP</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Paper-to-Digital Evaluation</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Manufacturing batch records are still paper-based at Site-002. Leadership wants to evaluate electronic batch record (EBR) implementation.<br><span class="key">[Role]</span> Digital Transformation Specialist in Pharma Manufacturing.<br><span class="key">[Instruction]</span> Create a framework for assessing readiness and benefits of EBR implementation.<br><span class="key">[Style]</span> Structured assessment checklist.<br><span class="key">[Parameters]</span> Consider: current process maturity, infrastructure requirements, regulatory implications, and change management needs.<br><span class="key">[Constraints]</span> RAI: No actual site names, batch record content, or proprietary processes. Source Accuracy: Reference 21 CFR Part 11 and Annex 11 requirements for EBR. Data Accuracy: Readiness assessment must be based on documented current state. Human Oversight: EBR implementation requires Quality and IT validation approval with regulatory notification.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> Digital readiness assessment prevents failed implementations by identifying gaps early.</div>
                    </div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Integration Strategy</span><span class="level-desc">CRISPE</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: System Landscape Modernization</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Current state: 15 siloed systems across R&D, Manufacturing, and Commercial. Data flows are manual, causing delays and errors. Target: integrated digital ecosystem.<br><span class="key">[Role]</span> Digital Transformation Lead.<br><span class="key">[Instruction]</span> Develop an integration strategy that balances quick wins with long-term architecture goals.<br><span class="key">[Style]</span> Technical strategy with business rationale.<br><span class="key">[Parameters]</span> Evaluate: API-first approach, iPaaS options, and master data management needs. Must maintain GxP system validation status.<br><span class="key">[Example]</span> Phase 1: Critical path integrations (ERP-MES). Phase 2: Data lake foundation. Phase 3: Advanced analytics enablement.<br><span class="key">[Constraints]</span> RAI: No actual system names, vendor details, or integration credentials. Source Accuracy: Reference industry integration patterns and GxP data integrity guidance. Data Accuracy: Data flow documentation must reflect validated system states. Human Oversight: Integration changes affecting GxP systems require validation and change control approval.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> Integration projects fail when trying to solve everything at once. This ensures phased, achievable approach.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Digital Operating Model</span><span class="level-desc">COSTAR</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Connected Factory Vision</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Company has 6 manufacturing sites with varying digital maturity (Level 1-3 on Industry 4.0 scale). New strategy calls for "Connected Factory" across all sites within 5 years. Budget: $50M over 5 years.<br><span class="key">[Objective]</span> Design a connected factory transformation program that delivers measurable value while building toward the long-term vision.<br><span class="key">[Style]</span> Strategic program document with implementation detail.<br><span class="key">[Tone]</span> Ambitious but pragmatic, ROI-focused.<br><span class="key">[Audience]</span> Chief Operations Officer and Site Directors.<br><span class="key">[Response]</span> Include: site maturity assessment approach, technology stack recommendations, implementation sequence based on value and readiness, capability building plan, and governance model. Show expected OEE improvements and cost savings by phase.<br><span class="key">[Constraints]</span> RAI: No actual site performance data, budget figures, or proprietary OEE metrics. Source Accuracy: Reference Industry 4.0 maturity frameworks and pharma digital transformation benchmarks. Data Accuracy: ROI projections must be based on documented assumptions. Human Oversight: Connected factory investments require Executive, Operations, and IT leadership alignment.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> Large-scale transformation requires balancing vision with practical execution across diverse sites.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">ReAct Application</span><span class="level-title">Implementation Troubleshooting</span><span class="level-desc">Interactive Troubleshooting</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Digital Adoption Failure Analysis</span><span class="method-badge">ReAct</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Role]</span> You are a Digital Transformation Specialist diagnosing a failed system rollout.<br><span class="key">[Goal]</span> Identify why a new digital system has low adoption 3 months post-launch and develop remediation plan.<br><span class="key">[Tools]</span> [UsageMetrics] - System login and feature usage data; [UserFeedback] - Survey results and help desk tickets; [TrainingRecords] - Completion rates and assessment scores; [ProcessComparison] - Old vs new workflow analysis.<br><span class="key">[Format]</span> Use Thought → Action → Observation loop.<br><br><span class="key">[Scenario]</span> New electronic lab notebook launched at Site-004. Only 35% of scientists using it; rest still on paper.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> 35% adoption after 3 months is concerning. Low adoption usually stems from: usability issues, inadequate training, or the new system making work harder. Let me check usage patterns first.<br><span class="key">Action:</span> [UsageMetrics] Show daily active users trend and most/least used features for ELN at Site-004<br><br><strong>You:</strong><br><span class="key">Observation:</span> DAU peaked at 60% week 2, now at 35%. Most used: experiment logging. Least used: template library, signature workflow.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Signature workflow being unused is concerning—that's a key compliance feature. Declining usage suggests people tried it and gave up. Let me check what users are saying.<br><span class="key">Action:</span> [UserFeedback] Show top 5 help desk ticket categories and recent survey comments<br><span class="key">[Constraints]</span> RAI: No actual user names, site identifiers, or confidential feedback. Bias Awareness: User complaints may indicate legitimate system issues, not user failure. Transparency: Acknowledge system limitations when communicating with users. Human Oversight: Remediation actions affecting validated systems require change control and Quality approval.</div></div>
                    </div>
                    <div class="method-explanation"><strong>Why this works:</strong> Digital transformation success depends on adoption. ReAct helps diagnose adoption barriers systematically.</div>
                </div>

                <!-- Process Automation Specialist -->
                <div id="automation" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/gear.svg" class="local-icon icon-red" alt="Automation"> Process Automation Specialist
                    </h2>
                    <p class="lead">Implementing RPA, workflow automation, and intelligent automation solutions in pharma operations.</p>

                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Automation Opportunity Assessment</span><span class="level-desc">CRISP</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: RPA Candidate Evaluation</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Finance team manually enters invoice data from PDFs into SAP—200 invoices/week, 15 minutes each. They want to explore RPA.<br><span class="key">[Role]</span> Process Automation Specialist.<br><span class="key">[Instruction]</span> Evaluate this process as an RPA candidate using standard assessment criteria.<br><span class="key">[Style]</span> Structured evaluation with scoring.<br><span class="key">[Parameters]</span> Assess: volume, rule-based nature, input consistency, exception rate, and ROI potential.<br><span class="key">[Constraints]</span> RAI: No actual invoice amounts, vendor names, or financial data. Data Accuracy: Volume and time metrics must be based on documented process studies. Source Accuracy: Apply industry RPA feasibility criteria objectively. Human Oversight: RPA implementations affecting financial systems require Finance, IT, and Audit approval.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> Not every process is suitable for RPA. This ensures systematic evaluation before investment.</div>
                    </div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Automation Solution Design</span><span class="level-desc">CRISPE</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Clinical Data Reconciliation Bot</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Clinical Data Managers spend 3 hours daily reconciling data between EDC and safety database. Process involves: export from System A, export from System B, comparison in Excel, documenting discrepancies, creating tickets.<br><span class="key">[Role]</span> Automation Specialist supporting Clinical Operations.<br><span class="key">[Instruction]</span> Design an automation solution that handles the reconciliation workflow while maintaining data integrity controls.<br><span class="key">[Style]</span> Technical solution design with process flow.<br><span class="key">[Parameters]</span> Must include: error handling for system unavailability, audit trail requirements, and human review checkpoints for GxP compliance.<br><span class="key">[Example]</span> Include decision points for: when to escalate vs auto-resolve discrepancies.<br><span class="key">[Constraints]</span> RAI: No actual patient data, study identifiers, or safety database content. Data Accuracy: Reconciliation rules must match validated business logic exactly. Source Accuracy: Reference ICH E6 and GxP data integrity requirements for clinical data automation. Human Oversight: Automated clinical data handling requires Clinical Operations and Data Management validation approval.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> GxP automation requires careful design of controls and audit trails. This prompt ensures nothing is overlooked.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Intelligent Automation Architecture</span><span class="level-desc">COSTAR</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Document Processing Platform</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Regulatory Affairs processes 5,000+ documents annually—submissions, correspondence, approvals. Current state: manual classification, filing, and tracking. Goal: intelligent document processing platform combining OCR, NLP, and workflow automation.<br><span class="key">[Objective]</span> Design an end-to-end intelligent automation architecture for regulatory document management.<br><span class="key">[Style]</span> Enterprise architecture document.<br><span class="key">[Tone]</span> Technical, scalable, compliance-aware.<br><span class="key">[Audience]</span> IT Architecture Review Board and Regulatory Affairs Leadership.<br><span class="key">[Response]</span> Include: component architecture (OCR, classification ML, workflow engine), integration with existing DMS, validation approach for AI components, scalability considerations, and phased implementation plan. Address 21 CFR Part 11 requirements for electronic records.<br><span class="key">[Constraints]</span> RAI: No actual regulatory submission content, document IDs, or filing details. Source Accuracy: Reference 21 CFR Part 11, Annex 11, and GAMP 5 AI/ML guidance. Data Accuracy: Document classification accuracy must be validated against labeled test sets. Human Oversight: AI-assisted regulatory document processing requires Regulatory Affairs and Quality validation before production use.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> Intelligent automation combines multiple technologies. This ensures holistic architecture thinking.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">ReAct Application</span><span class="level-title">Bot Failure Diagnosis</span><span class="level-desc">Interactive Troubleshooting</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: RPA Bot Exception Handling</span><span class="method-badge">ReAct</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Role]</span> You are an Automation Specialist troubleshooting production bot failures.<br><span class="key">[Goal]</span> Diagnose why an RPA bot is failing 40% of runs and implement fixes.<br><span class="key">[Tools]</span> [BotLogs] - Execution logs with screenshots; [ExceptionQueue] - Failed transaction details; [SystemStatus] - Target application health; [ChangeLog] - Recent updates to bot or target systems.<br><span class="key">[Format]</span> Use Thought → Action → Observation loop.<br><br><span class="key">[Scenario]</span> Invoice processing bot failing since Monday. Was working fine for 6 months.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Sudden failures after stable operation typically indicate: target system change, credential expiry, or infrastructure issue. Let me first understand the failure pattern—is it all runs or specific transactions?<br><span class="key">Action:</span> [ExceptionQueue] Show failure distribution by error type for past 5 days<br><br><strong>You:</strong><br><span class="key">Observation:</span> 85% failures: "Element not found - Submit button". 15%: Timeout errors. All failures on invoices from Vendor-XYZ.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Element not found suggests UI changed. Concentrated on one vendor's invoices means their PDF format likely changed. Let me check if there were any application updates.<br><span class="key">Action:</span> [ChangeLog] Show changes to SAP and invoice portal since last Friday<br><span class="key">[Constraints]</span> RAI: No actual vendor names, invoice details, or system credentials. Data Accuracy: Error categorization must be based on actual bot logs. Transparency: Communicate bot failures and workarounds clearly to affected users. Human Oversight: Bot fixes affecting financial processes require IT and Finance approval before redeployment.</div></div>
                    </div>
                    <div class="method-explanation"><strong>Why this works:</strong> RPA bots are fragile and break when environments change. ReAct structures rapid diagnosis to restore operations.</div>
                </div>

                <!-- Process Excellence Lead -->
                <div id="process-excellence" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/bar-chart.svg" class="local-icon icon-red" alt="Excellence"> Process Excellence Lead
                    </h2>
                    <p class="lead">Driving operational excellence through Lean Six Sigma, continuous improvement, and process optimization.</p>

                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Process Mapping Assistance</span><span class="level-desc">CRISP</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Value Stream Mapping</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I'm conducting a value stream mapping exercise for the batch release process. Current lead time is 15 days; target is 5 days.<br><span class="key">[Role]</span> Lean Six Sigma Black Belt in Pharma QA.<br><span class="key">[Instruction]</span> Help me structure the VSM analysis and identify typical waste categories to look for.<br><span class="key">[Style]</span> Structured framework with guiding questions.<br><span class="key">[Parameters]</span> Focus on pharmaceutical-specific wastes: documentation delays, approval queues, rework loops, and over-processing for GxP compliance.<br><span class="key">[Constraints]</span> RAI: No actual batch numbers, product names, or employee performance data. Data Accuracy: Time observations must be objectively measured, not estimated. Bias Awareness: VSM should identify process waste, not assign blame to individuals. Human Oversight: Process changes affecting batch release require Quality and Regulatory approval.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> VSM requires systematic thinking about waste. This prompt focuses on pharma-specific value stream issues.</div>
                    </div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Root Cause Analysis</span><span class="level-desc">CRISPE</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: OOS Investigation Pattern</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Site-003 has 3x higher OOS (Out of Specification) rate than sister sites. Same products, same equipment models. 18-month data available.<br><span class="key">[Role]</span> Process Excellence Lead conducting cross-site analysis.<br><span class="key">[Instruction]</span> Design a structured root cause analysis approach to identify factors driving the OOS difference.<br><span class="key">[Style]</span> Analytical framework with statistical considerations.<br><span class="key">[Parameters]</span> Include: hypothesis categories (people, process, equipment, materials, environment), data analysis methods, and validation approach for root causes.<br><span class="key">[Example]</span> Use fishbone structure: Primary category → Sub-factors → Measurable indicators → Data sources.<br><span class="key">[Constraints]</span> RAI: No actual site names, OOS details, or employee performance comparisons. Data Accuracy: OOS data must be verified from validated QC systems. Bias Awareness: Analysis must be objective—site differences may have valid explanations. Human Oversight: Root cause conclusions and corrective actions require Quality Management approval.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> Complex quality problems require structured analysis. This ensures systematic hypothesis testing.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Transformation Program Design</span><span class="level-desc">COSTAR</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Operational Excellence Rollout</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Company launching enterprise-wide Operational Excellence program across 8 sites, 5,000 employees. Current state: pockets of excellence, no standardized methodology, limited CI culture. Goal: sustainable improvement culture with measurable business impact.<br><span class="key">[Objective]</span> Design a multi-year OpEx program that builds capability while delivering quick wins to maintain momentum.<br><span class="key">[Style]</span> Strategic program document with tactical detail.<br><span class="key">[Tone]</span> Practical, change-management aware, results-focused.<br><span class="key">[Audience]</span> COO, Site Directors, and HR Leadership.<br><span class="key">[Response]</span> Include: maturity model, training curriculum (from awareness to Black Belt), project selection criteria, governance structure, recognition program, and KPI framework. Show how to balance quick wins with cultural transformation.<br><span class="key">[Constraints]</span> RAI: No actual employee counts, site performance rankings, or proprietary metrics. Source Accuracy: Reference established Lean Six Sigma and OpEx frameworks. Bias Awareness: Acknowledge that not all sites start from same baseline. Human Oversight: Enterprise OpEx programs require Executive Leadership and HR partnership for sustainable change.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> OpEx programs fail when focused only on tools, not culture. This ensures holistic program design.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">ReAct Application</span><span class="level-title">Improvement Project Coaching</span><span class="level-desc">Interactive Troubleshooting</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Stalled DMAIC Project</span><span class="method-badge">ReAct</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Role]</span> You are a Process Excellence Lead coaching a Green Belt through a stuck improvement project.<br><span class="key">[Goal]</span> Help identify why a cycle time reduction project has stalled in the Analyze phase and get it back on track.<br><span class="key">[Tools]</span> [ProjectCharter] - View scope, goals, and team; [DataSummary] - Current analysis results; [StakeholderPulse] - Team and sponsor engagement levels; [MilestoneTracker] - Timeline vs plan.<br><span class="key">[Format]</span> Use Thought → Action → Observation loop.<br><br><span class="key">[Scenario]</span> Packaging line cycle time project stuck for 6 weeks. Green Belt says "analysis is complex."<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> "Analysis is complex" often means: scope creep, analysis paralysis, lack of data, or lost sponsor support. Let me understand the current project status and what analysis has been completed.<br><span class="key">Action:</span> [ProjectCharter] Show original scope, timeline, and current DMAIC phase status<br><br><strong>You:</strong><br><span class="key">Observation:</span> Original scope: "Reduce changeover time by 30%." Current scope expanded to include all cycle time elements. Started Analyze 8 weeks ago, expected 3 weeks.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Scope creep confirmed—went from changeover time to all cycle time. This is a common trap. Let me check what data analysis has actually been done.<br><span class="key">Action:</span> [DataSummary] Show completed analyses and key findings to date<br><span class="key">[Constraints]</span> RAI: No actual employee names or performance critiques. Bias Awareness: Approach coaching supportively—project delays often have valid causes. Transparency: Acknowledge scope creep as common and fixable, not failure. Human Oversight: Project rescoping or timeline extensions require Sponsor and Process Excellence leadership alignment.</div></div>
                    </div>
                    <div class="method-explanation"><strong>Why this works:</strong> Improvement projects stall for predictable reasons. ReAct helps systematically diagnose and address blockers.</div>
                </div>

                <!-- Knowledge Management Specialist -->
                <div id="knowledge-mgmt" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/book.svg" class="local-icon icon-red" alt="Knowledge"> Knowledge Management Specialist
                    </h2>
                    <p class="lead">Capturing, organizing, and enabling access to organizational knowledge and expertise in pharma.</p>

                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Knowledge Capture Planning</span><span class="level-desc">CRISP</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Expert Retirement Knowledge Transfer</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Senior formulation scientist retiring in 6 months. 30 years of experience with our oral solid dosage forms. Need to capture critical tacit knowledge.<br><span class="key">[Role]</span> Knowledge Management Specialist in Pharma R&D.<br><span class="key">[Instruction]</span> Create a structured knowledge capture plan for this retirement transition.<br><span class="key">[Style]</span> Project plan with specific activities.<br><span class="key">[Parameters]</span> Include: interview framework, documentation templates, hands-on shadowing schedule, and validation approach to ensure knowledge is usable.<br><span class="key">[Constraints]</span> RAI: No actual employee names, proprietary formulations, or trade secrets. Data Accuracy: Captured knowledge must be validated by SMEs before documentation. Source Accuracy: Distinguish between documented procedures and personal preferences. Human Oversight: Technical knowledge capture requires R&D Management and Quality review before incorporation into official knowledge bases.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> Tacit knowledge walks out the door with retiring experts. This ensures systematic capture before it's lost.</div>
                    </div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Knowledge Base Architecture</span><span class="level-desc">CRISPE</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Technical Knowledge Repository</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Manufacturing has 200+ SOPs, 500+ troubleshooting guides, and decades of tribal knowledge scattered across shared drives, emails, and people's heads. Need a unified technical knowledge base.<br><span class="key">[Role]</span> KM Specialist designing enterprise knowledge architecture.<br><span class="key">[Instruction]</span> Design a knowledge base structure that enables rapid problem-solving on the manufacturing floor.<br><span class="key">[Style]</span> Technical architecture with user journey focus.<br><span class="key">[Parameters]</span> Must address: taxonomy design, search optimization, contribution workflows, and quality control for technical accuracy.<br><span class="key">[Example]</span> User scenario: Operator encounters unusual tablet appearance. Path to relevant knowledge should be &lt;30 seconds.<br><span class="key">[Constraints]</span> RAI: No actual SOP content, proprietary troubleshooting guides, or confidential tribal knowledge. Source Accuracy: Ensure knowledge base content is aligned with current approved SOPs. Data Accuracy: Taxonomy and tagging must be validated by subject matter experts. Human Oversight: Manufacturing knowledge base changes require Quality and Operations approval.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> Knowledge bases fail when designed for storage, not retrieval. This focuses on user needs.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">AI-Enhanced Knowledge Strategy</span><span class="level-desc">COSTAR</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Enterprise Knowledge AI Platform</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Company wants to leverage GenAI for knowledge access—chat interface to query technical documents, SOPs, and regulatory guidance. Current state: 50TB of unstructured documents across 15 systems. Concerns: accuracy for GxP use, hallucination risk, and data security.<br><span class="key">[Objective]</span> Design an AI-powered knowledge management strategy that maximizes value while managing risks appropriately.<br><span class="key">[Style]</span> Strategic recommendation document.<br><span class="key">[Tone]</span> Balanced—enthusiastic about potential, realistic about challenges.<br><span class="key">[Audience]</span> CIO, Chief Scientific Officer, and Quality leadership.<br><span class="key">[Response]</span> Include: use case prioritization (low-risk to high-risk), RAG architecture considerations, content preparation requirements, accuracy validation approach, user trust-building plan, and governance for GxP vs non-GxP use. Address how to handle conflicting information and version control.<br><span class="key">[Constraints]</span> RAI: No actual document content, confidential regulatory guidance, or proprietary data. Source Accuracy: AI-generated answers must cite source documents. Transparency: Clearly communicate AI limitations and hallucination risks. Human Oversight: AI for GxP knowledge access requires Quality validation, accuracy monitoring, and human verification of critical outputs.</div></div>
                        <div class="explanation-box"><strong>Why use this:</strong> AI for knowledge management has enormous potential but real risks. This ensures balanced strategic thinking.</div>
                    </div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">ReAct Application</span><span class="level-title">Knowledge Gap Analysis</span><span class="level-desc">Interactive Troubleshooting</span></div>
                    <div class="example-block">
                        <div class="example-header"><span>Scenario: Recurring Problem Investigation</span><span class="method-badge">ReAct</span><button class="btn-copy">Copy</button></div>
                        <div class="example-content"><div class="prompt-text"><span class="key">[Role]</span> You are a KM Specialist investigating why the same problems keep recurring despite documented solutions.<br><span class="key">[Goal]</span> Identify knowledge gaps causing repeat incidents and develop remediation plan.<br><span class="key">[Tools]</span> [IncidentHistory] - Past incident records with resolution; [KBSearch] - Query knowledge base; [UsageAnalytics] - KB article access patterns; [UserSurvey] - Feedback on knowledge findability.<br><span class="key">[Format]</span> Use Thought → Action → Observation loop.<br><br><span class="key">[Scenario]</span> Same equipment failure has occurred 5 times in 12 months. Fix is documented but operators keep missing it.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> If the solution is documented but not applied, it's likely: not findable, not understandable, or not trusted. Let me first verify the documentation exists and check if it's being accessed.<br><span class="key">Action:</span> [KBSearch] Find troubleshooting guide for "Mixer-007 seal failure"<br><br><strong>You:</strong><br><span class="key">Observation:</span> Found: KB-2019-0234 "Mixer Seal Replacement Procedure." Last updated: 2019. Page views: 12 in past year.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Very low page views for a recurring problem. Either people don't know it exists or can't find it. The 2019 date is concerning—may be outdated. Let me check how people tried to find help during incidents.<br><span class="key">Action:</span> [UsageAnalytics] Show search queries from operators during Mixer-007 incidents in past 12 months<br><span class="key">[Constraints]</span> RAI: No actual equipment identifiers, incident details, or operator names. Data Accuracy: Incident counts and patterns must be verified from quality records. Bias Awareness: Low usage may indicate findability issues, not user negligence. Human Oversight: Knowledge base updates affecting GxP procedures require Quality and Operations approval.</div></div>
                    </div>
                    <div class="method-explanation"><strong>Why this works:</strong> Knowledge management isn't about creating content—it's about ensuring knowledge flows to where it's needed. ReAct helps diagnose flow blockages.</div>
                </div>

                <!-- ========================================= -->
                <!-- RESEARCH & DEVELOPMENT SECTION           -->
                <!-- ========================================= -->

                <div id="research-scientist" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/search.svg" class="local-icon icon-red" alt="Research"> Research Scientist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Literature Review & Synthesis</span><span class="level-desc">Focus: Speed (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Literature Gap Analysis</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I'm conducting a literature review for a new research project on [therapeutic area/mechanism]. I need to identify gaps in the current scientific understanding that could inform our research direction.<br><span class="key">[Role]</span> PhD-level Research Scientist with expertise in literature analysis and scientific synthesis.<br><span class="key">[Instruction]</span> Help me structure a comprehensive literature gap analysis framework for [research topic]. Include: key questions to investigate, databases to search, search term strategies, and a framework for categorizing findings (established knowledge, conflicting evidence, unexplored areas).<br><span class="key">[Style]</span> Academic, rigorous, and methodical.<br><span class="key">[Parameters]</span> Framework should be applicable to peer-reviewed literature search. Include guidance on assessing publication quality and relevance.<br><span class="key">[Constraints]</span> RAI: No actual proprietary research directions or unpublished data. Source Accuracy: Recommend established scientific databases and peer-reviewed sources only. Human Oversight: Research direction decisions require scientific leadership review.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Experimental Design</span><span class="level-desc">Focus: Formatting (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Study Protocol Framework</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I'm designing a preclinical study to evaluate [compound/intervention] for [therapeutic indication]. This needs to meet regulatory expectations for IND-enabling studies while being scientifically rigorous.<br><span class="key">[Role]</span> Senior Research Scientist with experience in translational research and regulatory submissions.<br><span class="key">[Instruction]</span> Create a study design framework that addresses: (1) Primary and secondary endpoints; (2) Sample size justification approach; (3) Control group considerations; (4) Timing and duration rationale; (5) Key biomarkers to measure; (6) Statistical analysis plan overview.<br><span class="key">[Style]</span> Scientific protocol language with regulatory awareness.<br><span class="key">[Parameters]</span> Framework should align with ICH guidelines where applicable. Include considerations for reproducibility and data integrity.<br><span class="key">[Example]</span> For efficacy endpoints: "Primary: Tumor volume reduction at Day 28 vs. vehicle control. Secondary: Survival, biomarker modulation, PK/PD correlation."<br><span class="key">[Constraints]</span> RAI: No proprietary compound data, specific study designs, or unpublished research. Data Accuracy: Study design must be validated by scientific and regulatory experts before execution. Human Oversight: All study protocols require IACUC/Ethics approval and sponsor review.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Cross-Functional Research Strategy</span><span class="level-desc">Focus: Nuance (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Research Portfolio Prioritization</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Our research team has identified multiple promising directions for [therapeutic area]. Resources are limited, and we need to prioritize which programs to advance. Current portfolio includes 5 early-stage programs competing for 3 advancement slots.<br><span class="key">[Objective]</span> Develop a structured prioritization framework that balances scientific merit, commercial potential, feasibility, and strategic fit.<br><span class="key">[Style]</span> Strategic analysis appropriate for R&D leadership presentation.<br><span class="key">[Tone]</span> Objective, data-driven, but acknowledging uncertainty in early research.<br><span class="key">[Audience]</span> R&D Leadership Team, Chief Scientific Officer, and potentially Board of Directors.<br><span class="key">[Response]</span> Create a prioritization framework including: (1) Scoring criteria with weighting rationale; (2) Evidence requirements for each criterion; (3) Risk assessment methodology; (4) Portfolio balance considerations; (5) Decision-making process with stakeholder input; (6) Governance for ongoing re-evaluation.<br><span class="key">[Constraints]</span> RAI: No actual pipeline programs, proprietary data, or competitive intelligence. Bias Awareness: Ensure criteria don't inadvertently favor pet projects. Transparency: Make trade-offs explicit. Human Oversight: Final prioritization decisions require leadership consensus and board alignment.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">ReAct Application</span><span class="level-title">Unexpected Results Investigation</span><span class="level-desc">Interactive Troubleshooting</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Anomalous Data Investigation</span><span class="method-badge">ReAct</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Role]</span> You are a Research Scientist investigating unexpected experimental results that don't align with the hypothesis.<br><span class="key">[Goal]</span> Systematically investigate whether results represent: (A) experimental error, (B) genuine but unexpected biology, or (C) a need to revise the hypothesis.<br><span class="key">[Tools]</span> [LabNotebook] - Access experimental records; [LiteratureSearch] - Query scientific databases; [DataAnalysis] - Statistical tests and visualization; [EquipmentLogs] - Instrument calibration and maintenance records.<br><span class="key">[Format]</span> Use Thought → Action → Observation loop to investigate systematically.<br><br><span class="key">[Scenario]</span> In a cell-based assay, the test compound showed unexpected cytotoxicity at concentrations where it should be inactive based on mechanism. This wasn't seen in previous runs.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Unexpected cytotoxicity could be due to: (1) compound degradation, (2) cell line issues, (3) assay reagent problems, or (4) genuine off-target effect. Need to first check what changed between runs.<br><span class="key">Action:</span> [LabNotebook] Compare experimental conditions between current run and last 3 successful runs<br><br><strong>You:</strong><br><span class="key">Observation:</span> Different lot number for fetal bovine serum (FBS). New lot received 2 weeks ago. Also, cells are at passage 28 vs. typical passage 15-20.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Two variables changed: FBS lot and cell passage. Higher passage cells can have altered sensitivity. FBS lot variation is known to affect assay performance. Should test which variable is causative. Let me check if anyone else has reported issues with either.<br><span class="key">Action:</span> [LabNotebook] Search for any notes or issues reported with FBS lot #XYZ or passage 25+ cells in past month<br><span class="key">[Constraints]</span> RAI: No actual compound data, lot numbers, or proprietary assay details. Data Integrity: Document all investigational steps in lab notebook. Source Accuracy: Distinguish between confirmed root cause and working hypothesis. Human Oversight: Findings affecting program decisions require scientific leadership review before action.</div></div></div>
                    <div class="method-explanation"><strong>Why this works:</strong> Scientific investigation requires systematic hypothesis testing. ReAct mirrors the scientific method—form hypothesis, gather evidence, refine understanding.</div>
                </div>

                <div id="lab-manager" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/clipboard.svg" class="local-icon icon-red" alt="Lab"> Lab Manager
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Lab Operations</span><span class="level-desc">Focus: Speed (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Equipment Maintenance Schedule</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I manage a [type: analytical/biology/chemistry] lab with 25 pieces of equipment ranging from simple instruments to complex systems. I need to establish a preventive maintenance program that minimizes downtime while staying within budget.<br><span class="key">[Role]</span> Experienced Lab Manager with expertise in GxP-compliant laboratory operations.<br><span class="key">[Instruction]</span> Create a preventive maintenance framework that categorizes equipment by: criticality, maintenance frequency requirements, and resource needs. Include criteria for deciding between in-house maintenance vs. service contracts.<br><span class="key">[Style]</span> Practical operations management with compliance awareness.<br><span class="key">[Parameters]</span> Consider: FDA/regulatory inspection readiness, budget optimization, and minimizing research disruption. Include template for equipment maintenance log.<br><span class="key">[Constraints]</span> RAI: No specific equipment models, vendor names, or budget figures. Data Accuracy: Maintenance intervals must align with manufacturer recommendations and regulatory requirements. Human Oversight: Maintenance programs require Quality approval for GxP-critical equipment.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Resource Management</span><span class="level-desc">Focus: Formatting (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Lab Budget Justification</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Budget planning season. I need to justify a 15% increase in lab operations budget to support: new equipment acquisition, expanded team, and enhanced capabilities. Finance is pushing back on R&D spending.<br><span class="key">[Role]</span> Lab Manager building a business case for laboratory investment.<br><span class="key">[Instruction]</span> Help me structure a compelling budget justification that connects lab investments to business outcomes. Include: (1) Current state assessment; (2) Gap analysis; (3) Investment requirements with prioritization; (4) ROI framework (productivity gains, risk mitigation, capability enabling); (5) Phased implementation option.<br><span class="key">[Style]</span> Business case format that resonates with Finance and Leadership.<br><span class="key">[Parameters]</span> Balance scientific needs with business language. Quantify benefits where possible. Include "cost of not investing" analysis.<br><span class="key">[Example]</span> "Equipment failure risk: Current HPLC is 12 years old. Unplanned downtime = $X per day in delayed studies. Preventive replacement = $Y one-time vs. emergency replacement = $Z + study delays."<br><span class="key">[Constraints]</span> RAI: No actual budget figures, equipment costs, or internal financial data. Bias Awareness: Be honest about both benefits and limitations of proposed investments. Human Oversight: Budget submissions require R&D leadership approval and Finance review.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Lab Strategy & Transformation</span><span class="level-desc">Focus: Nuance (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Lab Modernization Strategy</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Leadership wants to transform our labs into "Labs of the Future"—more automated, data-driven, and efficient. Currently, we have manual processes, paper-based records, and siloed instruments. This is a multi-year transformation with significant change management challenges.<br><span class="key">[Objective]</span> Develop a phased lab modernization roadmap that delivers incremental value while building toward the long-term vision.<br><span class="key">[Style]</span> Strategic transformation plan with operational detail.<br><span class="key">[Tone]</span> Ambitious but realistic—acknowledge complexity while showing path forward.<br><span class="key">[Audience]</span> R&D Leadership, IT, Quality, and ultimately the scientists who work in these labs daily.<br><span class="key">[Response]</span> Create a modernization strategy including: (1) Current state assessment framework; (2) Future state vision with specific capabilities; (3) Technology enablers (LIMS, ELN, automation, IoT); (4) Phased roadmap with quick wins and long-term goals; (5) Change management approach; (6) Success metrics at each phase; (7) Risk mitigation for transformation challenges.<br><span class="key">[Constraints]</span> RAI: No proprietary systems, vendor names, or internal strategic documents. Regulatory Awareness: Ensure all changes maintain GxP compliance. Human Oversight: Lab transformation requires multi-stakeholder governance (R&D, IT, Quality, Finance) and phased validation.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">ReAct Application</span><span class="level-title">Lab Incident Investigation</span><span class="level-desc">Interactive Troubleshooting</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Equipment Failure Root Cause</span><span class="method-badge">ReAct</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Role]</span> You are a Lab Manager investigating a critical equipment failure that impacted ongoing studies.<br><span class="key">[Goal]</span> Determine root cause, assess impact on data integrity, and develop CAPA (Corrective and Preventive Actions).<br><span class="key">[Tools]</span> [EquipmentLogs] - Maintenance and calibration history; [EnvironmentMonitor] - Temperature, humidity, power logs; [StudyRecords] - Samples and data affected; [VendorSupport] - Technical documentation and support tickets.<br><span class="key">[Format]</span> Use Thought → Action → Observation loop for systematic investigation.<br><br><span class="key">[Scenario]</span> -80°C freezer alarm triggered overnight. Temperature rose to -65°C for approximately 4 hours before being discovered. Freezer contains samples from 3 ongoing studies.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Need to understand: (1) why it happened, (2) exact duration and temperature range, and (3) which samples were affected. First, let me get the full environmental data to understand the timeline precisely.<br><span class="key">Action:</span> [EnvironmentMonitor] Pull temperature log for Freezer-012 from 6PM yesterday to 8AM today<br><br><strong>You:</strong><br><span class="key">Observation:</span> Temperature stable at -82°C until 11:47PM. Rose to -65°C by 2:30AM. Alarm triggered at 2:15AM when it crossed -70°C threshold. Temperature stabilized at -65°C until 6:15AM when discovered and backup freezer transfer initiated.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> So we had about 4 hours at -65°C. Next need to understand cause. Common failures: compressor, door seal, power. The gradual rise suggests compressor or refrigerant issue rather than door. Let me check maintenance history.<br><span class="key">Action:</span> [EquipmentLogs] Show maintenance history and any recent service for Freezer-012<br><span class="key">[Constraints]</span> RAI: No actual freezer IDs, sample information, or study identifiers. Data Integrity: Temperature excursion documentation must be thorough and contemporaneous. Quality Notification: Events affecting GxP samples require immediate Quality notification. Human Oversight: Root cause determination and CAPA require Quality approval; sample disposition decisions require scientific and quality review.</div></div></div>
                    <div class="method-explanation"><strong>Why this works:</strong> Lab incidents require methodical investigation that documents the decision trail. ReAct ensures no steps are skipped and reasoning is captured for regulatory review.</div>
                </div>

                <div id="formulation" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/layers.svg" class="local-icon icon-red" alt="Formulation"> Formulation Scientist
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Formulation Screening</span><span class="level-desc">Focus: Speed (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Excipient Compatibility Assessment</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I'm starting formulation development for a new small molecule with [basic physicochemical properties: pKa, solubility, stability concerns]. Need to design an excipient compatibility screening study.<br><span class="key">[Role]</span> Formulation Scientist experienced in preformulation and excipient selection for oral solid dosage forms.<br><span class="key">[Instruction]</span> Design an excipient compatibility screening protocol that: identifies potentially problematic excipient-drug interactions early, prioritizes the most common excipients for the target dosage form, and provides a decision framework for interpreting results.<br><span class="key">[Style]</span> Scientific protocol with practical lab execution considerations.<br><span class="key">[Parameters]</span> Include: excipient categories to screen, stress conditions, analytical methods, acceptance criteria, and timeline estimate. Consider both physical and chemical compatibility.<br><span class="key">[Constraints]</span> RAI: No actual drug candidate properties, proprietary formulation data, or specific analytical methods. Source Accuracy: Excipient recommendations should be based on established pharmaceutical science. Human Oversight: Formulation decisions affecting product development require CMC leadership review.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Formulation Development</span><span class="level-desc">Focus: Formatting (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>DoE Study Design</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Moving from feasibility to optimization for an immediate-release tablet formulation. Need to understand the relationship between formulation variables (binder level, disintegrant type/level, compression force) and critical quality attributes (dissolution, hardness, friability).<br><span class="key">[Role]</span> Formulation Scientist applying Quality by Design (QbD) principles.<br><span class="key">[Instruction]</span> Design a Design of Experiments (DoE) study to map the design space for this formulation. Include: (1) Factor selection and ranges; (2) Response variables; (3) Experimental design type (factorial, RSM, etc.) with justification; (4) Sample size and resource estimate; (5) Analysis plan; (6) How results inform design space definition.<br><span class="key">[Style]</span> Technical but accessible to cross-functional team.<br><span class="key">[Parameters]</span> Design should be efficient (minimize experiments) while providing robust understanding. Consider regulatory expectations for QbD submissions.<br><span class="key">[Example]</span> Factor: Binder level (2-5% w/w), rationale: below 2% insufficient granule strength, above 5% over-wetting observed in feasibility.<br><span class="key">[Constraints]</span> RAI: No proprietary formulation compositions, specific excipient grades, or actual design space parameters. Data Accuracy: DoE designs must be validated statistically. Regulatory Awareness: Design space claims require scientific justification acceptable to regulators. Human Oversight: DoE studies supporting registration require CMC and Quality review of protocols and conclusions.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Complex Formulation Challenges</span><span class="level-desc">Focus: Nuance (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Bioavailability Enhancement Strategy</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> The drug candidate is BCS Class II (low solubility, high permeability). Early pharmacokinetic studies show high variability and food effect. Commercial viability requires a formulation that delivers consistent exposure without food restriction. Multiple enabling technologies are being considered: particle size reduction, amorphous solid dispersions, lipid-based formulations, and complexation.<br><span class="key">[Objective]</span> Develop a strategic evaluation framework to select the optimal bioavailability enhancement approach, considering scientific feasibility, manufacturability, stability, and commercial viability.<br><span class="key">[Style]</span> Strategic technology assessment for CMC leadership decision-making.<br><span class="key">[Tone]</span> Rigorous scientific analysis with business context.<br><span class="key">[Audience]</span> CMC Leadership, Project Team, and potentially R&D Leadership for investment decisions.<br><span class="key">[Response]</span> Create an evaluation framework including: (1) Technology assessment criteria (biopharmaceutical performance, manufacturability, stability, scalability, IP landscape, cost); (2) Go/no-go criteria for each technology; (3) Recommended evaluation sequence (fast-fail approach); (4) Resource and timeline estimates; (5) Risk assessment for each path; (6) Decision tree for technology selection.<br><span class="key">[Constraints]</span> RAI: No proprietary compound data, specific formulation compositions, or confidential commercial assessments. Bias Awareness: Present technologies objectively without favoring internal capabilities. Transparency: Clearly state assumptions and uncertainties in assessments. Human Oversight: Technology selection decisions require CMC leadership consensus and alignment with program strategy.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">ReAct Application</span><span class="level-title">Stability Failure Investigation</span><span class="level-desc">Interactive Troubleshooting</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Out-of-Specification Stability Result</span><span class="method-badge">ReAct</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Role]</span> You are a Formulation Scientist investigating an unexpected out-of-specification (OOS) result on stability.<br><span class="key">[Goal]</span> Determine whether this is: (A) analytical error, (B) formulation/process issue, (C) storage condition excursion, or (D) genuine product degradation requiring reformulation.<br><span class="key">[Tools]</span> [StabilityData] - Historical stability results; [AnalyticalRecords] - Method details, system suitability, sample prep; [ManufacturingBatch] - Batch records, in-process data; [StorageLogs] - Chamber temperature/humidity history.<br><span class="key">[Format]</span> Use Thought → Action → Observation loop for systematic OOS investigation.<br><br><span class="key">[Scenario]</span> 6-month stability sample at 40°C/75%RH shows assay of 94.2% vs. specification of NLT 95.0%. Previous timepoints were 98.5% (initial), 97.8% (3M). This is faster degradation than predicted.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> OOS investigation should follow established protocol: first rule out analytical error, then examine storage, then consider true product behavior. A 3.6% drop from 3M to 6M is significant. Let me first check if the analytical run was in control.<br><span class="key">Action:</span> [AnalyticalRecords] Pull system suitability and standard results for the 6M assay run<br><br><strong>You:</strong><br><span class="key">Observation:</span> System suitability: All passed. Standard recovery: 99.8%. Duplicate injections: 94.1% and 94.3% (good precision). Analyst: Qualified, same as previous timepoints.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Analytical run looks clean—it's not an analytical error at the injection level. Could be sample preparation or genuine product result. Let me check if storage conditions were maintained properly throughout the interval.<br><span class="key">Action:</span> [StorageLogs] Pull chamber 40C-75RH-02 logs from 3M timepoint to 6M sampling date, flag any excursions<br><span class="key">[Constraints]</span> RAI: No actual stability data, batch numbers, or product-specific degradation information. Data Integrity: OOS investigations must follow cGMP procedures and be documented thoroughly. Quality Notification: OOS results require immediate Quality notification before investigation begins. Human Oversight: OOS conclusions and resulting actions require Quality approval; impact assessment requires cross-functional review.</div></div></div>
                    <div class="method-explanation"><strong>Why this works:</strong> OOS investigations must be systematic and documented. ReAct provides a structured approach that mirrors regulatory expectations for laboratory investigations.</div>
                </div>

                <div id="analytical-dev" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/chart-bar.svg" class="local-icon icon-red" alt="Analytical"> Analytical Development
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Method Development</span><span class="level-desc">Focus: Speed (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>HPLC Method Strategy</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I need to develop an HPLC method for a new drug substance that will support development through commercialization. The compound has [basic properties: chromophore, pKa, stability considerations]. Method needs to be stability-indicating and suitable for eventual validation.<br><span class="key">[Role]</span> Analytical Development Scientist with expertise in chromatographic method development for pharmaceuticals.<br><span class="key">[Instruction]</span> Outline a systematic HPLC method development strategy including: (1) Initial scouting conditions to try; (2) Column and mobile phase screening approach; (3) Forced degradation study design; (4) Method optimization sequence; (5) Criteria for declaring the method "development complete" and ready for validation.<br><span class="key">[Style]</span> Technical protocol with practical efficiency considerations.<br><span class="key">[Parameters]</span> Balance thoroughness with speed. Assume access to standard analytical development equipment. Consider both isocratic and gradient approaches.<br><span class="key">[Constraints]</span> RAI: No proprietary compound structures, actual method parameters, or confidential development data. Source Accuracy: Recommendations should follow ICH guidelines and established analytical science. Human Oversight: Method development strategies require Analytical leadership review; validated methods require Quality approval.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Method Validation</span><span class="level-desc">Focus: Formatting (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Validation Protocol Framework</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Preparing to validate an HPLC method for drug substance assay and related substances. This method will be used for release testing and stability studies, and needs to meet regulatory expectations for NDA filing.<br><span class="key">[Role]</span> Analytical Development Scientist preparing validation documentation for regulatory submission.<br><span class="key">[Instruction]</span> Create a validation protocol framework that covers: (1) Validation characteristics per ICH Q2(R1); (2) Acceptance criteria for each characteristic; (3) Experimental design (number of preparations, concentration levels); (4) Sample and standard preparation procedures; (5) Data analysis approach; (6) Deviation handling; (7) Documentation requirements.<br><span class="key">[Style]</span> Formal protocol format suitable for Quality review and regulatory inspection.<br><span class="key">[Parameters]</span> Must address: specificity, linearity, range, accuracy, precision (repeatability and intermediate), detection/quantitation limits (for impurity methods), robustness. Include acceptance criteria rationale.<br><span class="key">[Example]</span> Precision (Repeatability): Six preparations at 100% target concentration. Acceptance: RSD ≤2.0% for assay, ≤10% for impurities at specification level. Rationale: Per USP <1225> and industry standards.<br><span class="key">[Constraints]</span> RAI: No actual method parameters, acceptance criteria, or proprietary analytical procedures. Regulatory Compliance: Protocol must align with ICH Q2(R1) and applicable pharmacopeial requirements. Human Oversight: Validation protocols require Analytical Development, CMC, and Quality approval prior to execution.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Lifecycle Management</span><span class="level-desc">Focus: Nuance (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Analytical Control Strategy</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Developing the overall analytical control strategy for a drug product as part of the CMC section of a regulatory submission. This needs to articulate how analytical methods and specifications work together to ensure product quality throughout the lifecycle.<br><span class="key">[Objective]</span> Develop a comprehensive analytical control strategy that demonstrates scientific understanding of the product and regulatory compliance while allowing appropriate flexibility for post-approval changes.<br><span class="key">[Style]</span> Regulatory submission quality—clear, justified, comprehensive.<br><span class="key">[Tone]</span> Confident scientific narrative that anticipates reviewer questions.<br><span class="key">[Audience]</span> Regulatory reviewers (FDA/EMA), internal CMC and Quality leadership.<br><span class="key">[Response]</span> Create a control strategy framework addressing: (1) Critical Quality Attributes (CQAs) and their link to safety/efficacy; (2) Analytical methods for each CQA with justification for method selection; (3) Specification setting rationale (regulatory, safety, process capability); (4) Method lifecycle management approach; (5) In-process controls and their relationship to release testing; (6) Comparability testing strategy for process/site changes; (7) Continuous improvement provisions.<br><span class="key">[Constraints]</span> RAI: No actual specifications, method details, or proprietary control strategy documents. Regulatory Alignment: Framework must be consistent with ICH Q8/Q9/Q10 principles. Transparency: Be clear about scientific rationale and uncertainties. Human Oversight: Control strategy requires CMC, Quality, Regulatory, and potentially Clinical input; final strategy requires senior leadership approval.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">ReAct Application</span><span class="level-title">Method Transfer Issues</span><span class="level-desc">Interactive Troubleshooting</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Failed Method Transfer Investigation</span><span class="method-badge">ReAct</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Role]</span> You are an Analytical Development Scientist troubleshooting a method transfer failure between sites.<br><span class="key">[Goal]</span> Identify the root cause of transfer failure and develop remediation plan to achieve successful transfer.<br><span class="key">[Tools]</span> [MethodDocumentation] - SOPs and method details; [TransferData] - Results from sending and receiving sites; [EquipmentComparison] - Instrument configurations at both sites; [AnalystTraining] - Qualification records.<br><span class="key">[Format]</span> Use Thought → Action → Observation loop to systematically investigate.<br><br><span class="key">[Scenario]</span> HPLC assay method transfer from development site to QC site failed. Receiving site results consistently 2-3% lower than sending site on same samples. Method validation showed good precision at both sites independently.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Consistent bias (not random scatter) suggests systematic difference rather than analyst technique issue. Could be: instrument calibration, column differences, mobile phase preparation, or environmental factors. Let me first verify we're comparing apples to apples on instrument setup.<br><span class="key">Action:</span> [EquipmentComparison] Compare HPLC configurations: column brand/lot, detector wavelength calibration, flow rate verification, injection volume accuracy<br><br><strong>You:</strong><br><span class="key">Observation:</span> Same column brand, different lots (sending: Lot A, receiving: Lot B). Wavelength calibration: both within spec. Flow rate: sending 1.000 mL/min, receiving 0.998 mL/min. Injection volume: both 10.0 μL verified.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Column lot difference is interesting—lot-to-lot variability can affect selectivity. Flow rate difference is negligible. Let me check if the same samples were analyzed or if this could be sample handling differences.<br><span class="key">Action:</span> [TransferData] Confirm sample handling: were identical samples (same vials) analyzed at both sites, or were samples prepared separately from same bulk?<br><span class="key">[Constraints]</span> RAI: No actual site names, method parameters, or proprietary transfer data. Data Integrity: Transfer investigation must be documented per site SOPs. Quality Involvement: Failed transfers require Quality notification and oversight. Human Oversight: Root cause conclusions and remediation plans require approval from Analytical Development and Quality at both sites.</div></div></div>
                    <div class="method-explanation"><strong>Why this works:</strong> Method transfers fail for systematic reasons. ReAct helps isolate variables methodically, which is exactly what regulators expect to see in transfer investigation documentation.</div>
                </div>

                <div id="process-dev" class="tab-content">
                    <h2>
                        <img src="assets/icons/SVG/cube.svg" class="local-icon icon-red" alt="Process"> Process Development
                    </h2>
                    <div class="level-header"><span class="level-badge">Level 1: Entry</span><span class="level-title">Process Documentation</span><span class="level-desc">Focus: Speed (CRISP)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Batch Record Drafting</span><span class="method-badge">CRISP</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> I've completed process development for a [synthesis step/unit operation] and need to draft the batch record that will be used in the pilot plant. This needs to capture the process clearly for operators while meeting GMP documentation requirements.<br><span class="key">[Role]</span> Process Development Scientist with experience translating lab processes to manufacturing documentation.<br><span class="key">[Instruction]</span> Create a batch record template for this process step that includes: (1) Header information (batch ID, date, operators, equipment); (2) Material requirements with calculations; (3) Step-by-step instructions with critical process parameters highlighted; (4) In-process testing requirements and acceptance criteria; (5) Verification signatures at key points; (6) Yield calculations; (7) Documentation requirements.<br><span class="key">[Style]</span> Clear, unambiguous instructions that minimize interpretation and operator error.<br><span class="key">[Parameters]</span> Use action verbs. Include "why" for critical steps. Specify what to do if parameters are out of range. Consider operator experience level.<br><span class="key">[Constraints]</span> RAI: No actual process conditions, proprietary procedures, or confidential manufacturing details. Data Integrity: Batch records must comply with ALCOA+ principles. Human Oversight: Batch record templates require Quality approval before use in GMP manufacturing.</div></div></div>

                    <div class="level-header"><span class="level-badge">Level 2: Intermediate</span><span class="level-title">Process Characterization</span><span class="level-desc">Focus: Formatting (CRISPE)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Process Parameter Risk Assessment</span><span class="method-badge">CRISPE</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Preparing for process characterization studies to support a regulatory filing. Need to prioritize which process parameters to study based on their potential impact on critical quality attributes (CQAs).<br><span class="key">[Role]</span> Process Development Scientist applying QbD principles to process characterization.<br><span class="key">[Instruction]</span> Develop a risk assessment framework to prioritize process parameters for characterization. Include: (1) Risk ranking criteria (severity, probability, detectability); (2) Parameter categorization approach (critical, key, non-critical); (3) CQA linkage analysis; (4) Prior knowledge incorporation; (5) Study prioritization matrix; (6) Characterization study design guidance based on risk level.<br><span class="key">[Style]</span> Technical risk assessment format suitable for regulatory submission.<br><span class="key">[Parameters]</span> Use FMEA-based approach where appropriate. Justify risk scores. Include governance for risk assessment reviews.<br><span class="key">[Example]</span> Parameter: Reaction temperature. CQA link: Impurity A formation (established mechanistically). Severity: High (affects purity specification). Probability: Medium (within normal control). Detectability: High (monitored continuously). Risk score: Medium-High → Include in characterization studies.<br><span class="key">[Constraints]</span> RAI: No actual process parameters, CQA data, or proprietary risk assessments. Source Accuracy: Risk assessment approach must align with ICH Q9 principles. Human Oversight: Risk assessments require cross-functional review (Process Development, Analytical, Quality, Regulatory).</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">Level 3: Advanced</span><span class="level-title">Tech Transfer & Scale-up</span><span class="level-desc">Focus: Nuance (COSTAR)</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Technology Transfer Strategy</span><span class="method-badge">COSTAR</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Context]</span> Preparing to transfer a drug substance manufacturing process from development to a commercial manufacturing site (internal or CMO). Process includes multiple synthetic steps, crystallization, and drying. Need a comprehensive tech transfer plan.<br><span class="key">[Objective]</span> Develop a technology transfer strategy that ensures successful process transfer with maintained product quality and regulatory compliance.<br><span class="key">[Style]</span> Strategic transfer plan with operational detail.<br><span class="key">[Tone]</span> Thorough, risk-aware, collaboration-focused.<br><span class="key">[Audience]</span> CMC leadership, manufacturing site, Quality, and Regulatory.<br><span class="key">[Response]</span> Create a tech transfer strategy including: (1) Transfer team composition and responsibilities; (2) Knowledge transfer activities (documentation, training, hands-on); (3) Equipment qualification requirements; (4) Process validation approach; (5) Analytical method transfer; (6) Material qualification (starting materials, intermediates); (7) Scale-up considerations and risk mitigation; (8) Batch progression (demo, PPQ, commercial); (9) Success criteria at each stage; (10) Communication and escalation protocols; (11) Regulatory considerations (site change, comparability).<br><span class="key">[Constraints]</span> RAI: No actual site information, process details, or confidential transfer plans. Regulatory Compliance: Transfer strategy must support regulatory filing requirements. Human Oversight: Tech transfer requires governance from both sending and receiving sites, plus CMC and Quality leadership oversight.</div></div></div>

                    <div class="level-header"><span class="level-badge cell-accent text-white">ReAct Application</span><span class="level-title">Scale-up Problem Solving</span><span class="level-desc">Interactive Troubleshooting</span></div>
                    <div class="example-block collapsible expanded"><div class="example-header"><span>Unexpected Scale-up Issue</span><span class="method-badge">ReAct</span><button class="btn-copy">Copy</button><img src="assets/icons/SVG/chevron-right.svg" alt="" class="accordion-toggle icon-grey"></div><div class="example-content"><div class="prompt-text"><span class="key">[Role]</span> You are a Process Development Scientist troubleshooting an unexpected issue during scale-up from lab to pilot scale.<br><span class="key">[Goal]</span> Identify root cause of the scale-dependent behavior and develop solution that maintains process performance at larger scale.<br><span class="key">[Tools]</span> [ProcessData] - Lab and pilot batch records and data; [EquipmentSpecs] - Vessel geometries, agitator specs, heat transfer data; [MaterialProperties] - Physical properties of intermediates; [ScaleCalculations] - Dimensionless numbers, mixing correlations.<br><span class="key">[Format]</span> Use Thought → Action → Observation loop for systematic investigation.<br><br><span class="key">[Scenario]</span> Crystallization step that worked well at 10L scale is producing larger particle size distribution and more fines at 200L pilot scale. Same process conditions (temperature, cooling rate, seed amount) were used.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Crystallization is highly scale-sensitive. "Same conditions" at different scales often aren't truly the same. Key factors: mixing (shear, circulation time), heat transfer (cooling surface-to-volume ratio), supersaturation profiles. Let me first compare the actual mixing conditions.<br><span class="key">Action:</span> [EquipmentSpecs] Compare: impeller type, tip speed, power input per volume, turnover time for 10L and 200L vessels<br><br><strong>You:</strong><br><span class="key">Observation:</span> 10L: Pitched blade turbine, tip speed 2.1 m/s, P/V = 0.8 W/L, turnover 15s. 200L: Retreat curve impeller, tip speed 1.8 m/s, P/V = 0.3 W/L, turnover 45s.<br><br><strong>AI (ReAct Mode):</strong><br><span class="key">Thought:</span> Significant differences—different impeller type, lower power input, much longer turnover time at pilot scale. Lower shear could explain larger crystals (less breakage). Longer turnover with cooling could create local supersaturation differences explaining the fines. Let me check the actual cooling profiles.<br><span class="key">Action:</span> [ProcessData] Compare temperature profiles: bulk temperature vs. jacket temperature difference during cooling for both scales<br><span class="key">[Constraints]</span> RAI: No actual process conditions, equipment specifications, or proprietary crystallization data. Data Integrity: Investigation findings must be documented in development reports. Scientific Rigor: Root cause determination requires supporting data, not assumption. Human Oversight: Scale-up solutions affecting product quality require Process Development leadership review and Quality concurrence before implementation.</div></div></div>
                    <div class="method-explanation"><strong>Why this works:</strong> Scale-up troubleshooting requires connecting fundamental engineering principles with observed behavior. ReAct structures the scientific investigation and ensures systematic comparison.</div>
                </div>

            </div>
        </div>
    </main>

    <script src="app.js" defer></script>
</body>
</html>